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Abstract 
The analgesic effects of cannabis-based medicines are widely 
described and elevation of the endocannabinoids (ECls), by 
inhibition of endocannabinoid metabolism, also produces analgesia. 
Measurement of endocannabinoids (ECls) and metabolites, in low 
weight biological tissue, provides an important tool for investigating 
the potential therapeutic effects of this receptor system. 
The main aims of this thesis were to develop an analytical method to 
measure ECls, and cyclooxgenase-2 (COX-2) metabolites of 
anandamide (AEA) and 2-arachidonoylglycerol (2-AG), and to apply 
the method to determine their role in nociceptive processing in 
models of acute and chronic inflammatory pain. 
A liquid chromatography-tandem mass spectrometry (lC-MS/MS) 
method, which allowed for the simultaneous measurement of AEA, 
oleoylethanolamide (OEA), palmitoylethanolamine (PEA) and 2-AG, 
as well as COX-2 metabolites of AEA and 2-AG was developed and 
validated. This method was demonstrated to be able to quantify 
ECls and related compounds in rat hindpaw, brain, spinal cord and 
cell samples. 
The effects of TRPV1 activation on levels of intracellular calcium 
[Ca2+]i and ECls in sensory nerves were investigated. The TRPV1 
agonist, capsaicin, dose dependently increased [Ca2+]i, which was 
blocked by the TRPV1 antagonist iodoresiniferatoxin (IRTX). 
Although synthesis of ECls is activity and calcium dependent, there 
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was no relationship between the TRPV1-mediated increases in 
[Ca2+]j, and levels of intracellular or extracellular ECls. The 
mechanism of sensitization of primary afferent nociceptors by the 
proinflammatory cytokine tumor necrosis factor-a (TNFa), which is 
heavily implicated in inflammatory responses, was also studied. 
TNFa facilitated capsaicin-evoked calcium responses, an effect 
which was mediated by p38MAPK-induced phosphorylation. 
The ability of inhibition of fatty acid amide hydrolase (FAAH) to 
modulate inflammatory pain responses, and the sites at which ECls 
were elevated, was studied in the carrageenan model of 
inflammatory pain. This model was considered ideal for the 
investigation of the role of alternative metabolism of ECls by COX-2 
as inflammatory pain is associated with an up-regulation of COX-2. 
The effects of acute and repeated administration of URB597 (0.3 
mgkg-1), a selective inhibitor of FAAH metabolism of ECls, on 
carrageenan-evoked changes in weight bearing and hindpaw 
oedema were determined. Behavioural effects were considered in 
parallel with the changes in levels of ECls and COX-2 metabolites of 
AEA and 2-AG in the hindpaw and spinal cord. Acute administration 
of URB597 delayed the onset and attenuated carrageenan-induced 
hyperalgesia, an effect which was associated with increased levels of 
AEA, OEA and PEA in the spinal cord. By contrast, carrageenan-
induced hyperalgesia was not altered by repeated administration of 
URB597 and levels of AEA in the spinal cord were not significantly 
increased by this treatment. There was no evidence for the 
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metabolism of ECls via COX-2 in the hindpaw, or spinal cord, of 
carrageenan-treated rats, under basal conditions or following 
inhibition of FAAH. 
The role of the endocannabinoid system in a model of osteoarthritis 
(OA) pain was also investigated. Intra-articluar injection of the 
chondrocyte inhibitor monosodium iodoacetate (MIA, 1 mg/50I .. II) 
produced histological changes reminiscent of joint damage in OA 
patients, and a time dependant decrease in paw withdrawal 
thresholds and weight bearing on the injured (ipsilateral) side. These 
behavioural pain responses were accompanied with an increase in 
ECls in the spinal cord, suggestive of a role of ECls in modulation of 
OA-induced pain. 
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General Introduction 
1 General Introduction 
1.1 Pain 
Pain is defined as "an unpleasant sensory and emotional experience 
associated with actual or potential tissue damage, or described in 
terms of such damage" (Merskey, 1994). The term pain 
encompasses the emotional, behavioural and cognitive responses to 
the physiological sensation of a noxious stimulus. Pain is part of the 
body's defense system, triggering a reflex reaction to retract from a 
painful stimulus. It is a major symptom in many diseases and 
pathological conditions, significantly interfering with a person's quality 
of life and general functioning. This problem can be difficult to treat, 
particularly when it is present in addition to other pathological 
conditions such as cancer and inflammation. Although there are 
many different types of pain, the mechanisms involved in producing 
the pain can be loosely separated into inflammatory or neuropathic 
pain. However, in order to develop effective medicines to treat this 
wide ranging problem, the basic mechanisms by which pain is 
perceived and transduced into a behavioural response must be 
understood. 
In 1906 Sherrington defined a nociceptor as a receptor that responds 
to stimuli which damage tissue, or have the potential to do so 
(Sherrington, 1906). Importantly nociceptors do not respond to 
innocuous stimuli (Sherrington, 1906, Meyer, 2006). Some time 
later, the gate control theory of pain was proposed, which is a 
16 
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complex mechanism of nociceptive transmission, where activation of 
nerves that do not transmit pain signals can interfere with signals 
from pain fibers and inhibit an individual's perception of pain. 
(Melzack and Wall, 1965). When pain is sensed, there is usually an 
increase in neuronal activity, resulting in the perception of pain, 
however when the gating mechanism is activated, the pain signal can 
be curtailed due to pre-synaptic inhibition (Melzack and Wall, 1965). 
This mechanism involves a sequence of complex interactions at 
peripheral, spinal and supraspinal sites, and provides various 
potential pharmacological targets (Melzack and Wall, 1965). 
1.2 Primary afferent nociceptors 
Pain is associated with increased electrical firing in small diameter 
sensory nerve afferent fibres. Nociceptors transduce mechanical, 
thermal and chemical stimuli and the generated electrical signals are 
propagated along sensory neurones to the spinal cord and brain. Cell 
bodies of these fibres are located in the dorsal root ganglia (DRG), 
and are categorised into 3 different classes, according to their 
diameter, structure, and conduction velocity (Meyer, 2006). Cells 
with the largest cell bodies give rise to large diameter (>10IJm) 
fastest conducting, myelinated AI3 fibres, these fibres are cutaneous 
mechanoceptors which respond to innocuous stimulation such as 
light touch; however, they are also thought to play a minor role in 
nociceptive transmission (Koltzenburg et aI., 1994). The two major 
sensory fibres associated with nociceptive processing are thin, 
myelinated, relatively fast A6 fibres and un-myelinated, slow 
17 
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conducting C-fibres. AfJ fibres respond to mechanical and thermal 
noxious stimulation, with varying receptor thresholds, with the lowest 
threshold in the innocuous range. AfJ fibres discharge increasingly 
upon stimulation in a stimulus intensity-dependent manner. C-fibres 
are sensitive to thermal, chemical and mechanical stimuli, and are 
often termed 'polymodal receptors'. However, sub-populations of C-
fibre nociceptors have been identified. These nociceptors are not 
activated equally by thermal, chemical and mechanical stimuli. 
Some mechanically sensitive C-fibres are unresponsive to heat 
(Schmidt et aI" 1997), while another group are only responsive to 
heat (Schmidt et aI" 1995), however can be sensitised to mechanical 
stimuli following repeated noxious mechanical stimulation (Schmidt et 
al., 2000). Other differences in C fibre sub-populations include their 
neurochemical content. One class of fibre, classed as the 
peptidergic population, contains substance P and CRGP (Averill et 
aI" 1995, Molliver et aI., 1997). They require the neurotrophin nerve 
growth factor (NGF) for development during embryonic life and 
express the receptor for NGF, TrKA (Molliver et aI., 1997). However 
not all neurones express TrKA, and these form the non-peptidergic 
population. These fibres are sensitive to glial cell derived 
neurotrophic factor (GDNF), and express GDNF receptors, the ATP-
gated ion channel P2X3 receptors, and IB4-lectin binding site. In 
addition a sub group of nociceptors, named sleeping nociceptors, are 
insensitive to mechanical and thermal stimuli under normal 
conditions, but can become sensitised under pathological conditions 
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such as inflammation (Schaible and Schmidt, 1988, Schmidt et aI., 
1995). It has been suggested that these nociceptors are recruited 
and thought to contribute to hyperalgesia (an increased response to 
a noxious stimulus) (Schmidt et aI., 1995, Besson, 1999). 
Responses of primary afferent fibres are part of the normal protective 
response to pain. However, increased intensity of firing or prolonged 
firing of these fibres can lead to hyperalgesia or allodynia. 
Hyperalgesia as defined above is an increased response to a 
noxious stimulus and occurs when nociceptive responses are 
increased and prolonged (Merskey, 1994). Allodynia is a noxious 
response to a previously innocuous stimulus, due to normally 
innocuous AJ3-fibre input into a sensitized area perceived as noxious 
(Merskey, 1994), which can occur from biochemical changes 
peripherally and centrally. 
1.2.1 TRPV1 
TRPV1 channels are non-selective cation channels belonging to the 
transient receptors potential family (TRP). TRPV1 is a - 95kDa 
protein that has six transmembrane domains(Caterina, 1997) . 
TRPV1 is expressed primarily by small to medium diameter primary 
afferent fibres and is activated by noxious heat (>43 DC), low pH and 
capsaicin, an ingredient of chilli peppers. Activation increases the 
permeability of the plasma membrane to cations, such as sodium 
and calcium (Szallasi, 1994, Caterina, 1997). Several 
phosphorylation sites for PKC and PKA, as well as several 
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glycosylation sites playa pivotal role in the regulation of the activity 
of the TRPV1 receptor (see review (Nagy et aI., 2004». Evidence 
suggests that post-translation modification of TRPV1, such as 
phosphorylation increase the activity of TRPV1 receptor, PKA-
mediated phosphorylation increased the response of TRPV1 receptor 
to external activators such as prostaglandin E2 and AEA (Lopshire 
and Nicol, 1998, De Petrocellis et aI., 2001c), and reduces the heat 
threshold of the receptor (Rathee et aI., 2002). PKC-mediated 
phosphorylation of TRPV1 has been shown to be involved in the 
sensitising effects of some inflammatory mediators such as 
bradykinin, prostaglandins, and NGF released from injured tissue 
(Cesare and McNaughton, 1996, Caterina, 1997, Tominaga et aI., 
1998, Premkumar and Ahern, 2000), lowering the threshold of 
activation, thus implementing a role of TRPV1 in inflammation. 
Furthermore, TRPV1 expression is essential for the development of 
inflammatory heat hyperalgesia, which is absent in TRPV1 knock out 
mice (Caterina et aI., 2000, Davis et aI., 2000), and is upregulated 
following inflammation (Ji et aI., 2002b, Amaya et aI., 2003) (see 
chapter 3 for more detail). 
In contrast to this pro-nociceptive role of TRPV1 activation, 
prolonged activation the primary afferent neuron by an increase in 
intracellular calcium results in desensitisation, reduced activity of the 
sensory nerves (Cholewinski et aI., 1993, Koplas et aI., 1997) leading 
to reduced pain, and thus represents an intriguing target for the 
treatment of pain (Sasamura and Kuraishi, 1999). However the 
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mechanisms underlying desensitisation is unclear. The acute loss of 
neuronal activity may be due to a voltage-dependant inhibition of 
sodium or calcium channels that occurs at positive membrane 
potentials (Docherty et aI., 1991), whereas the long term inhibition 
through repeated exposure or high concentrations, capsaicin exerts 
neurotoxic effects in primary sensory neurones (Bevan and 
Szolcsanyi, 1990). The increase in intracellular calcium following 
capsaicin application causes the activation of Ca2+ -dependant 
enzymes and a decrease in mitochondrial function. Excessive influx 
of Na+ induces passive transport of cr into the cells, with a rise in 
osmotic pressure and finally cell death (Bevan and Szolcsanyi, 
1990). Desensitisation has been shown to depend on a variety of 
factors including capsaicin concentration, the duration and time 
between applications and the presence of extracellular calcium (Craft 
and Porreca, 1992; Liu and Simon, 1998) 
1.3 The dorsal horn of the spinal cord 
The dorsal hom of the spinal cord is comprised of 6 laminae (figure 
1.1), first described by Rexed in 1952, with laminae I, V, VI and X, 
and the outer part of laminae " associated with nociceptive 
processing (Todd, 2006). Dorsal hom neurones are made up of 
projection cells and intemeurones. Projection neurones relay 
information from the white mater to various supra-spinal sites, while 
intemeurones process information within the spinal cord. 
Intemeurons make up the majority of the neuronal population in the 
21 
General Introduction 
dorsal horn, and can be divided into two main functional classes: 
inhibitory interneurons, which use gamma amino butyric acid (GABA) 
as a transmitter, and excitatory interneurons, which are 
glutamatergic. The release of GABA, and, in many cases, co-
releasing glycine (Todd and Sullivan, 1990) is particularly relevant 
spinally and supraspinally in the modulation of nociceptive 
transmission (Malcangio and Bowery, 1996). This is illustrated by 
the finding that local blockade of GABAA receptors (GABAARs) and 
glycine receptors (GlyRs) replicates symptoms of neuropathic and 
inflammatory pain (Yaksh, 1989, Sivilotti and Woolf, 1994). 
Furthermore blocking this form of inhibition also allows low threshold 
input to be relayed to nociceptive specific neurons (Baba et aI., 2003, 
Torsney and MacDermott, 2006). 
With regards to their processing of nociceptive input, neurones in the 
dorsal horn can be divided into 3 populations. The first type consists 
of non-nociceptive low threshold neurones located in laminae II, III, 
and VI, and receive input from AI3 fibres. The second type consists 
of nociceptive-specific neurones, these are high threshold neurones, 
which are typically silent, and activated by noxious stimUli via A ~ ~ and 
C fibres. The third are wide dynamic range neurones, which are 
typically found in laminae IV, V, X, however also located in laminae I 
and II. These neurones encode information from a wide range of 
stimuli including noxious and innocuous inputs relayed by AI3, A ~ ~ and 
C fibres (Millan, 1999b, Willis, 2004). Interneurones relay 
information from primary afferent fibres between and within each of 
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the laminae, while projection neurones transmit nociceptive 
information from laminae I, V, and VI to higher brain centres (Millan, 
1999a). 
Figure 1.1 
__ - Aa.fiber 
__ - A ~ f i b e r r
.-- Aofiber 
C fiber 
Anatomy of the dorsal horn, divided into laminae I -VI and primary 
afferent fibre innervation. Taken from (Squire, 2003)©. 
1.3.1 Ascending pathways 
From the dorsal horn neurones, noxious messages are relayed to the 
brain via various ascending pathways. The major pathways involved 
in pain processing are the spinothalamic tract (STT), and the 
spinobulbar tracts (consisting of the the spinomesencephalic tract, 
the spinoparabrachial tracts, the spinohypothalamic tract and the 
spinoreticular tract) (Millan , 1999b, Dostrovsky, 2006) see Figure 1.2. 
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The STT originates from 3 distinct regions, laminae I accounting for 
approximately 50% of the STT cells, laminae IV-V, accounting for 
25% of the SIT cells and the remaining 25% are found in laminae 
VII-VIII. These neurones project to various parts of the thalamus, 
which plays a key role in the integration and transmission of 
nociceptive information (Millan, 1999b). The thalamus can be 
divided into lateral thalamus, responsible for the sensory and 
discrimative aspects of pain, the medial thalamus, involved in the 
affective and motivational aspects of pain, and the ventroposterior 
thalamus, leading to the somatosensory cortex, thought to be 
important in regulating pain perception (Dostrovsky, 2006). 
Branches of the SIT also travel to the PAG, and drive inhibitory 
control mechanisms. 
The spinobulbar tract projections terminate in 4 main region; the 
regions of catecholamine cell groups (A1-A7); the parabrachial 
nucleus (PB); the periaqueductal grey (PAG); the brain stem reticular 
formation (Dostrovsky, 2006). Catecholamine cell groups form part 
of the autonomic nervous system and activate somato-autonomic 
reflexes as well as descending pro and anti nociceptive mechanisms 
(Dostrovsky, 2006). A major target of the spinomesencephalic tract 
is the parabrachial nucleus (PS) of the pons. The PB projects to the 
hypothalamus, amygdala, midline and intralaminar thalamus, and to 
part of the ventrobasal thalamus (VMb, or VPMpc). Two pathways 
also run to the PB; the spinoparabrachiohypothalamic and 
spinoparabrachioamygdaloid pathways, thus the PB can be 
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accessed by several ascending pathways making it the main 
pathway by which nociceptive information reaches areas involved in 
the emotional aspects of pain. The hypothalamus and medial 
thalamus also have projections to the periaqueductal gray (PAG) and 
are again involved in emotional aspects of pain (Dostrovsky, 2006). 
The PAG is a major site of homeostatic and limbic motors output, as 
well as having ascending and descending projections to the spinal 
cord. Activation of this region produces descending inhibitory control 
of nociceptive processes, making it a region involved antinociception. 
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Figure 1.2 
The major ascending and descending spinal pathways involved in 
nociceptive processing. The prominant ascending pathways shown in 
(a) are the spinoparabrachial pathway (red), and the spinothalamic 
pathway (blue) originating in superficial layers of the dorsal horn, 
projecting to the thalamus and hypothalamus. The descending 
pathway shown in (b) originates from the amygdala and 
hypothalamus and terminates in the periaqueductal grey (PAG). 
Subsequently neurones project from to the rostral ventral medulla 
(RVM) and control many of the antinociceptive and autonomic 
responses that follow noxious stimulation. 
(A, adrenergic nucleus; bc, brachium conjunctivum; cc, corpus 
callosum; Ce, central nucleus of the amygdala; Hip, hippocampus; ic, 
internal capsule; LC, locus coeruleus; PB, parabrachial area; Po, 
posterior group of thalamic nuclei; Py, pyramidal tract; RVM, 
rostroventral medulla; V, ventricle; VMH, ventral medial nucleus of 
the hypothalamus; VPL, ventral posteriolateral nucleus of the 
thalamus; VPM; ventral posteriomedial nucleus of the thalamus.) 
(take from (Hunt and Mantyh, 2001). 
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1.3.2 Descending pathways 
Pain can arises from actual or potential tissue damage, and serves 
as a protective mechanism; however, many factors including other 
stimuli and stress can affect the perception of pain, via a number of 
centrally mediated inhibitory pathways. This is an essential 
mechanism of protection to enhance an individual's survival. 
The PAG plays a major role in the mediation and transmission of 
nociceptive signals within the eNS (Fields et aI., 1991), and inhibition 
of nociceptive responses is produced by descending pathways from 
supraspinal sites to the spinal cord, see Figure 1.2 (Millan, 2002). 
Indeed, the first evidence for it's role in the control of nociceptive 
responses was when Berhbehani et al demonstrated that direct 
stimulation of the PAG produces analgesia (8ehbehani and Fields, 
1979). The PAG projects to the rostal ventromedial medulla (RVM) 
and nociceptive information and modulation of the pain response in 
the dorsal horn is under bi-directional control from the PAG and the 
RVM (Fields and Heinricher, 1985). The RVM contains two types of 
neurones that mediate the inhibitory effects from the RVM to DH, 
'ON' and 'OFF' cells, which either produce a burst of activity prior to a 
behavioural response or stop firing prior to the behavioural response, 
respectively. Descending inhibition is thought to be modulated by 
'OFF' cells, whereas, 'ON' cells are involved in descending facilitation 
of nociception, with neurones terminating in the dorsal horn. The 
RVM is an important site of action for opoid mediated analgesia 
(Mitchell et aI., 1998), as well as analgesic actions of cannabis-based 
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compounds (Meng et aI., 1998). Microinjection of WIN55,212-2, the 
CB1/CB2 agonist into the RVM produced an increase in tail-flick 
latency (Meng et aI., 1998), however this effect was not inhibited by 
the opoid receptor antagonist, naloxone, suggesting that the 
inhibitory effects of cannabinoids is not mediated by opioids (Meng et 
aI., 1998), demonstrating a role of endogenous cannabinoid receptor 
system in nociceptive processing. 
1.4 Peripheral sensitisation 
Peripheral sensitisation contributes to the pain hypersensitivity found 
at the site of tissue damage and inflammation. Peripheral 
sensitisation is a reduction in threshold and an increase in 
responsiveness of the peripheral ends of nociceptors that transfer 
nociceptive information from peripheral targets (skin, muscle, joints 
and the viscera) though peripheral nerves to the central nervous 
system. Sensitisation arises due to the action of inflammatory 
mediators released around the site of tissue damage or inflammation. 
Tissue damage can either directly, or indirectly, cause the release of 
glutamate, bradykinin, cytokines, substance P, opioids, calcitonin 
gene related protein (CGRP), histamine, protons, nitric oxide, 
adenosine phosphates (including adenosine triphosphate, ATP) and 
arachidonic acid metabolites, such as prostaglandins from 
neighboring cells including neutrophils and mast cell. These 
mediators can exert direct effects by activating nociceptors, or 
indirectly by activating immune cells, thus increasing the 
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responsiveness of peripheral nociceptors to produce hyperalgesia 
(Meyer, 2006). In addition to these mediators, cytokines and 
neurotrophins are also generated during tissue damage which can 
contribute to changes in receptor expression and ion channels 
permeability, decreasing the threshold required for their activation, 
such as the TRPV1 (figure 1.3). 
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Figure 1.3 Overview of peripheral sensitisation of nociceptive neurons following tissue injury. Tissue injury leads to 
the synthesis and release of pro-inflammatory mediators from tissue around the site of injury, this leads to the 
activation of respective receptors and voltage gated ion channels. Collectively this leads to an increase in 
intracellular calcium, activation of adenylyl cyclase and subsequent activation of PLC/PKA pathways, leading to the 
sensitisation and phosphoryltion TRPV1 receptors, Na + channels of the peripheral terminals of nociceptive neurons, 
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ASIC, acid-sensing ion channel; TRPV1, transient receptor potential vanilloid receptor 1; CLR, Calcitonin-like 
receptor; B1/2, Bradykinin receptor; EP1-4, prostaglandin receptors; TrKA, neurotrophic tyrosine kinase receptor; 
CGRP, calcitonin gene related protein; ATP, adenosine triphosphate; NGF, nerve growth factor; PGE2, 
prostaglandin E2; PKA, protein kinase A; PKC, protein kinase C; PLC, phosholipase C; Many changes are effected 
by phosphorylation of receptors or channels (P), (adapted from Meyer., 2006). 
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The mechanisms by which inflammatory mediators exert their effects 
differ greatly depending on the compound in question. 
Bradykinin is formed from kininogen precursor's proteins following 
tissue damage and plays an important role in inflammatory pain and 
hyperalgesia. It acts at G protein coupled B 1 and B2 receptors. B2 
receptors are constitutively expressed on a wide range of cells, 
including nociceptive neurones. B1 receptors are not expressed under 
normal conditions, but are induced following tissue injury, thought to be 
as a result of cytokine release (Perkins and Kelly, 1994). Bradykinin 
mediated activation of sensory neurons is via a marked rise in [Ca2+]j 
and activation of the diacylglycerol (DAG) and protein kinase C (PKC) 
pathway (Burgess et aI., 1989, Bleakman et aI., 1990b). However 
another route by which bradykinin is thought to exert its effects is via 
sensitisation of TRPV1 receptor in a PKC-dependent manner 
(Premkumar and Ahern, 2000, Sugiura et aI., 2002). B2 receptor 
agonists have also been shown to drive the generation of 
prostaglandins (Lembeck et aI., 1976, Sauer et aI., 1998), which in turn 
can sensitise neurones (Dray et aI., 1992, Maubach and Grundy, 1999). 
Prostaglandins are synthesized form arachidonic acid, derived from 
membrane phospholipids which are metabolised by cyclooxygenase 
enzymes (COX-1 and COX-2). COX-2 is induced following 
inflammation, and is responsible for the production of PGE2 and PGI2, 
which play a role in acute and chronic inflammation (Minami et aI., 
2001; Stock et aI., 2001). Prostaglandins act upon distinct prostanoid 
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receptors including EP1, EP2, EP3, EP 4 and IP that activate several 
different G protein-coupled signalling pathways including the stimulation 
of adenylyl cyclase and subsequent increase in cAMP (Narumiya et aL, 
1999, Breyer et aL, 2001, Narumiya and FitzGerald, 2001). PGE2 and 
PGI2 sensitise afferent neurones via a PKC and PKA dependant 
pathway (Pitchford and Levine, 1991, Lopshire and Nicol, 1998, Smith 
et aL, 2000) as well as increasing intracellular calcium (Gu et aI., 2003) 
ATP also plays an important role in nociceptive processing; it is 
released following damage to cells or activation of nociceptors. ATP 
binds to P2X receptors, which are cation selective ATP-gated ion 
channels on neurones asnd activation results in rapid depolarisation 
and increase in intracellular calcium (Millan, 1999b). An increase in 
extracellular protons, results in a reduction in pH, which has also been 
demonstrated to produce sustained discharges in DRG neurons (Steen 
et aL, 1995, Vyklicky et aL, 1998). The role of neurotrophins such as 
NGF and brain-derived neurotrophic factor (BDNF) in mediating 
neuronal responses under pathological conditions is becoming more 
evident. NGF stimulates mast cells to release histamine and serotonin 
and can induce heat hyperalgesia by acting directly on the peripheral 
terminals of primary afferent fibres (Chuang et aI., 2001). Furthermore 
NGF increases the percentage Ar5 fibres that respond to mechanical 
stimuli (Stucky et aI., 1999) and is implicated in inflammation-induced 
changes in nociceptor response properties, such as an increase in 
incidence of ongoing activity of dorsal root ganglion neurons (Djouhri et 
al., 2001). Cultured DRG neurons innervating inflamed tissue exhibit 
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spontaneous activity, and cultured DRG neurons from non-inflamed 
tissue exhibit spontaneous activity when cultivated for 1 day with NGF 
(Kasai and Mizumura, 2001), suggesting a role of NGF in spontaneous 
activation of DRG neurones. Moreover, NGF also potentiates the 
responses of the TRPV1 receptor (and NGF-induced hyperalgesia is 
absent in TRPV1-knockout mice (Chuang et aI., 2001) indicating that 
this channel protein plays a critical role in inflammation-induced heat 
hyperalgesia (Caterina et aI., 2000, Davis et al., 2000). 
1.5 Central sensitisation 
Central sensitisation is an increase in the excitability of neurons within 
the central nervous system, so that normal inputs begin to produce 
abnormal responses, resulting in hypersensitivity to pain signals. The 
increased excitability is triggered by a burst of activity in nociceptors 
(such as that evoked by an injury), which alter the strength of synaptic 
connections between the nociceptor and the neurons of the spinal cord 
(namely activity-dependent synaptic plasticity), which ultimately causes 
an increase in membrane excitability, or reduced inhibition. Low-
threshold sensory fibers activated by innocuous stimuli activate 
normally high-threshold nociceptive neurons, producing allodynia. The 
pain, although evoked by a stimulus in the periphery, essentially arises 
as a result of changes in sensory processing within the CNS, and 
represents an abnormal state of responsiveness or an increased gain of 
the nociceptive system. Repetitive discharge of primary afferent 
nociceptors results in a release of modulators such as glutamate, 
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neuropeptides (substance P and (CGRP» and BDNF from the central 
terminals of the nociceptors (Kidd and Urban, 2001) which on binding to 
their corresponding receptors contribute to central sensitisation. For 
example, substance P, which is co-released with glutamate (Afrah et 
aI., 2002), binds to neurokinin-1 receptor (NK1), and causes long-
lasting membrane depolarization, which is abolished following NK1 
ablation using SPR-expressing neurons using the selective cytotoxin 
conjugate substance P-saporin (SP-SAP) (Khasabov et aI., 2002). 
Furthermore, CGRP, also synthesised in small diameter neurones 
(Woolf and Wiesenfeld-Hallin, 1986), potentates the effects of 
substance P and participate in central sensitisation through activation of 
postsynaptic CGRP1 receptors, which also activate PKA and PKC 
pathways (Sun et aI., 2004). 
The excitatory neurotransmitter glutamate acts at ionotropic glutamate 
receptors (AMPA, kainate and NMDA) or metabotropic glutamate 
receptors (mGluRs). Activation of the ionotropic glutamate receptors 
have been shown to play a role in central sensitisation. 
Phosphorylation of ionotropic glutamate receptors leads to an increase 
in synaptic efficacy by changing channel open time, increasing bursting, 
and removing the Mg2+ channel blockade at these receptors (Dickenson 
et al., 1997; Woolf and Salter, 2000). Inhibition of phosphorylation via 
the deletion of genes for isoforms of adenylate cyclase, protein kinase A 
and protein kinase C, impairs the development of pain hypersensitivity 
in transgenic mice (Malmberg et aI., 1997; Wei et aI., 2002). The role of 
activated glial cells in sensitisation of neurones in pathological 
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conditions has become more evident (Bruce-Keller, 1999, Hains and 
Waxman, 2006, Moalem and Tracey, 2006), with dorsal horn astrocytes 
and microglia activated following peripheral inflammation (Fu et aI., 
1999) and spinal nerve injury (Hashizume et aI., 2000), activating p38 
mitogen activated protein kinases (p38MAPK), and releasing pro-
inflammatory cytokines such as I L - 1 ~ ~ and TNFa, which increase COX-2 
activity and produces prostaglandins (Seybold et aI., 2003), such as 
PGE2, which binds to EP2 receptors to potentiate AMPA and NMDA 
receptors (Kohno et aI., 2008), thus reducing inhibitory glycine 
transmission (Ahmadi et aI., 2002). 
1.6 Animal models of pain 
Experiments on pain using human subjects are practically challenging, 
subjective, and ethically self-limiting, and thus laboratory animal models 
of pain are widely used. Animal models of pain are critical in 
understanding the mechanistic aspects of nociception, as well as 
understanding the analgesic activity of novel, or existing compounds. 
There are a number of different models commonly used, often in 
rodents, which mimic different clinical manifestations of pain. Models of 
acute nociception include the tail-flick, hot-plate and writhing tests 
(Walker et aI., 1999, Le Bars et aI., 2001), are useful for analysing the 
analgesic properties of drugs, but, bear few similarities to chronic 
pathological pain conditions observed in humans. Models of the 
mechanisms underlying chronic pain include injection of formalin, 
capsaicin, carrageenan or complete Freund's adjuvant (CFA) for 
inflammatory pain (Chapman et aI., 1985), and a nerve ligation to 
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induce neuropathic pain (Bennett and Xie, 1988). These models 
produce complex pathologies, similar to the clinical situation, with time-
dependent changes in nociceptive processing. 
1.7 Inflammatory Pain 
Inflammation is an essential protective reaction to irritation, injury or 
infection of tissue. It can be characterised by four signs; heat (calor), 
pain (dolor), redness (rubor), and swelling (tumor) as defined by Celsus 
in 1489. Pain arising from inflamed or injured tissues may arise 
spontaneously in the absence of an external trigger. Alternatively, 
responses to noxious stimuli may be enhanced (hyperalgesia) or 
normally innocuous stimuli may produce pain (allodynia). Tissue 
damage can be divided into 2 regions of pain, primary hyperalgesia, 
and secondary hyperalgesia. Primary hyperalgeisia is an area of actual 
tissue damage, which displays an increase in sensitivity to mechanical, 
thermal and chemical stimuli. This is due to a decrease in activation 
threshold, and therefore sensitisation of primary afferent fibre. 
Thresholds to mechanical stimuli are unaltered following heat or 
mechanical injury; however there is evidence that mechanical 
insensitive afferents become 
(Thalhammer and LaMotte, 
sensitised following inflammation 
1982, Campbell et aI., 1988). 
Responsiveness to suprathresold stimuli maybe augmented, where 
inflammation of the rat hind paw resulted in an enhanced response to 
mechanical stimuli, spontaneous activity, and an expansion of receptor 
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fields for both A- and C-fibre nociceptors results in the activation of a 
greater number of fibres (Levine, 1999). Under normal circumstances, 
the production of pain from activation of nociceptors with mechanical 
stimuli is modulated in the eNS by the simultaneous activation of low-
threshold mechanoreceptors. Injury decreases the responsiveness of 
low-threshold mechanoreceptors (Beck et aI., 1974), thus hyperalgesia 
to mechanical stimuli may be due to injury to low-threshold 
mechanoreceptors, which would lead to a central disinhibition of 
nociceptor input. Injury also results in the local release of pro-
inflammatory mediators, such as TNFa, bradykinin, prostaglandins, and 
histamine, and can lead to recruitment of immune cells local to the site 
of injury, such as T-cells, B-cells, mast cells and leukocytes (Levine and 
Reichling, 1999). Proinflammatory mediators can lead to a sensitisation 
of the nociceptor response, as well as having synergistic effects in 
potentiating nociceptor responses. Secondary hyperalgesia involves 
the area surrounding the region of tissue damage and displays an 
increase to mechanical stimuli only. When nociceptive input from the 
eNS is spared at the time of injury, hyperalgesia does not develop 
(LaMotte et aI., 1991), suggesting that central sensitisation, not 
peripheral sensitisation, plays a major role in secondary hyperalgesia 
(Levine, 1999). As mentioned previously, in order to investigate the 
mechanisms underlying inflammatory pain, several animal models of 
inflammatory pain have been developed, one of which is the 
carrageenan model of inflammation. 
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1.7.1 The carrageenan model of inflammation 
Carrageenan is a polysaccharide extract of the red seaweed, chrondus 
crispus used to induce inflammation in animals. Injection of the noxious 
stimulant, first described by Winter et ai, 1962, is a model of rapid onset 
inflammatory pain (Winter et aI., 1962). Inflammation induced by 
carrageenan, is an acute, and non-immune response. In rats, 
carrageenan, when injected subcutaneously into the plantar surface of 
a paw, produces characteristic inflammation, oedema, redness and 
associated hyperalgesia, which can be assessed through changes in 
weight bearing and paw pressure sensitivity (Hargreaves et ai, 1988). 
Tissue damage following carragaeenan results in the release of 
inflammatory mediators such as prostaglandins (Blackman et ai, 1979), 
Nitric Oxide (NO) (Salvemini et ai, 1996) Histamine (AI-Haboubi et ai, 
1983), bradykinin (Buritova et ai, 1997), pro-inflammatory cytokines 
(Loram et ai, 2006) and NGF (McMahon et ai, 1996), from the site of 
injury or by infiltrating cells which migrate to the site of inflammation, 
such as neutrophils and mast cells. Carrageenan-induced pain 
behaviour is dependant on the release of histamine (Oi Rosa et aI., 
1971, Stochla and Maslinski, 1982, AI-Haboubi and Zeitlin, 1983), as 
well a NGF from mast cells (Friedman et aI., 1990, Leon et aI., 1994), 
which can activate and/or sensitise receptors and primary afferent fibres 
leading to a increase in hindpaw receptive field size (Elmes et aI., 
2005). These pain-related behaviours peak at approximately 3hours 
following carrageenan injection (Hargreaves et ai, 1988). This model 
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can therefore be used to quantify the anti-inflammatory or anti-
hyperalgesic actions of drugs. 
1.8 Current analgesic treatments 
Opioids are the major analgesics in the treatment of moderate to severe 
pain, however due to there adverse side effects such as constipation, 
nausea, respiratory depression, and tolerance towards the compounds 
(Ikeda et aI., 2002), further pharmacological agents are necessary. 
Non-selective NSAIDs such as aspirin, ibuprofen and diclofenac are 
commonly used for the treatment of mild to moderate acute and 
inflammatory pain. They act both centrally and peripherally (during 
inflammation), by inhibiting COX metabolism of arachidonic acid to pro-
inflammatory and pro-nociceptive prostaglandins (see review (Rao and 
Knaus, 2008». Two isoforms of the COX enzyme have been identified 
namely COX1 (Vane, 1971, 1976) and COX2 (Masferrer et aI., 1990, 
Xie et aI., 1991). The COX-1 isoform is constitutively expressed in high 
levels in cells and tissues such as endothelium, monocytes, and 
platelets (Smith and Dewitt, 1996), and is thought to be responsible for 
unwanted effects of NSAIDs on the gastrointestinal tract (Chan et aI., 
1995). The COX-2 enzyme is induced by mediators of inflammation 
such as, IL-1, and TNF-a in a wide variety of cells and tissues such as 
vascular endothelium, and macrophages, hence playa prominent role 
in inflammation. Therefore it was thought that targeting the COX-2 
isoform would improve current anti-inflammatory and analgesic agents, 
with reduced adverse side effects compared to current NSAIDS. In 
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1999, Pfizer launched the first selective COX-2 inhibitor celecoxib, 
which was followed by the launch of Merck's selective COX-2 inhibitor 
rofecoxib prescribed for long term pain relief with reduced side effects 
associated with NSAIDs. However both drugs were removed from the 
markets due to adverse cardiovascular effects (Melnikova, 2005, 
Sanghi et aI., 2006). Thus inhibition of COX2 may not be an ideal 
target for the development of analgesic medicines. There is still a lack 
of effective treatments for chronic inflammatory conditions such as 
rheumatoid arthritis (RA), without adverse effects. Furthermore, some 
conditions require specific treatment targeting key inflammatory 
mediators specific to the condition. TNFa levels are increased in the 
synovial fluid of patients suffering from RA (McNearney et aI., 2004), 
hence TNFa antagonists are used to treat RA patients unresponsive to 
NSAIDs (Rankin et aI., 1995, Maini et aI., 1999a, Maini et aI., 1999b, 
Curtis et aI., 2007, Wendling et aI., 2008, Li et aI., 2009). 
1.9 Cannabinoids 
Cannabinoid drugs have emerged as novel analgesics for the treatment 
of pain. The evidence for this is based on both clinical and preclinical 
research many individuals self-medicating with cannabis to relieve a 
range of conditions including MS and depression (Consroe et aI., 1997, 
Goodin, 2004, Prentiss et aI., 2004, Bottorff et aI., 2009). Additionally 
cannabis relieved chronic neuropathic pain from HIV-associated 
peripheral neuropathy (Abrams et aI., 2007), while MS patients self-
medicate with cannabis to relieve spasticity and chronic pain associated 
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with the disease (Consroe et aI., 1997, Goodin, 2004). In addition to 
smoking cannabis, a9-tetrahydrocannabinol (a9-THC) was found to 
alleviate chronic pain condition (Naef et aI., 2003, Svendsen et aI., 
2004, Nurmikko et aI., 2007, Narang et aI., 2008) suggesting a clinical 
potential of cannabis based medicines. This lead to the development 
and licensing of a9-THe based medicines such as Marinol (dronabinol) 
Sativex. Marinol is a pure synthetic version of a9 -THC and is used to 
treat loss of appetite in people with AIDS, and to treat severe nausea 
and vomiting associated with cancer chemotherapy (Seamon, 2006). 
Sativex is a whole plant extract containing a9-THC and cannabidiol 
(CBO) (another active constituent of cannabis) in a known quantity/ratio 
of each compound and is used for the treatment of chronic pain, such 
as neuropathic pain in patients with MS and cancer-related pain 
(Nurmikko et aI., 2007, Rog et aI., 2007). It has also been reported that 
Sativex produces a significant analgesic effect and suppresses disease 
activity in patients with RA (Blake et aI., 2006). Collectively, these 
applications suggest a clinical potential of cannabis-based medicines. 
1.10 Cannabinoid Receptors 
The analgesic properties of the cannabis sativa plant have been known 
for thousands of years. Cannabis contains 60 or more bioactive 
phytocannabinoid compounds including a9 -THC which is the major 
psychoactive component (Mechoulam and Gaoni, 1967). These 
compounds interact with cannabinoid receptors, two of which (CB1 and 
CB2) have been cloned. 
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The CB1 receptor is expressed in neuronal tissue, both centrally and 
peripherally, as well as in other peripheral organs. CB1 receptors are 
also present at lower densities in the heart, lung, testis, ovary, bone 
marrow, thymus, uterus and immune cells (Galiegue et a/., 1995). The 
CB1 receptor is the most abundant G protein-coupled receptor in the 
brain (Herkenham et a/., 1990), with particularly high levels of 
expression in the striatum, cerebellum, basal ganglia, cerebral cortex 
and hippocampus (Herkenham et aI., 1990, Herkenham et aI., 1991). 
The widespread distribution of the CB1 receptor is consistent with the 
range of effects of cannabinoid agonists, including hypomotility, 
increased food intake, disruption of short term memory, antinociception, 
and anxiolysis effects. The distribution of CB1 receptors in the PNS and 
CNS corresponds with several major sites involved pain transmission 
and modulation, such as dorsal root ganglion (DRG), spinal cord, 
thalamus, periaqueductal grey (PAG), amygdala and rostroventromedial 
medulla (Tsou et aI., 1998, Hohmann and Herkenham, 1999, Ahluwalia 
et al., 2000). 
CB2 receptors are mainly expressed, at high densities, in immune 
tissues, including macrophages, mast cells, and the spleen. However, 
recent work has reported the presence of CB2 mRNA in the spinal cord 
of control rats (Beltramo et al., 2006) and CB2 receptor protein in brain 
tissue (Van Sickle et aI., 2005, Gong et aI., 2006). However a 
functional imaging study demonstrated that CB2 receptor antagonism 
did not alter brain activation evoked by systemic administration of a 
non-selective cannabinoid agonist, whereas CB1 receptor antagonism 
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did (Chin et al., 2008), suggesting that there is little CB2-mediated 
cannabinoid-induced changes in brain activity under control conditions. 
Both CB1 and CB2 receptors are inhibitory Gi protein-coupled receptors 
reducing the formation of the key second messenger, cyclic AMP 
(Matsuda et al., 1990). CB1 receptor activation also inhibits N-, L-, and 
P/Q-type Ca2+ channels and activates K+ channels and MAP kinases 
(for review see Howlett at al., 2002). Thus, CB1 activation inhibits 
neurotransmitter release and neuronal excitability. CB1 receptors are 
present pre-synaptically on axons and terminals of neurones (Egertova 
and Elphick, 2000) and are ideally located for the modulation of 
synaptic activity. 
CB2 receptors are also coupled to similar signal transduction 
mechanism to CB1 in terms of their actions on adenylyl cyclase and 
MAP kinases, but do not share the same interactions with ion channels 
as CB1 receptors (for review see Howlett at al., 2002). 
A third G protein-coupled receptor, GPR55, binds a number of 
cannabinoid ligands and, therefore, has been proposed to be a member 
of the cannabinoid receptor family (Brown, 2007, Johns et aI., 2007, 
Ryberg et aI., 2007, Lauckner et aI., 2008, for review see Ross, 2009). 
There is increasing evidence for cannabinoid receptor-independent 
effects of cannabinoids, some of which are mediated through the 
peroxisome proliferator activator receptor (PPAR) family of nuclear 
receptors (Rockwell et aI., 2006, O'Sullivan, 2007, Russo et aI., 2007b, 
Sun et aI., 2007, Costa et aI., 2008). Three major isoforms (a, 13 and y-) 
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of this ligand-dependent transcription factor have been identified, with 
their roles in the regulation of lipid metabolism are well characterised 
and studied. Recent studies have demonstrated the involvement of 
PPAR-a and V in pain and inflammation (Genovese et aI., 2005, 
Cuzzocrea et aI., 2006, Sun et aI., 2007, Costa et aI., 2008, Jhaveri et 
aI., 2008b, Sagar et aI., 2008a, Staumont-Salle et aI., 2008). 
1.10.1 Cannabinoid receptor-mediated analgesia 
The analgesic effects produced by activation of CB1 receptors are well 
described and extensively reviewed (for reviews see Pertwee, 2001, 
Iversen and Chapman, 2002, Walker and Huang, 2002a). Activation of 
CB1 receptors in the spinal cord (Hohmann et aI., 1998, Kelly and 
Chapman, 2001) and in the periphery (Kelly et aI., 2003) attenuates 
nociceptive responses of dorsal horn neurones in na'ive rats. Supra-
spinal CB1 receptors contribute to the anti nociceptive effects of 
cannabinoids in models of acute pain (Welch and Stevens, 1992, 
Lichtman et aI., 1996, Welch et aI., 1998, Martin et aI., 1999). In 
addition to the analgesic effects seen following systemic and spinal 
administration of cannabinoids, peripheral mechanisms of cannabinoid 
analgesia have also been demonstrated. Anti-nociceptive effects of a 
CB1 receptor agonist were substantially reduced in mice with CB1 
receptor gene deletion in the peripheral nociceptors (Agarwal et aI., 
2007) and hindpaw injection of CB1 receptor agonists produces 
antinociceptive effects in models of inflammatory and chronic pain 
(Richardson et aI., 1998b, Clayton et aI., 2002, Kelly and Chapman, 
45 
General Introduction 
2002, 2003, Kelly et aI., 2003, Scott et aI., 2004, Elmes et aI., 2005). 
However, the broad distribution of CB1 receptors in the brain promotes 
both therapeutic effects, such as analgesia, as well as their unwanted 
psychotropic side-effects. 
A number of studies have demonstrated analgesic effects of CB2 
receptor agonists in models of acute and chronic pain, and have been 
reported to be devoid of CNS-mediated side effects (reviewed 
elsewhere by Jhaveri et aI., 2007a, Guindon and Hohmann, 2008). 
Administration of CB2 receptor agonists systemically (Malan et aI., 
2001, Valenzano et aI., 2005, Ibrahim et aI., 2006) or locally into the 
hindpaw (Malan et aI., 2001, Elmes et aI., 2004) attenuates nociceptive 
responses in naIve rats. Furthermore, there is evidence for a functional 
role of CB2 receptors in the spinal cord (Sagar et aI., 2005, Romero-
Sandoval et aI., 2008, Yamamoto et aI., 2008) and thalamus (Jhaveri et 
al., 2008a) of neuropathic rats. CB2 receptors are functionally up-
regulated in the ipsilateral spinal cord (Beltramo et al., 2006) and 
ipsilateral dorsal horn (Wotherspoon et al., 2005) in neuropathic rats. 
CB2 knockout mice exhibit exacerbated neuropathic pain behaviour, 
thought to be caused by enhanced microglia and astrocyte activation, 
where CB2 receptors are highly expressed, and may play important role 
in regulating neuropathic pain behaviour (Maresz et aI., 2005, Racz et 
aI., 2008). Collectively there is broad base of evidence supporting an 
important role of spinal CB2 receptors in the modulation of neuropathic 
pain responses. 
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1.11 Endocannabinoids 
Anandamide (N-arachidonyl ethanolamine, AEA) was the first 
endogenous ligand of the cannabinoid recptor to be isolated and 
characterised (Devane et aL, 1992a). It was identified by screening 
solvent extracts of porcine brain in a cannabinoid receptor radioligand 
binding assay, where AEA displaced radiolabelled cannabinoid 
receptors ligands. Determination of structure was performed using 
collision-induced dissociation GC-MS and NMR (Devane et aL, 1992b). 
Following advances in sensitivity and specificity of mass spectrometry, 
further ECs have been identified, namely, 2-arachidonoyl glycerol (2-
AG; Mechoulam et al., 1995), noladin ether (Hanus at al., 2001), 
virodhamine (Porter et al., 2002) and N-arachidonoyl dopamine (NADA; 
Huang et al., 2002). The structurally-related, N-acylethanolamines 
(NAEs) N-oleoyl ethanolamine (OEA) and N-palmitoyl ethanolamine 
(PEA) are also widely distributed in the CNS and periphery but are not 
considered endocannabinoids due to their lack of binding affinity for 
CB1 and CB2 receptors. They are, however, PPAR ligands (Guzman et 
aL, 2004, LoVerme et aL, 2006b). AEA, 2-AG, noladin ether, 
virodhamine and NADA display sub ~ M M affinity for cannabinoid 
receptors (Sugiura et al., 1995, Huang et aL, 2001, Porter et aL, 2002), 
however 2-AG has been suggested to be the most biologically 
important EC, as it occurs in greater concentrations in tissues, and 
shows greater binding efficacy at CB1 and CB2 receptors, than AEA 
(Sugiura et aL, 1997, Sugiura et aL, 1999, Sugiura et aL, 2000). 
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Endocannabinoids are widely believed to be synthesised on demand 
(i.e. not stored in any cellular compartment awaiting release) and their 
actions are rapidly terminated by being taken up into cells where they 
are subject to enzymatic hydrolysis. The anti-nociceptive effects of 
exogenously administered endocannabinoids have been well described. 
AEA has anti nociceptive effects in behavioural models of acute and 
chronic pain (for review see Pertwee, 2001). Similarly, 2-AG reduces 
pain behaviour in tail-flick (Mechoulam at al., 1995) and formalin tests 
(Guindon et al., 2007). 
1.12 Measurement of Endocannabinoids 
Much research has been devoted to studying the formation and 
deactivation of ECls in mammalian tissues. These analyses have 
initially relied on techniques such as thin-layer chromatography (TlC) 
and gas chromatography-mass spectrometry (GC/MS) (Giuffrida and 
Piomelli, 1998, Okamoto et aI., 2005). However, these techniques often 
require multiple analytical steps which are very time-consuming. Recent 
progress in liquid chromatography/mass spectrometry (lC/MS) has 
greatly facilitated these efforts, making it possible for the simultaneous 
measurements of varying components of the endocannabinoid system 
(precursors and metabolites), rather than its individual components, 
invaluable to the elucidation of the physiopathological roles of this 
signalling system. lC/MS allows the identification and quantification of 
individual endocannabinoid molecules in a single step. Furthermore, 
tandem mass spectrometry (MS/MS) provides detailed structural 
information necessary for the characterization of lipids in complex 
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biological matrices (Hansen et al., 1999). Ionization techniques such as 
electrospray ionization (ESI) and atmospheric pressure chemical 
ionization (APCI), which permit the direct coupling of lC to MS, has 
allowed researchers to identify and quantify the endocannabinoids with 
greater sensitivity than was possible with other techniques (Weber et 
aI., 2004, Richardson et aI., 2007, Schreiber et aI., 2007, Williams et aI., 
2007). Thus lC/MS is the ideal method for endocannabinoid analyses. 
These techniques have primarily used solvent based extractions 
methods to extract ECls from biological matrix (Schmid et aI., 1995, 
Giuffrida et aI., 2000a, Oi Marzo et aI., 2000 (a), Richardson et aI., 
2007). levels of ECls, particularly 2-AG are rapidly increased post-
mortem (Sugiura et a/., 2001), hence tissue must be snap-frozen to 
prevent artificial changes that may occur and interfere with the analysis. 
1.12.1 Endocannabinoid synthesis 
Several different pathways are suggested to contribute to the synthesis 
of the ECls (Figure 1.4). NAEs (AEA, OEA and PEA) are synthesised 
via their corresponding N-acylphosphatidyl ethanolamine (NAPE) 
precursor and are synthesized through the action of acyltransferase, 
which hydrolyses fatty acids from sn-1 position of phosphatidylcholine, 
and transfers it to the amine of phosphatidyethanolamine (PE). This 
was initially identified as a calcium dependant pathway (Hansen et aI., 
1995, Cadas et aI., 1996), however a calcium-independent PE N-
acyltransferase has recently been described (Jin et a/., 2007). The 
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NAPE-phospholipase D (PLD) pathway of NAE synthesis has been 
most widely studied (for review see Ahn et aI., 2009), producing NAEs 
and phosphatidic acid (Schmid et al., 1983). The regional expression of 
NAPE-PLD in the mouse brain has been reported (Egertova et al., 
2008). Disruption of NAPE-PLD gene in mice increased levels of the 
precursor NAPE, and decreased brain levels of saturated N-acyl chains 
(OEA and PEA) (Leung et al., 2006). By contrast, levels of longer chain 
polyunsaturated NAEs, including AEA (C20:4) were unaltered in knock-
out mice, compared to NAPE-PLD+1+ mice (Leung at al., 2006). 
Furthermore, in HeLa cells over expressing NAPE-PLD, cellular levels 
of OEA and PEA were increased, while levels of AEA were unaltered 
(Fu et al., 2008). This suggests that other pathways may contribute to 
the synthesis of AEA in the brain under control conditions. 
Two alternative pathways involving phospholipase-C (PLC)-PTPN22 
(Liu et al., 2008) and a ~ ~ hydrolase ( a ~ H 4 ) - G D E 1 1 (Simon and Cravatt, 
2008) are able to generate NAEs, including AEA (Figure 1.4). The 
functional relevance of these multiple pathways is yet to be determined, 
but they may subserve differential synthesis of NAEs that might be 
dependent on the tissue in question. Production of NAEs occurs 
following the PLC hydrolysis of NAPE producing acylethanolamine-O-
phosphates, which can be further hydrolysed by phosphatases PTPN22 
or SHIP1 (Liu at al., 2008). The role of PTPN22 and SHIP1 in EC 
synthesis, to date, requires further investigation. In vitro studies have 
suggested cross-talk between the PLC-PTPN22 pathway and the 
NAPE-PLD pathway (Liu et al., 2008). Lipopolysaccharide (LPS) 
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treatment of RAW264.7 cells increased levels of AEA despite reducing 
NAPE-PLD mRNA. siRNA knockdown of NAPE-PLD in RAW264.7 
cells did not alter basal levels of AEA, but increased LPS-stimulated 
AEA generation, compared to mock-transfected cells (Liu et al., 2008), 
providing further support for cross-talk between these synthetic 
pathways. These in vitro data suggest that when NAPE-PLD 
generation of AEA is compromised, the PLC-PTPN22 pathway may 
have a compensatory role in maintaining levels of AEA. 
Recent work has shown that biosynthesis of NAEs, such as AEA, 
occurs via a apH4-GDE1 pathway in mouse brain and testes (Simon 
and Cravatt, 2008). aJ3H4 is a Iysophospholipase/phospholipase B that 
hydrolyses NAPEs through removal of both O-acyl chains from NAPE to 
yield glycerophosphoNAE (GpNAE) (Simon and Cravatt, 2006). aJ3H4 
shows little selectivity between acyl groups, generating PEA at an equal 
rate to AEA (Simon and Cravatt, 2006). GDE1, an acyl chain specific 
phosphodiesterase, then converts GpNAE to NAE (Simon and Cravatt, 
2008). Blockade of this phosphodiesterase activity with EDTA 
increased levels of long chain polyunsaturated GpNAEs (C20:4, 
GpAEA) as well as shorter chain saturated and monounsaturated 
GpNAEs, (C16:0, GpPEA; C18:1, GpOEA) with no effects on long chain 
saturated (C20:0) species detected (Simon and Cravatt, 2008). The 
identification of these additional synthetic pathways is essential for the 
further investigation of the relative contribution of these pathways to 
functional levels of endocannabinoids under control conditions, as well 
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as under different pathological conditions, such as chronic pain states 
which are associated with elevated levels of endocannabinoids. 
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Figure 1.4 Proposed biosynthetic pathways for the generation of 
AEA from its arachidonoyl containing NAPE (NArPE) precursor. 
Abrev: PLC, phospholipase c: pAEA, phospho anandamide: SHIP1, 
SH2-containing inositol phosphatase: PTPN22, Protein tyrosine 
phosphatase, non-receptor type 22; AEA, anandamide; NArPE, N-
arachido- noylphosphatidylethanolamine; NAPE-PLO, N-acyl 
phosphatidyl ethanolamine; aJ3h4 N-acylphosphatidylethanolamine 
lipase; GP-AEA, glycerophospho anandamide; GOE1, 
glycerophosphoinositol phosphodiesterase. (Adapted from (Liu et 
aI., 2008, Simon and Cravatt, 2008)) 
The major pathway for the biosynthesis of 2-AG comprises sequential 
hydrolysis of arachidonic acid-containing inositol phospholipids by PLC 
and OAGL. 2-AG, is produced from hydrolysis of arachidonate-
containing membrane phosphoinositides (PI) or phosphatidic acid (PA) 
depending on the cell type (for review see; Bisogno et al., 2005). 2-AG 
is synthesized in response to many extracellular stimuli, such as, 
neurotransmitters, antigens, and growth factors (see review (Oi Marzo, 
2008, Wang and Ueda, 2008)), PLCs catalyze the hydrolysis of 
phosphatidylinositol-4,5-bisphosphate, thereby generating two second 
messengers, inositol 1,4,5-trisphosphate and diacylglycerol (Sugiura et 
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al., 1995). DAGL exhibits strong selectivity for diacylglycerols over 
phospholipids, monoacylglycerols, triacylglycerols and fatty acid 
amides, and prefers the acyl group at sn-1 position to that at sn-2, to 
yield monoacylglycerol and free fatty acid. Recently two cloned isomers 
have been identifed, DAGLa and ~ ~ (Bisogno at al., 2003). DAGLa 
appeared to be more abundant in the adult brain and D A G L ~ ~ abundant 
in the developing brain (Bisogno et aI., 2003). Interestingly, the cellular 
localization of two isomers shifted during brain development. They 
appeared to be co-localized with CB1 in neuronal axons of the pre-natal 
nervous system, while they moved to a location corresponding to CB1, 
i.e. to post-synaptic neurons, in the adult brain (Bisogno at al., 2003) 
Recent morphological studies confirmed that DAGLa is localized on 
postsynaptic sites that face CB1-expressing terminals in the cerebellum 
and hippocampus, (Yoshida et aI., 2006, Suarez et aI., 2008) supporting 
the role of 2-AG as a retrograde messenger (Hashimotodani at al., 
2008). Although DAGL has long been identified and well characterised, 
its role in modulation of nociceptive processing is only just starting to 
emerge. DAGLa mRNA is present in the superficial dorsal horn 
neurones of the spinal cord (Nyilas at al., 2009), a region that plays a 
key role in the receipt and processing of nocieptive inputs. 
1.12.2 Endocannabinoid modulation of nociception 
It is well established that cannabinoid receptor ligands produce 
analgesia, however investigating whether endogenously produced 
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Eels have anti-nociceptive effects is more complex. Electrical 
stimulation of the PAG produced anti-nociceptive effects, which was 
associated with an increase in AEA in microdialysate (Walker et aI., 
1999a). levels of endocannabinoids are altered under pathological 
conditions such as inflammation and neuropathic pain (see review 
(Jhaveri et al., 2007a». We have demonstrated a significant reduction 
in levels of AEA and PEA in the hindpaw of rats with carrageenan-
induced hindpaw inflammation (Jhaveri et al., 2008a). Similarly, levels 
of AEA, 2-AG and PEA were decreased in the hindpaw following 
intraplantar injection of formalin (Maione et al., 2007). By contrast, 
Beaulieu et al., reported no significant alteration in levels of AEA, 2-AG 
and PEA in the hindpaw of formalin-treated rats (Beaulieu et aI., 
2000b). In addition to altering levels of endocannabinoids at the site of 
injury, inflammation can caused an increase in levels of Eels at other 
sites involved in nociceptive processing. Intraplantar injection of 
formalin increased levels of AEA in the PAG indicating a role for 
endocannabinoids in descending control of pain processing (Walker et 
al., 1999b). Furthermore, levels of Eels are altered in different pain 
states, which may reflect altered synthesis or catabolism. levels of 
Eels are increased in the spinal cord (Jhaveri et aI., 2006, Petrosino et 
aI., 2007, Jhaveri et aI., 2008b) and DRG (Mitrirattanakul at al., 2006) 
following peripheral nerve injury. 
1.12.3 Endocannabinoid metabolism 
To date, hydrolase and oxygenase pathways have been shown to be 
the major pathways responsible for the metabolism of the 
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endocannabinoids, in particular AEA and 2-AG (Figure1.5). 
Hydrolysing enzymes include fatty acid amide hydrolase (FAAH), 
monoacylglycerol lipase (MAGL) and N-acylethanolamine-hydrolysing 
acid amidase (NAAA). AEA and other NAEs are mainly hydrolysed by 
FAAH through the hydrolytic cleavage of the amide bond to form 
arachidonic acid and ethanolamine (Deutsch and Chin, 1993, Cravatt et 
aL, 1996, Vandevoorde and Lambert, 2007). FAAH is a membrane 
bound enzyme found predominately in microsomal and mitochondrial 
fractions (Schmid et aL, 1985, Desarnaud et aL, 1995, Hillard et al., 
1995, Ueda et aL, 1995a). FAAH has an intracellular substrate binding 
site for fatty acid ethanolamides (Cravatt et aL, 1996) and has a high 
level of expression in rat brain and liver (Desarnaud et aL, 1995, 
Egertova et aL, 1998, Watanabe et aL, 1998), as well widespread 
distribution in neuronal cells throughout the CNS (Thomas et aL, 1997). 
The distribution of FAAH is correlated with that of the CB1 receptor, 
FAAH enzyme activity is high in the hippocampus, neocortex, 
cerebellum and olfactory bulb regions of the rat brain, areas which are 
also enriched with cannabinoid receptors (Herkenham, 1991). FAAH is 
expressed in neurons that are postsynaptic to CB1-expressing axons 
(Egertova et aI., 1998). An additional isoform of FAAH, FAAH2, has 
been identified in humans and other primates, but not in rodents (Wei et 
a/., 2006). 
2-AG is mainly metabolised by MAGL to arachidonic acid and glycerol 
(Oinh et aI., 2002, Vandevoorde and Lambert, 2007). NAAA is a 
lysosomal enzyme with optimum activity at an acid pH. It can 
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metabolise AEA and PEA to their corresponding fatty acids and 
ethanolamine, but 2-AG is a poor substrate (Tsuboi et al., 2007). It is 
poorly expressed in the brain and is unlikely to be an important route of 
endocannabinoid metabolism under normal conditions. 
AEA and 2-AG are also substrates for the oxidative enzymes, such as 
COX-2, lipooxygenase (LOX) and cytochrome p450s (CYP450s) (see 
review (Kozak and Marnett, 2002). COX, LOX and CYP450 are not 
specific to endocannabinoid catabolism, however their effects on 
endocannabinoids is of great interest, due to the potential production of 
pharmacologically active metabolites. 
COX-2 is constitutively expressed in the kidney, spinal cord, 
hippocampus, cortex and hypothalamus (Vandevoorde and lambert, 
2007) and it is up-regulated in pathological states, such as inflammation 
(Sam ad et al., 2001). AEA and 2-AG can be converted by COX-2 to 
prostaglandin-ethanolamides (Prostamides; PG-EA) and prostaglandin 
glyceryl esters (PG-GE), respectively (Burstein et aI., 2000, Kozak et 
aI., 2001 a, for reviews see; Kozak and Marnett, 2002), of which seem to 
be biologically active. The PG-EAs are weakly active at cannabinoid 
CB1 and CB2 receptors and PGF2a-EA has weak agonist effects at 
TRPV1 (Matias et aI., 2004, Fowler, 2007). Numerous in vitro studies 
have shown the ability of COX-2 to metabolise Eels (Kozak et aI., 
2001a, Kozak et al., 2002a, Kim and Alger, 2004, Ho and Randall, 
2007, Rockwell et al., 2008), however, evidence for a physiological role 
in vivo is more elusive. PGD2-EA and PGE2-EA are present, following 
systemic administration of AEA, in mouse lung and kidney, with higher 
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levels seen in AEA-treated FAAH knockout mice, compared to control 
mice. PGF2a-EA was only detected in the liver, kidney, lung and small 
intestine of AEA-treated FAAH knockout mice (Weber et al., 2004). 
Biological effects of the COX2 metabolite of 2-AG, PG-GEs have been 
demonstrated in the hippocampus where they modulate GABAergic 
mediated inhibitory synaptic transmission (Sang et al., 2006) and 
enhance hippocampal glutamategic transmission and neurotoxocity 
(Sang et al., 2007). The potential role of COX2 metabolites of 2-AG in 
pain processing have not been widely studied. Intraplantar injection of 
PGE2-GE produced mechanical analgesia and thermal hyperalgesia, 
suggesting that pro-nociceptive ligands could be generated by the 
COX2 metabolism of 2-AG in vivo (Hu at al., 2008). They also detected 
the presence of PGE2-GE in the naIve and inflamed rat hindpaw, with 
levels unaltered following inflammation when COX-2 would be 
upregulated. Levels of PGE2-GE were below detection limits in the 
spinal cord and brain in naIve rats and inflamed rats (Hu et al., 2008). 
Further studies are required to determine whether PG-EA and PG-GE 
are produced, and involved in nociceptive processing in models of 
inflammatory or neuropathic pain. 
The ECs are also metabolised by lipooxygenases (LOX) and 
cytochrome p450s (CYP450s). The main isoforms of lipooxygenase 
that metabolise AEA and 2-AG are 5-LOX, 12-LOX and 15-LOX 
generating hydroperosyeicosatetraenoic acids (HPETEs) (see review 
(Kozak and Marnett, 2002). LOX metabolites are also 
pharmacologically active at CB1 and CB2 receptors (Edgemond et al., 
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1998), TRPV1 receptors (Craib et al., 2001) and PPAR receptors 
(Kozak et al., 2002b). CYP450 enzymes 206, 3A4 and 4F2 produce 
several metabolites of NAEs including 5,6-epoxyeicosatrienoic acid 
ethanolamide (5,6-EET-EA), which is more stable than AEA in brain 
homogenate and is a potent and selective CB2 agonist in vitro. 
Activated BV-2 microglial cells had an increased capacity to convert 
AEA to 5,6-EET -EA, which may have relevance to neuropathic pain 
states. However, the role of CYP450s metabolites such as 5,6-EET-EA 
in the modulation of central sensitisation in models of chronic pain is 
unknown, and warrants investigation. A group of CYP450 metabolites 
of AA were identified in the spleen, kidney and brain and were termed 
2-epoxyeicosatrienoyl-glycerols (2-EGs). Some of these products, 2-
(11,2-epoxyeicosatrienoyl)glycerol (2-11,12-EG) and 2-(14,15-
epoxyeicosatrienoyl)glycerol (2-14, 15-EG) have high affinity for CB1 and 
CB2 receptors in transfected CHO cells (Chen et al., 2008). 2-EG is 
present in the brain, however, whether 2-EG produces CB1 receptor-
mediated analgesia remains to be determined. Overall these studies 
have shown that the metabolism of endocannabinoids via the hydrolase 
and oxidative pathways has the potential to generate various 
modulators of physiological I pathophysiological processing. 
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Figure 1.5 Proposed metabolic pathways for the breakdown of AEA 
(red) and 2-AG (blue) via hydrolase and oxygenase pathways. Red= 
metabolites of AEA, Blue=metabolites of 2-AG. 
1.12.4 Attenuation of endocannabinoid catabolism 
The role of F AAH in the metabolism of endocannabinoids has been 
demonstrated in mice lacking FAAH, which exhibit 15 fold elevated 
levels of AEA, compared to wild-type mice. FAAH-1- mice display 
phenotypic hypoalgesia in models of acute and inflammatory pain 
(Cravatt et aI., 2001, Lichtman et aI. , 2004b), but not neuropathic pain 
(Lichtman et al., 2004b). Furthermore, pharmacological inhibition of 
FAAH is antinociceptive in models of acute and inflammatory pain 
(Kathuria et aL , 2003a, Lichtman et aL, 2004a, Fegley et aL , 2005, 
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Chang et al.. 2006. Jayaman'ne et aI., 2006a, Ahn et aI., 2009). For 
example, a single systemic injection of the FAAH inhibitor URB597 
significantly reduced thermal allodynia and mechanical hyperalgesia in 
the Complete Freunds adjuvant (CFA) model of inflammation 
(Jayamanne et aI., 2006a). In the carrageenan model of inflammation, 
intraplantar injection of URB597 increased levels of AEA and 2AG in 
hindpaw skin and reduced carrageenan-hyperalgesia (Jhaveri at al., 
2008b). The effects of FAAH inhibition in models of inflammatory pain 
will be discussed in greater detail in chapter 4. The effects of inhibition 
of FAAH on neuropathic pain behaviour are less consistent than those 
reported for inflammatory pain states. Acute systemic injection of 
URB597 (0.3 mg/kg, Lp.) did not alter mechanical allodynia in a model 
of peripheral neuropathy (Jayamanne et aI., 2006a). Similarly, a single 
oral dose of URB597 (10 mg/kg, p.o.) had limited effects on mechanical 
hyperalgesia in the chronic constriction injury (Cel) model of peripheral 
neuropathy (Russo et al., 2007a). By contrast, repeated administration 
of URB597 (10 mg/kg, for 4 days p.o.) significantly reduced thermal and 
mechanical hyperalgesia (Russo et al., 2007a), suggesting that 
repeated administration of a FAAH inhibitor may produce analgesia, 
and have more therapeutic relevance. 
The focus of research in this area has centred on prevention of AEA 
catabolism by FAAH, largely due to the lack of selective inhibitors for 
the major 2-AG catabolic enzyme; MAGL (Comelli et aI., 2007, Guindon 
et aI., 2007, Vandevoorde et aI., 2007). Recently a novel compound, 
JZL 184, which has over 300 fold selectivity for MAGL over FAAH in 
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vitro, significantly increases levels of 2-AG in vivo and produces 
analgesia in mouse models of acute and inflammatory pain has been 
described (long et al., 2009). 
Indeed, the quantification of ECls and their metabolites in tissues 
involved in pain processing is required in order to understand the 
mechanisms involved, and may lead to a more targeted approach to the 
development of cannabinoid-based analgesics. 
Considerable progress has been made in understanding the 
physiological and pathological roles of endocannabinoids. Advances 
liquid chromatography (lC) and mass spectrometry (MS) have aided 
these developments, and can be combined with genetic and 
pharmacological studies to address many unexplained questions on the 
roles and regulation of endocannabinoid signalling 
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1.13 Aim and objectives: 
The aim of this thesis is to develop a sensitive lC-MS/MS method 
capable of measuring levels of endocannabinoids and COX-2 
metabolites of AEA and 2-AG, in one analytical step, and determine 
their role in nociceptive processing in acute and chronic models of 
inflammation. 
Objectives 
1. The development of sensitive lC-MS/MS method capable of 
measuring levels of ECls and COX-2 metabolites of AEA and 2-
AG in biological tissue. 
2. To determine the role of FAAH and other catabolic pathways in 
the regulation of ECs in models of inflammatory pain. 
3. To investigate the contribution of peripheral versus spinal sites of 
action of elevated ECls in mediating the analgesic effects of 
FAAH inhibition. 
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Chapter 2. 
Development and validation of a 
quantitative analytical method to 
measure levels of 
endocannabinoids and COX-2 
metabolites in rat tissue 
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2 Development and validation of a quantitative 
analytical method to measure levels of 
endocannabinoids and COX-2 metabolites in rat 
tissue 
2.1 Introduction 
Measurement of levels of ECls and related compounds in biological 
tissue can provide vital information regarding the role of the EC system 
in various disease states, and the therapeutic relevance of the ECl 
system. 
Quantification of ECls by lC/MS has been carried out in a wide variety 
of biological matrices, including brain (Gonzalez et aI., 2002, Valenti et 
aI., 2004, Richardson et aI., 2007), cell (Ahluwalia et aI., 2003a. van der 
Stelt et aI., 2005, Vellani et al .• 2008). and blood plasma (Giuffrida et al.. 
2000a, Balvers et al .• 2009. Oi Marzo et al.. 2009, Koppel et al.. 2009). 
but current methods do not allow for the simultaneous profiling of ECls 
and related compounds. such as COX-2 metabolites, now known to be 
potentially involved in physiological and pathophysiological conditions. 
For example. bimatoprost a structural analogue of prostaglandin-F2a 
ethanolamide (PGF2a-EA), has therapeutic potential as an anti-
glaucoma agent due to its effects on ocular hypotension (Woodward et 
al.. 2004), and prostaglandin-E2 glycerol ester (PGE2-GE) has been 
shown to modulate inhibitory synaptic transmission in primary 
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hippocampal neurons (Hu et aI., 2008). Thus, the development of new 
analytical methodology would help to gain an insight into ECl 
regulation, such as monitoring their synthesis and metabolism, thus 
providing a better insight into the role of the ECl system in many 
disease states. 
2.1.1 Endocannabinoid metabolism 
Although many aspects of endocannabinoid metabolism are under 
investigation (see reviews (Oi Marzo, 1999, Alexander and Kendall, 
2007, 8asavarajappa, 2007, Jhaveri et aI., 2007a), the specific 
contributions of each of the biosynthetic and degradative enzymes that 
have been identified in ECl generation and metabolism are still not fully 
understood. There is great interest in delineating the detail of ECl 
metabolic pathways, but progress is difficult with the available analytical 
methodology. AEA is predominately metabolised by fatty acid amide 
hydrolase (FAAH), and 2-AG by monoacyl glycerol lipase (MAGl), 
however, AEA and 2-AG can be also be metabolized, via oxidation, by 
cyclooxygenase-2 (COX-2), 12- and 15-lipoxygenase (lOX), and 
cytochrome P450 (CYP450) to generate ethanolamide and glycerol 
derivatives respectively (see Figure 1.5, chapter 1). 
2.1.2 Measured levels of endocannabinoids metabolites 
using LC-MS/MS 
To date, there are limited stUdies which demonstrate the presence of 
metabolites of AEA and 2-AG in vivo. lC/MS/MS analysis of rat 
hind paw detected the ammonium adduct of PGE2-GE, which was 
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further confirmed using quadrapole time of flight mass spectrometer 
(Hu et aI., 2008). The hindpaw extract was partially purified on solid-
phase extraction columns and further purified on a HPlC column prior 
to structural identification using nano-lC Q-TOF. However, the 
extraction and lC/MS method was not validated and quantification was 
via direct injection of standards of only one metabolite of 2-AG (Hu et 
aI., 2008). COX-2 metabolites of AEA were present in mice liver, kidney 
lung and small intestine following the exogenous administration of AEA 
in FAAH knock-out mice (Weber et aI., 2004). However, they were 
unable to separate PGD2-EA and PGE2-EA, therefore, the 
concentrations of these two PG-EAs were reported as the sum, PG-E2-
EA and PGD2-EA. Furthermore, quantification was performed using 
two sets of MRM transitions: one MRM set involved monitoring parent 
ions [M+Ht ~ w a t e r r loss [M+Ht - H20 daughter ions; and the second 
set of MRM monitored parent ions [M+Ht ~ t h a n o l a m i d e e selective mlz 
62 daughter ions, where [M+Hr -iwater loss [M+Ht - H20 was used for 
the quantification of prostamides, however the MRM ion pair of [M+Ht 
> ion of mlz 62 and retention times, confirmed that these were PG-EAs 
containing the ethanolamide moiety, and that the peaks quantitated 
were PG-EAs (Weber et aI., 2004). Mouse brain homogenates contain 
CYP450 metabolites of AEA (5,6-epoxyeicosatrienoic acid 
ethanolamide (5,6-EET -EA» which were detected using the less 
sensitive and specific selected reaction monitoring (SRM) (Snider et aI., 
2009). Many of the analytical methods used for ECl metabolites lack 
full validation of the extraction and quantification procedures. The lack 
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of consistent data on ECl metabolites may be due to the low sensitivity 
of available methods, or the lack of specific extraction procedures to 
provide adequate recovery of the less lipophilic ECl metabolites. The 
extraction solvent usually contains appropriate internal standards, which 
also act to compensate for analyte loss during sample preparation. 
Careful consideration of extraction procedures, may extract other 
relevant lipids, such as the more polar metabolites of AEA and 2-AG, 
known to be biologically relevant, such as COX-2 metabolites of AEA 
and 2-AG. 
Prior to analysis, ECls and metabolites must first be efficiently 
extracted from the biological matrix. The extraction procedures, unless 
managed carefully can lead to several problems leading to false results 
such as the rapid biosynthesis or metabolism of ECls in vivo, and 
variable recovery of the polar/non-ploar lipids. Also, levels of ECls can 
rapidly increase post mortem (Sugiura et al., 2001), therefore the 
amount of time between death and tissue collection and snap freezing 
must be as quick as possible to prevent artificial changes in levels and 
consistency between tissues for comparison. 
Due to the relatively hydrophobic nature of the ECls, a variety of 
mixtures of organic solvents have been utilized to extract lipid classes 
from biological samples, including 1:1 methanol:acetonitrile (Koppel et 
aI., 2009), 9:1 ethyl acetate:hexane (Kingsley and Marnett, 2003, 
Richardson et aL, 2007), 2:1 chloroform/methanol (Oi et aI., 2005, 
Williams et aL, 2007, Vellani et aL, 2008). However, metabolites of 
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ECls, such as COX-2 metabolites of AEA and 2-AG, are more polar, 
thus requiring more polar extraction solvents, such as acetonitrile 
(Weber et aI., 2004), acetonitrile:water (Kozak et aI., 2000) and 
methanol (Hu et aI., 2008). The extraction procedure for both class of 
compounds are not necessarily compatible, thus leading to potential 
difficulties in their simultaneous quantitative measurement in biological 
samples. 
There is also significant interest in the quantification of Eels and 
related compounds in biological matrixes with very low sample weight 
such as synovial fluid, and microdiaysate samples. Furthermore, 
metabolites of ECs are expected to be in low concentration, so also 
would require a sensitive method for the detection of these compounds. 
Recently published data has shown the amount of PGE2-GE in the 
hindpaw to be in the femtomole range, whereas 2-AG is found in the 
nanomole range (Hu et aI., 2008). Thus, there is the requirement for a 
more sensitive method capable of measuring EeLs in low weight tissue, 
as well as their metabolites. This type of sample requires methods to 
have even more increased sensitivity but with sufficient robustness to 
allow routine analysis. Use of nanospray ionisation in mass 
spectrometry has, for example, increased sensitivity but has not proved 
very useful, with blocked columns, leaks and pressure drops to name 
but a few problems (for review see(Noga et aI., 2007). Thus there is the 
need for a single analytical method, capable of quantifying EeLs, PG-
EA's and PG-GE's, in one analytical step, which could provide important 
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mechanistic detail in models of pain, and perhaps other models 
involving the EC signalling system. 
2.2 Aims and objectives 
The main specific objectives are: 
1. To optimise lC separation and MS conditions for the 
simultaneous and high sensitivity analysis of ECls and their 
COX-2 metabolites 
2. To asses tissue extraction methods to give optimal recovery if 
ECls and metabolites. 
3. To validate the lC-MS/MS method for application to rat bio fluids 
and tissue. 
4. To evaluate the method and compare with existing 
methodologies. 
Upon successful completion of these aims, the developed method will 
then be used in subsequent chapters of this thesis, to quantify ECls 
and related compounds in spinal cord, paw, and cell samples, as well 
as other tissue of interest in in vivo models of peripheral inflammation 
and in vitro model of sensory sensitisation, to investigate the role of the 
EC system in nociceptive processing. 
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2.3 Method 
2.3.1 Chemicals 
Acetonitrile, anhydrous chloroform, ethanol, toluene, ethyl acetate, 
hexane, ammonium acetate, triethylamine (TEA), trifluoroacetic acid 
(TFA) and formic acid were all from Fisher Scientific (Loughborough, 
UK). AEA, 2-AG, virodhamine, DEA, PEA, PGD2-EA, PGE2-EA, 
PGF2a-EA, PGE2-GE, PGF2a- GE, deuterated anandamide (AEA-d8), 
deuterated 2-AG (2-AG-d8) , and deuterated prostaglandin F2a 
ethanolamide (PGF2a-EA-d4) were from Cayman Chemicals (Cayman 
Europe, Estonia). HPLC grade water, (Elga Ltd., High Wycombe, UK) 
was used for all experiments. Trichlorotrimethyl silane was from Sigma-
Aldrich (Steinheim, Germany). All solvents and chemicals were of HPLC 
grade or higher. 
Mobile phases were filtered using 0.47 IJm nylon filters before use 
(Whatman, Maidstone, UK). 100 mg silica, solid phase extraction 
cartridges were used (Phenomenex, Macclesfield, UK). 
AEA, AEA-dS, virodhamine, OEA, PEA, PGD2-EA, PGE2-EA, PGF2a-
EA, and PGF2a-EA-d4 stock solutions were prepared in ethanol. 2-AG 
is known to be more stable in acetonitrile and, therefore, this solvent 
was used in all dilutions of 2-AG and the structurally related glycerol 
compounds such as 2-AG-d8, PGE2-GE, and PG F2a-GE. All stock 
solutions were stored at -SOoC. Further dilutions were carried out as 
70 
Development and validation of a quantitative analytical method to measure levels of 
endocannabinoids and COX-2 metabolites in rat tissue 
appropriate in LC mobile phase, acetonitrile or ethanol, and were used 
within two weeks, following storage at -800 C. There was no evidence of 
degradation of the standards under these conditions of storage. 
2.3.2 LC-MS/MS conditions 
A triple quadrupole Quattro Ultima mass spectrometer (Waters 
Micromass, Manchester, UK) was used in conjunction with an Agilent 
1100 LC system (Agilent Technologies, Waldbron, Germany), with 
cooled 4°C autosampler. The final optimised method LC column was a 
Waters Symmetry C18 column (100 x 2.1 mm id, 3 . 5 ~ m m particle size, 
Hertfordshire, UK), maintained at 40°C with a mobile phase flow rate of 
0.3 ml/min. When more sensitivity was required, a triple 
quadrupole/linear ion trap (4000QTRAP) mass spectrometer (AB Sciex 
Instruments, UK) was used in conjunction with Shimadzu LC system 
(Shimadzu, Milton Keynes, UK) using a Thermo Hypersil-Keystone BDS 
C18 (150 x 1mm Ld 5 ~ m m particle size, Thermo Fisher Scientific, 
Runcorn, UK). Gradient elution mobile phases consisted of A (water, 
1 gIL ammonium acetate, 0.1 % formic acid at pH 3.6) and B 
(acetonitrile, 19/L ammonium acetate, 0.1 % formic acid). The gradient 
and flow rates for both LC/MS systems were slightly different and are 
summarised in table2.1. 
Sample temperature was maintained at 4°C in the auto sampler prior to 
analysiS. During method development stages other LC columns and 
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conditions were tested and used to optimise results, and are discussed 
later in the chapter. 
Quattro Qtrap 
Time 'lOA 'lOB Flow(ml/min) Time 'lOA 'lOB Flow(ml/min) 
0 15 85 0.3 0 15 85 0.15 
2 25 75 0.3 2 25 75 0.15 
6 25 75 0.3 4 25 75 0.15 
8 35 65 0.3 10 45 55 0.15 
9 0 100 0.3 12 100 0 0.15 
15 0 100 0.3 14 100 0 0.15 
16 85 15 0.3 14.2 15 85 0.15 
20 85 15 0.3 20 15 85 0.15 
Table2.1 HPLC conditions 
Quantification of analytes was undertaken using tandem electrospray 
mass spectrometry, in positive ion mode (ES+). MS parameters, such 
as cone voltage and positioning (for Quattro MS), and declustering 
potential (for QTRAP MS) were optimised to maximise production of the 
precursor ion by direct infusion of the standard into the MS, using single 
MS monitoring. Cone and desolvation gas flows of 174 and 844 Uhr 
with source and desolvation temperatures of 125°C and 350°C 
respectively were used. Subsequently, MS-MS product ion spectra 
were acquired, monitoring for each precursor [M+H]+ ion with varying 
entry, collision and exit energies. The dominant product ion for each 
compound was selected for monitoring in MRM mode, with optimisation 
of collision energy (argon gas induced dissociation). Identification of 
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compounds in biological tissue was confirmed by comparison of 
precursor and product ion m/z values and LC retention times, with 
standards. Peaks were then integrated and the software package 
MassLynx version 4 (Waters, Micromass, Manchester, UK) for Quattro, 
or using Analyst (for QTRAP) used to quantify levels of the ECLs. 
Optimised mlz values for Quattro MS showing the chosen precursor 
and product ions, cone voltages and retention times for each compound 
are shown in Table 2.2, whereas table 2.3 shows the optimised m/z 
values for QTRAP MS, including precursor and product ions, 
declustering potential, retention times, and entrance and exit energies. 
2.3.3 Sample extraction 
The extraction solvents acetonitrile, methanol, hexane and ethyl 
acetate/hexane were investigated in various combinations, to determine 
optimal conditions for maximum recovery of analytes from rat brain 
tissue (male Sprague-Dawley rats, Charles River UK). 
Because some of the analytes are endogenously produced in brain 
tissue there is a lack of an appropriate 'blank' matrix. Analytes were, 
therefore, spiked into rat brain tissue to determine accuracy, precision 
and recovery of method, correcting for the presence of endogenous 
analytes. To ensure homogeneity, brain tissue was placed into liquid 
nitrogen, and ground in a porcelain pestle and mortar, before being split 
into approximately equal 100 mg aliquots for recovery and validation 
experiments. This ensured that there were constant and equivalent 
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background concentrations of all the endogenous cannabinoids in the 
samples used for recovery and validation. 
Recoveries were calculated by spiking 20 IJI of 1 nM, 10 nM and 100 
nM of AEA, DEA, PEA and virodhamine, 10 nM, 100 nM and 1 IJM of 2-
AG, PGD2-EA, PGE2-EA, PGF2a-EA, PGE2-GE, and PG F2a-GE into 
100mg rat brain tissue. The peak area obtained was then subtracted 
from back ground concentrations and expressed as a percentage of 
non-extracted standards at the same concentration. Recovery 
experiments were replicated a minimum of 3 times. Homogenisations 
were carried out on ice to prevent any degradation of analytes or 
internal standards. Adaptations of the extraction procedure were also 
investigated in order to allow extraction from other types of biological 
tissue including rat paw, rat spinal cord tissue, and cell tissue. ECls 
were extracted from rat brain tissue in the final method using an 
acetonitrile extraction, adapted from a previously published method 
(Weber et aI., 2004). Tissue was minced using scalpel blades, and 
transferred into a glass tube with acetonitrile and internal standards. 
This mixture was then briefly homogenised to break up the tissue and 
shaken at 4°C for 60 min. Samples were centrifuged (7,OOOxg, 5 min, 
4°C) and the supernatants transferred to clean glass tubes. The 
homogenisation, mixing and centrifugation steps were repeated twice, 
with the supernatants pooled, to optimise recovery. The pooled 
supernatants were then evaporated to dryness under vacuum and 
stored at -80°C until analysis. 
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2.3.4 Validation 
For each of the analytes of interest triplicate six-point calibration curves 
were prepared at concentrations of 0.001 nmol/g, 0.0.1 nmol/g, 0.1 
nmol/g, 0.5 nmol/g, 2.5 nmol/g, and 10 nmol/g using rat brain tissue. 
The peak area of each analyte, expressed as a ratio to internal 
standard peak area was then calculated and used to ensure linearity of 
the method. The appropriate internal standard for each analyte was 
selected based on structural similarities, as shown in Figure 2.1. The 
slope, intercept and regression coefficient of each calibration line was 
determined. 
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Analyte Retention Precursor ion Product ion Cone voltage Collision 
time (min) (m/zvalue) (mlzvalue) (eV) energy (eV) 
PEA 14.22 300.30 62.00 35 15 
OEA 14.30 326.40 62.00 51 16 
AEA 13.42 348.30 62.00 35 12 
Virodhamine 12.55 348.30 62.00 35 12 
AEA-d8 13.42 356.33 62.00 48 21 
PGD2-EA 9.81 378.24 62.00 35 24 
PGE2-EA 8.58 378.24 62.00 35 24 
PGF2a-EA 8.24 380.50 62.00 35 37 
PGF2a-d4-EA 8.17 384.5 62.00 35 37 
2-AG 13.78 379.20 287.50 55 15 
2-AG-dB 13.78 387.35 96.17 43 34 
PGE2-GE 11.31 409.20 91.30 43 70 
PGF2a-GE 10.31 411.20 91.30 43 70 
Table 2.2 
Selected precursor and product rnlz values with appropriate retention times, cone and collision voltages used 
to identify and quantify analytes, using MRM mode on the Quattro tandem-mass spectrometry machine. 
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Analyte Retention Time Q1 Mass (amu) Q3 Mass (amu) Declustering Entrance Collision Exit Potential 
Potential Potential E n e r g ~ ~
AEA 15.6 348.5 62.2 51 10 41 15 
PEA 15.47 300.5 62.2 50 10 35 15 
OEA 15.53 326.4 62.2 70 5 35 5 
2-AG 15.35 379.2 287.02 60 10 17 15 
AEA-d8 15.14 356.5 63.2 50 10 41 15 
2-AG-d8 15.32 387.2 96 60 10 80 15 
PGD2-EA 9.56 378.5 62.2 80 10 36 10 
PGE2-EA 9.10 378.4 62.2 80 10 38 10 
PGF2a-EA 9.10 380.4 62.2 65 10 40 10 
PGE2-GE 10.51 409.3 91.3 80 10 75 15 
PGF2a-GE 10.40 411.3 91.3 80 10 90 15 
PGF2a-EA-d4 9.10 384.3 62 70 10 35 15 
Table2.3 Selected precursor and product mlz values with appropriate retention times, cone and collision voltages used to identify 
and quantify analytes, using MRM mode on the QTRAP4000 mass spectrometry machine. 
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Figure 2.1 Chemical structures of the endocannabinoids and related 
compounds, (A) ) - shows AEA and structurally related compounds 
using AEA-ds as an internal standard; (8) shows prostamides using 
prostaglandin ethanolamide as an internal standard (C) - shows 2-AG 
and structurally related compounds using 2-AG-ds as an internal 
standard. 
To determine intra-day (n=6) and inter-day (n=6 over a period of 5 
separate days) preCision and accuracy, analyte concentrations of 0.001 
nmol/g, 0.1 nmol/g and 1 nmol/g of AEA, PEA ,OEA and virodhamine, 
0.1 nmol/g, 1 nmol/g, 10 nmol/g 2-AG, 0.005 nmol/g , 0.1 nmol/g , 1 
nmollg PG-EAs, and 0.5 nmollg, 2.5 nmollg, and10 nmollg PG-GEs 
were spiked into rat brain tissue and homogenised with extraction 
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solvent then analysed for all compounds. Due to the reduced MS 
ionisation efficiency of 2-AG and PG-GEs higher concentrations were 
used for these analytes. Precision was calculated from the RSD% of 
the replicates, and accuracy by comparison of measured levels of 
spiked analytes with expected concentrations (RSD%). A RSD% of 
20% was considered acceptable for accuracy and precision at the lower 
limit of quantitation (LLOQ). The limit of detection (LOD) of each 
compound was defined as the concentration at which a signal to noise 
ratio of greater than 3: 1 was achieved following direct analysis from a 
stock solution. Recovery was calculated by comparison of the 
integrated area under the curve for each of the eight analytes at the 
low, medium and high analyte concentrations with 100% standards. To 
allow accurate calculation of recovery, endogenous levels of ECs and 
related compounds were determined and corrections made to 
calculations. The recovery of all three internal standards (AEA-d8, 2-
AG-d8 and PGF2a-EA-d4) was also determined, but as they are not 
present in biological tissue, without any correction for endogenous 
concentration. 
Validation procedures were based on the recommendation of 
Bioanalytical method validation published by the US Food & Drug 
administration (FDA). 
2.3.5 Quantification of endocannabinoids, prostaglandin 
ethanolamides and prostaglandin glycerol esters 
Quantification was accomplished through at least a five point calibration 
curve. The peak area was expressed as a ratio of the peak area of the 
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corresponding internal standard, based on structure similarity, as shown 
in figure 2.1. AEA-d8 was used for the quantification of AEA, OEA and 
PEA, PGF2a-d4 was used for the quantification of PG-EA's, and 2-AG-
d8 was used for 2-AG and PG-GEs as there is no commercially 
available internal standard for PG-GE. A standard regression curve 
was plotted to ensure linearity. The slope, intercept, and regression 
coefficient was calculated, and the slope was used in calculation for 
amounts of each compound of interest, with correction for dilution and 
weight. Data are expressed as pmollg for AEA, PGD2-EA, PGE2-EA, 
PGF2a-EA, PGD2-GE, and PG F2a-GE and nmollg for OEA, PEA and 
2-AG 
2.3.6 Direct comparison of two MS systems to ensure 
consistency in data 
To ensure direct comparision of methods used in this research, samples 
were also ran on a triple quadrupole Quattro Ultima mass spectrometer 
and compared to the data obtained using a triple quadrupolellinear ion 
trap (4000QTRAP) mass spectrometer. 
Animals were killed by stunning and then decapitation (see chapter 4 for 
further details). Hindpaw were dissected rapidly on ice and placed 
immediately onto dry ice. Tissue collection was standardised as far as 
possible to minimise differences between researchers, and samples 
were stored immediately at -80°C to minimize postmortem increases in 
Eel levels. Then this tissue was extracted and analysed, as previously 
described on both systems, to provide a direct quantitative comparison 
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of levels of Eels and related compounds in rat hind paw on both 
instruments. Samples were stored at -80°C to prevent degradation of 
compounds prior to analyses. 
2.3.7 Data Analysis 
Comparison of concentrations of ECs between treatment groups was 
carried out using Mann-Whitney non-parametric test, as these data 
were shown not to be normally distributed. Significance level was set at 
the P<0.05. Data are expressed as mean ± SEM. 
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2.4 Results and Discussion 
2.4.1 Analytical Development 
2.4.1.1 MS parameters 
The LC-MS/MS method was optimised from Richardson et aI., (2007) to 
allow for the quantification of COX-2 metabolites of AEA and 2-AG. 
The strong ethanolamine fragment (m/z 62) was selected as the product 
ion for ethanolamine containing ECs (AEA, OEA, PEA), PGD2-EA, 
PGE2-EA and PGF2a-EA which are consistent with other work done in 
both our group (Richardson et aI., 2007) and others (Weber et aI., 2004, 
Yang et aI., 2005), respectively. PGD2-EA and PGE2-EA had identical 
fragmentation patterns, with both compounds having identical 
precursors at m/z 378 and product ion at m/z 62, but were 
distinguishable by a difference in chromatographic retention time. The 
parent ions of PG02-EA, PGE2-EA and PGF2a-EA (m/z 395.5 and 
397.5 respectively) were not detected due to in source fragmentation; 
hence 378 and 380 (loss of water) was used as the precursor for these 
compounds. AEA and virodhamine also have identical precursors and 
product ions, having [M+Ht at m/z 348>62, however they have a 
different LC retention time. The precursor/product ion values for 
PGF2a-EA were selected at m/z 380, which corresponds to the parent 
compound, with a loss of water, and the ethanolamine product ion at 
m/z 62. It was also noticed that the MS responses of 2-AG, COX-2 
metabolites of 2-AG, and other glycerol-containing compounds had 
reduced MS responses compared to other compounds. This is due to 
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reduced ion field from these compounds when using ESI method of 
fragmentation. The glycerol containing compounds did not produce 
such an obvious product ion, although continuing with previous studies 
m/z 92 was selected which corresponded to the loss of glycerol 
fragment (Bradshaw et aL, 2006, Richardson et aL, 2007, Hu et aL, 
2008). It was also noticed in the product ion spectra of compounds 
such as AEA, 2-AG, PG-EA, and PG-GE, the MS spectra looked more 
noisy, this was due to an increase in product ions that were spaced at 
approximately 14amu and 18 amu intervals, which may represent the 
systematic loss of methyl groups from the alkyl chain, and the loss of 
water from the prostaglandin-containing compounds (Figure 2.2). 
2.4.2 HPLC Development 
The main requirements of the HPlC method development were to 
1) Provide optimised retention/separation of ECls and the various 
metabolites. 
2) Separate PGE2-EA and PGD2-EA, as well as between AEA and 
virodhamine as they share the same molecular weight and give 
identical fragmentation patterns by ES+ MS (m/z values of 
precursor and product ions on MS). 
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Figure2.2 Product ion mass spectrums for each of the EC and PG-EA 
and PG-GE compounds, with the chosen precursor ion indicated with 
[M+Hr and product ion indicated by *, The common product fragment of 
all ethanolamide-containing compounds (m/z of 62) represents the 
ethanolamide portion of the compound, 
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2.4.2.1 Effects of column stationary phase on separation 
A direct comparison was made between a C8 and C 18 reversed phase 
HPlC column. The C8 column as this was found to give good analyte 
peak shape and resolution of ECs. However the C8 column gave a 
poor performance for the quantification of PG-EA and PG-GE, since 
these compounds are polar and were not retained on the column 
(Figure 2.3). The C18 column however, retained both the PG-EA and 
PG-GE and ECls, however better separation and resolution was 
achieved with a 100 mm, 3.5 IJm particle size column, compared to a 
150 mm, 5 IJm particle size length column (Figure 2.3). It has been 
previously shown that the use of C 18 columns for the quantification of 
PG-EA and PG-GE provides retention and resolution of these 
compounds, ( Hu et aI., 2008; Kingsley et aI., 2005; Kozak et aI., 2002; 
Weber et al., 2004), thus a Waters Symmetry C18 column (100 x 
2.1 mm id, 3.5 IJm particle size, Hertfordshire, UK) was used. 
For the analysis of ECls, PG-EA and PG-GE in low weight tissue 
samples such as cell and micro-dialysate samples maximum sensitivity 
was required, which was achieved using a C18 micro column, 1mm 
diameter coupled to QTRAP MS. The reduction from a 2.1 mm internal 
diameter to a 1 mm internal diameter increases the sensitivity 5 times, 
based on the equation (i.d2/Ld2) (Steiner, 1991), thus (2.1 2/1 2)=4.41x 
increase in sensitivity. 
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2.4.2.2 Effects of mobile phase composition on separation 
Mobile phase composition was varied to determine the optimum 
separation composition and condition. This was based on the previous 
analytical method used within our group (Richardson et aI., 2007) and 
on currently used analytical methods for the measurement of COX-2 
metabolites (Kozak et aI., 2002a, Weber et aI., 2004, Kingsley et aI., 
2005). This included varying the amount of acetonitrile as the organic 
component, varying the acid and buffer concentrations and trying 
isocratic and gradient based methods. It was also noted that for 
PGF2a-EA, a peak was detected in biological tissue at approximately 
15 min, however due to the retention time of the synthetic standard 
being approximately 8 min; this was deemed to be an unknown 
compound and not PGF2a-EA (Figure 2.5). Obtaining the correct 
organic starting composition proved vital in this method, as this 
controlled whether separation of PGD2-EA and PGE2-EA was 
achieved, and it was found that 15% organic achieved this, the final 
gradient conditions are summarised in table 2.1 There was a subtle 
effect of mobile phase pH on the retention of analytes, and varying the 
pH of the mobile phase did not significantly improve separation of 
PGD2-EA and PGE2-EA, therefore as in previous studies, a pH of 3.6 
was used (Richardson et ai, 2007). A typical extracted ion 
chromatogram of the optimised method is shown in Figure 2.4. 
Therefore for modified LC method a C18 column, with internal diameter 
of either 2.1 mm or 1 mm was used depending on the tissue, with a 
starting acetonitrile organic concentration of 15% was used to 
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successfully retain and separate PGD2-EA from PGE2-EA, and AEA 
from virodhamine. The final method is described in section 2.3.2- 2.3.3. 
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Figure2.3 Comparison of chromatographic separation of A, PG-EA and PG-
GE; B, AEA, OEA, PEA, 2-AG and virodhamine; using 2 different stationary 
phases, C8 and C 18 . (1) Initially a Thermo Hypersil-Keystone HyPurity 
Advance column was used (150 x 2.1 mm internal diameter, 50 particle 
size)(Richardson et aI., 2007). (2) Improvements in PG-EA and PG-GE 
retention were seen with a Waters Symmetry C18 column, (150 x 3.5mm 
internal diameter, 50 particle size) (3) However, the most significant 
improvement observed was with a shorter Waters Symmetry C18 column (100 
x 2.1 mm id, 3.5 Om particle size, Hertfordshire, UK), with further retention of 
prostamides. Chromatograms were obtained using a Hewlett Packard 1100 LC 
system. 
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Figure 2.4 Representative chromatograms of the optimised separation 
of synthetic standards. Virodhamine and AEA and PGE2 EA and PGD2 
EA standards share the same precursor and product m/z values, and 
are therefore, differentiated solely by chromatographic separation. 
Appropriate retention oftimes compounds shown by *. 
2.4.3 Extraction of Eels and related compounds 
After optimisation of the MS settings and LC separation the next stage 
was to evaluate a range of extraction solvents to enable the efficient 
extraction of ECs, PG-EAs and PG-GE from rat brain tissue. 
2.4.4 Effect of extraction solvent on recovery 
Previous stUdies have confirmed the presence of ECs in a variety of 
biological tissues, but there are conflicting reports regarding the 
presence of PG-EA and PG-GE in na'ive animal tissue. The majority of 
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evidence for the presence of PG-EA and PG-GE is derived from in vitro 
studies (Yu et aI., 1997, Kozak et aI., 2002a), yet there is evidence for a 
role of this route of metabolism under certain conditions in vivo, (which 
will be investigated further in chapter 4). PG-EAs were not detected in 
na"ive rat tissue, but were however detected following exogenous 
administration of AEA in FAAH knockout mice (Weber et aI., 2004). 
PGE2-GE was however, detected in the rat hindpaw (Hu et aI., 2008). 
Ethyl acetate:hexane (9:1) has been shown to give good recoveries of 
all the main ECs ranging from 78% to 138% (Richardson et aI., 2007). 
However, it was found that recovery of PG-EA and PG-GE was low, 
ranging from 38% to 57%. Therefore a new extraction solvent was 
needed. Literature searches have shown that methanol or acetonitrile 
can be used in the extraction of ECs, PG-EA and PG-GE (Kozak et aI., 
2000, Kozak et aI., 2001a, Weber et aI., 2004, Hu et aI., 2008). We 
therefore investigated the extraction of these compounds with various 
solvents at varying compositions (Table2.4). 
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% Recovery 
Extraction Solvent AEA 2-AG PGD2-EA PGE2-EA PGF2-EA PGD2-GE PGE2-GE 
Acetonitrile 91.2±3.5 87.3±8.1 87.1±13.5 92.1±3.4 94.2±13.7 71.6±14.9 76.3±12.2 
Methanol 89.1±5.1 74.2±9.1 42.2±16.5 23.7±5.7 43.7±12.5 65.2±15.8 75.3±10.2 
50:50 92.3±2.9 71.3±5.8 48.3±11.5 63.1±8.2 72.1±18.4 58.2±11.7 68.9±6.1 
Acetonitrile:Methanol 
50:50 Acetonitrile: Ethyl 89.39±7.2 69.2±6.7 79.2±11.5 92.8±3.5 87.2±13.7 39.7±14.2 47.3±12.0 
Acetate 
9:1 Ethyl Acetate: 98.8±8.2 85.3±2.4 36.5±19.5 56.2±9.2 42.0±10.2 27.8 ±3.7 38.2±7.2 
Hexane 
9:1 Acetonitrile: 86.2±9.5 71.2±8.5 59.3±19.4 63.4±14.2 43.8±19.3 49.3±17.4 87.3±7.7 
Methanol 
9:1 Ethyl Acetate: 91.2±6.3 88.3±7.5 56.2±17.5 78.2±12.3 77.2±13.5 59.1±13.2 68.1±10.3 
Acetonitrile 
8:1:1 Ethyl Acetate: 83.2±7.2 66.3±8.2 31.2±15.8 21.8±5.2 28.7±9.8 33.4±9.8 42.0±8.4 
Acetonitrile: Hexane 
8:1:1 Ethyl Acetate: 84.2±10.2 68.3±6.1 58.7±16.3 28.7±7.9 18.7±4.2 51.2±11.0 49.2±7.9 
Methanol Hexane 
Table2.4 The recovery of a representative structurally similar compound, AEA for ethanolamine containing EC, 2-AG, for glycerol 
containing compounds, prostaglandin E2 ethanoloamide and prostaglandin E2 glycerol ester for COX-2 metabolites of AEA and 2-
AG respectively.(n=4). 
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To control for variability in recovery, and to ensure accurate 
quantification of ECs and related compounds, we used three internal 
standards (AEA-d8, 2-AG-d8, and PGF2a EA-d4). 
2.4.4.1 Effect of silanisation of glassware 
Silanisation of glassware was previously used to improve 
reproducibility, however further work showed that recovery and 
reproducibility was not affected by silanisation (Table2.5). A 
comprehensive washing schedule was therefore used to prevent 
contamination. For some low weight sample such as whole cell and cell 
supernatant, these were extracted in an Eppendorf tube, which did not 
require silanisation. 
Analyte % recovery 
Silanised Non-silanised Glassware 
Glassware 
AEA 0.001 86.8±3.8 89.0±4.8 
0.01 85.1±2.3 93.2±7.2 
0.5 91.8±4.7 94.3±3.1 
2-AG 0.001 79.3±6.3 75.1±3.6 
0.01 7S.3±2.1 78.7±S.9 
O.S 81.3±S.2 85.S±8.3 
PGE2-EA 0.001 91.3±4.3 89.7±7.3 
0.01 87.3±2.3 8S.8±4.5 
0.5 93.6±7.5 91.2±S.3 
Table 2.5 Recovery of Anandamide, 2-AG and PGE2 ethanolamide 
from spiked synthetic standards at 0.001, 0.01, and 0.5uM into silanised 
and non-silanised glass ware (n=3). 
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2.4.4.2 Evaluation of solid phase extraction 
The inclusion of solid phase extraction step in previous methods 
(Schmid et aI., 2000, Richardson et aI., 2007) was found to increase MS 
specificity and sensitivity as well as prolonging the HPLC column life. 
However SPE (based on (Richardson et aI., 2007» for the extraction of 
PG-EAs and PG-GEs was not viable as very poor recovery was 
achieved (Table 2.6). Furthermore, SPE is useful when in preventing 
HPLC overload with large amounts of tissue (>200 mg), however due to 
the small tissue weight «70 mg) used in future experiments, it was 
therefore decided to exclude this step from the extraction procedure. 
Analyte 
AEA 
prostaglandin 
ethanolamide 
prostaglandin 
glycerol ester 
% Recovery 
SPE 
87.2±7.3 
E2 21.9±10.5 
E2 15.2±6.9 
Non-SPE 
91.2±9.2 
92.2±12.3 
86.3±8.2 
Table 2.6 Comparison of percentage recovery of AEA, prostaglandin E2 
ethanolamide, and prostaglandin E2 glycerol ester, with, or without the 
use of solid phase extraction for sample preparation. 
After extraction, samples were reconstituted in 100%, and a 
reconstitution volume of 200 J,JI was used for tissues with high sample 
weight (>50 mg), whereas 100 J,JI was used for low sample weight tissue 
«50 mg). 
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2.4.5 Validation 
The validation data for the method are shown in Table 2.7. The results 
confirm that the method provides high recoveries of all analytes and is 
sufficiently linear, sensitive, precise and accurate for application to the 
measurement of these analytes in small amounts (100 mg) of brain 
tissue using Quattro MS. 
The intra-run precision was within an RSD% of 5.67 % to 19.8 % and 
the inter-run precision was between 8.02% to 20.1%. The values for 
recovery of the ECs and related compounds were greater than 71% at 
all concentrations (Table 2.3). AEA, OEA and PEA demonstrated a 
lower limit of quantification (LLOQ) of 2.5 pmol/g, PG-EAs had a LLOQ 
of 10 pmol/g, 2-AG demonstrated a LLOQ of 50 pmol/g, and the PG-
GEs had a LLOQ of 100 pmollg. The LLOQ of ECs reported here of 
2.5-50 pmol/g consistent with previous studies in our group (Richardson 
et aI., 2007). The LLOQ for ECs, PG-EAs, and PG-GEs were 
determined from spiked rat brain tissue, and hence are more realistic 
compared to values determined using standard solutions. However, 
using direct injection of standards the LLOD for our method were 5 fmol 
for AEA, virodhamine, OEA, and PEA, 20 fmol for PG-EAs, 100 fmol for 
2-AG, and 200 fmol for PG-GEs. Other studies quote on column limits 
of quantification using direct injection of standards of between 8 fmol- 2 
pmol for AEA (Beaulieu et al., 2000a, Giuffrida et aI., 2000b, Clarke and 
Guttman, 2002, Kingsley and Marnett, 2003), 1.25 pmol PEA and 0.6 
pmol OEA using LC-single quadrupole MS (Giuffrida et aI., 2000a) and 
1 pmol-13 fmol 2-AG (Beaulieu et aI., 2000a, Kingsley and Marnett, 
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2003). llOD and lOa for PG-EAs and PG-GEs are less documented, 
with only one study to date providing lOD values for PGE2-GE (Hu et 
aI., 2008), even though other groups have quantified PG-EAs (Kozak et 
aI., 2000, Kozak et aI., 2001a, Kozak et aI., 2002a, Weber et aI., 2004). 
The limits of detection for ECls are better than the majority of methods 
published and allow the quantification of these compounds in mg 
amounts of tissue, whilst maintaining a high level of analyte specificity. 
Previously, there have been very few details reported regarding 
percentage recovery of ECls and associated compounds from a 
biological matrix. Calculations of recovery are hindered by the 
endogenous nature of some of these compounds, and post mortem 
changes. However, subtracting 'spiked' areas from endogenous levels 
area, or from synthetic standard areas (for non-endogenous 
compounds) supported the efficient extraction of all the analytes from 
brain tissue (Table 2.7). These data show the high and reproducible 
recovery of ECls, PG-EAs and PG-GEs for a range of concentrations, 
providing high confidence in this method for the extraction and detection 
of Eels, PG-EAs and PG-GEs in biological tissue. 
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R2 Slope (ratio to Concentration Intraday (n = 5) Interday (n = 4) Analyte IStSD) (nmoUg) Recovery % (tSD) Precision Accuracy Precision Accuracy (RSD%) {RSD%1 (RSD%) (RSD%) 
0.001 98.2t6.21 7.34 104 16.1 116 
PEA 0.975 2.075±O.404 0.1 111±19.3 15.1 98 19.3 112 
1 96.3±15.7 8.99 94.7 13.2 94.3 
0.001 101±4.76 10.1 83.0 8.02 81.2 
OEA 0.993 1.564±O.387 0.1 102±11.5 12.4 123 11.2 125 
1 98.8±13.5 7.53 98.4 11.4 112 
0.001 71.1±22.1 14.5 123 18.4 135 
Virodhamine 0.987 0.473±O.093 0.1 91.0±19.3 15.9 102 16.8 142 
1 74.1±13.3 14.6 134 18.9 98.7 
0.001 111.3%19.2 12.6 81.3 15.7 78.2 
AEA 0.992 1.053±O.263 0.1 105.9%21.6 11.4 99.4 20.1 114 
1 98±15.7 5.67 113 17.1 109 
0.1 125±19.9 17.1 109 11.5 111 
2-AG 0.984 1.563±O.395 1 111±13.1 19.8 123 21.3 127 
10 112±19.7 17.4 106 11.2 121 
0.005 112±12.9 8.72 100 14.05 102 
PGD2EA 0.95 0.401±O.103 0.01 101±8.51 12.8 109 16.7 101 
0.1 118%22.9 9.04 121 14.8 96.2 
0.005 109%5.45 12.4 103 12.4 107 
PGE2EA 0.993 0.473±O.132 0.01 97.4±15.6 11.7 192 21.0 98.3 
0.1 103.±12.4 15.3 88.8 7.32 112 
0.005 102t11.9 11.2 100 9.75 103 
PGF2aEA 0.984 0.621 ±O.0.171 0.01 95.2±14.5 19.4 119 15.8 111 
0.1 121±22.7 11.0 105 10.8 107 
0.5 111±4.06 14.1 93.7 7.42 91.2 
PE2GE 0.971 0.441±O.0.099 2.5 102:t7.5 9.24 103 14.6 108 
10 98.9%12.8 10.3 104 11.9 102 
0.5 99.4±11.7 9.67 107 14.0 101 
PGF2aGE 0.964 0.397±O.0.078 2.5 103:t12.9 13.1 94.8 14.9 109 
10 111±13.7 17.1 103 9.03 121 
Table 2.7 Recovery and intraday, interday assay precision and assay of the LC-MSIMS method for the measurement of ECs and 
COX-2 metabolite compounds in rat brain tissue, based on 100mg tissue. 
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2.4.6 Analysis of rat brain extract 
The validated method was used to extract, identify and quantify 
concentrations of AEA (43.4±11.2 nmol/g), OEA (0.16±0.03 nmol/g), 
PEA (0.21±0.08 nmol/g) and 2-AG (11.24±3.48 nmol/g) in rat brain, 
which is consistent with previous studies analysing whole brain tissue 
(Kathuria et aL, 2003b, de Lago et aL, 2005, Fegley et aL, 2005, 
Bradshaw et aL, 2009). This provides confidence in the modified 
extraction and quantification method. Figure 2.5 shows a 
representative chromatogram of the analytes detected in rat brain. The 
method validated here was unable to detect the presence of 
virodhamine, PG-EA and PG-GEs rat brain analysed, consistent with 
previous studies. Richardson et aI., (2007) was unable to detect 
virodhamine in various rat brain regions, while virodhamine was 
reported to be present in rat brain microdialysate and tissue (Clarke and 
Guttman, 2002). Due to the close structural similarities of AEAI 
virodhamine, and similar retention times, it may be possible that, under 
particular conditions AEA may be mislabelled/detected as virodhamine. 
The lack of COX-2 metabolites of AEA and 2-AG in vivo is conflicting, 
with the detection of PG-EAs in FAAH-1- mice following exogenous 
administration of AEA (50mg/kg), however not in na'ive tissue (Weber et 
aI., 2004). This suggests that in vivo these compounds are formed only 
when levels of AEA are high, or when EC metabolism has been 
compromised (see chapter 4 for more details). PG-GEs have however, 
been detected and quantified in na'ive rat paw tissue (Hu et aI., 2008). 
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The LC-MS/MS method used for PGE2-GE had a limit of detection from 
injection of synthetic standards of 15 fmol. This is lower than our 
reported limit of detection, however Hu et aI., (2008) method was not 
validated, the lack of detailed information on limits of quantification cast 
doubt as to whether this limit in correct for biological tissue. PG-EAs, 
have however been quantified in vitro using using either sodium-
containing mobile phases to generate [M+Nat ions of PG-EA and PG-
GE(Kozak et aI., 2000, Kozak et aI., 2001a). The use of ammonium 
cation (NH4 +) utilised this technique for the analysis of PG-GEs and 
prostaglandins from cell media (Kingsley et aI., 2005) as PGE2-GE from 
an in vivo sample (Hu et aI., 2008). The precursor ion is the [M+NH4r 
complex and the fragment ion is one of several masses mil 409 and 
mil 391 are dehydration products which result from the loss of NH3 and 
one or two molecules of H20. Hu et aI., (2008) also used these 
fragments as precursor ions and used mil 91 and mIl 79 as fragment 
ions to verify the presence of PGE2-GE in rat tissue, similar to our 
method, which looked at mIl 409<91 for PGE2 GE. It may also be 
feasible that the enzymes required for the conversion of the 
intermediate products of metabolism, may not be present in our sample 
tissue. Indeed incubation of 2-AG with COX-2 and specific 
prostaglandin H2 (PGH2) isomerases in cell cultures and isolated 
enzyme preparations results in PG-GE formation (Kozak et aI., 2002a), 
suggesting these compounds may only be produced in certain types of 
tissue. 
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Figure 2.5 Representative chromatograms of the optimised separation 
of endogenous compounds in rat brain. PGD2-EA, PGE2-EA, PGF2a-
EA, PGE2-GE and PGF2a-GE were below the limit of detection. 
Appropriate retention of times compounds shown by *. 
2.4.7 Comparison of two analytical methods 
When higher sensitivity was required, depending on tissue/biological 
matrix under investigation (for example neuroblastoma cells), HP 1100 
LC system was coupled to QTRAP for extra sensitivity, and in some 
cases the LLOQ was 5 times lower, allowing quantification of ECs and 
related compounds in lower weight tissue. For example AEA, OEA and 
PEA demonstrated a lower limit of quantification (LLOQ) of 0.5 pmol/g, 
the PG-EAs had a LLOQ of 5 pmol/g, 2-AG demonstrated a LLOQ of 10 
pmol/g, and the PG-GEs had a LLOQ of 100 pmollg (see Table 2.8). 
The relative amounts of analytes present in sample was tissue was 
comparable when using both the QTRAP, and Quattro to analyse the 
same samples (Figure 2.5), for example: the endogenous levels of AEA, 
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OEA, PEA and 2-AG quantified in hindpaw tissue data acquired from 
the using the more sensitive QTRAP MS coupled to microbore column, 
compared to Quattro MS coupled to narrowbore column are roughly 
equal, with and R2 value of approximately 1. However, the using 
QTRAP, we were able to detect and quantify levels of AEA in sample 
tissue that were below the LLOQ of the Quattro, supporting further the 
extra sensitivity in using a microbore column coupled to QTRAP MS 
(Figure 2.6). 
Compound Quattro QTRAP 
AEA pmollg 2.5 0.5 
OEA pmollg 2.5 0.5 
PEA pmollg 2.5 0.5 
2-AG pmollg 50 10 
PGD2-EA pmollg 10 5 
PGE2-EA pmollg 10 5 
PGF2a-EA pmollg 10 5 
PGE2-GE pmol/g 100 100 
PGF2a-GE pmollg 100 100 
Table 2.8 A comparison of the LOQ for two different MS instruments for 
the quantification of ECs and COX-2 metabolites in rat brain tissue. 
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2.4.8 Quantification of EC in biological matrices 
The method was developed and validated in rat brain tissue, however it 
has also allowed the quantification of ECs and related compounds in a 
wide range of biological matrixes, such as rat paw, brain, liver, bone 
and spinal tissue. Table 2.9 shows the basal values of ECs and related 
compounds quantified in spinal cord, paw, liver, cell and bone samples. 
The development of these methods allow for the identification and 
quantification of ECs and COX-2 metabolites of AEA and 2-AG, giving 
the equivalent quantitative values of endogenous levels of ECs in 
biological matrices, no matter what MS instrument has been used. This 
allows for comparisons between samples that have been analysed on 
both MS instruments, allowing the use of QTRAP detector when 
sensitivity is compromised. The exclusion of SPE from sample 
preparation has proved not to affect chromatography or sensitivity, and 
has allowed for faster extraction of biological samples. 
The specific and sensitive method described in this chapter allows 
quantitative profiling of AEA, OEA, PEA, and 2-AG in biological tissue, 
and the detection of COX-2 metabolites of AEA and 2-AG, although 
their production in vivo and in vitro remains to be investigated further. 
The measurement of ECs and their metabolites is vital in understanding 
the role of the endocannabionoid system in pathological conditions. 
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Figure 2.6 Levels of AEA, OEA, PEA and 2-AG obtained using both analytical methods coupled to either QTRAP or Quattro MS. 
Levels of AEA, PEA, OEA and 2-AG are comparable using both methods, however the red arrow shows levels of AEA, that were 
where previously below the LLOQ using Quattro are now quantifiable using QTRAP. 
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Rat A E A p m o V ~ ~ 2-AGnmol/g OEAnmol/g PEAnmoVg PG-EA pmol/g PG-GE pmollg 
Tissue Observed published Observed published Observed Published Observed published Observed published Observed published 
spinal 18.7 51 , 102 , 51.4 ± 0.5', 14 , 1.0 ± 0.1 0.24,;1 0.4' 0.8± 0.1 0.23.4, NO NO NO NO 
cord ±1.6 11 3 304 9.6 1<Y 1.41 , 
Paw 6.5 ±0.5 0.7°, 121>, 9.6 ± 0.4 31> , 5' , 0.1±0.03 l' 0.2±0.02 0.11>, NO NO NO 0.0027 
201 51 50.87 0.55,201 
Liver 14.4±1.1 16 , 5'0 6.9±0.7 1'0 , 29 , 0.3±0.05 15'2, 0.1±0.01 50" NO NO NO NO 
616 511 , 68 0.0513 0.213 
0.314 0.116 
0.0815 
Cell 6.0±1.0 0.5'11 2'" 0.4±0.01 0.05" 0.03± 12U 0.072 ' 0.2±0.03 22U 0.121 NO NO NO NO 
320921 0.218 0.004 922 322 
0.2520 
0.121 
Bone 4.1±0.5 NO 0.3±0.1 NO 0.09±0.01 NO 0.08±0.01 NO NO NO NO NO 
--
Table 2.9 Concentrations of basal ECs and related compounds measured using QTRAP or Quattro MS in a variety of rat tissue and 
published values. 
(Jhaveri et aI., 2006) 2(Suplita et aI., 2006) 3(Cravatt et aI., 2004) 4(Petrosino et aI., 2006), 5 (Beaulieu et al., 2000a), 6 (Guindon et al., 2007), 7 (Hu et aI., 
2008) 8 (Batetta et aI., 2009) 9 (Avraham et aI., 2008) 10 ~ G u i j a r r o o et aI., 2008) 11 hArtmann et aI., 2008) 12 (Astarita et aI., 2006) 13 (LoVerme et aI., 2006a) 14 
~ o d r i g u e z z de Fonseca et aI., 2001) 15(Fu et al., 20071 6 (Fegley et aI., 2005) (Bisogno et al., 2009), 18 (Ligresti et al., 2003) 19 (Burstein et aI., 2002), 
(Maccarrone et al., 2001), 1 (Gonthier et aI., 2007), 22(Matias et aI., 2007). 
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This newly developed analytical method has been shown to be 
suitable for quantitative profiling of ECls and is readily adaptable to 
different types of biological samples. Concentrations of ECls have 
been successfully measured in rat paw, rat spinal cord, and human 
cell lines, and rat neurones (see future chapters), with levels similar 
to that published form other groups (Table 2.9). The similarity in 
these levels provides confidence with the validated extraction and 
quantification method developed, and casts doubt as to whether PG-
EA and PG-GE are present in na'ive tissue under normal pathological 
conditions, at least to the limit of quantification of the method. 
Chapter 4 investigates the production of these compounds under 
inflammatory conditions. 
Profiling not only ECls, but also their precursors and metabolites in 
diseased tissue or following noxious stimulation is crucial in 
understanding the role and fate of the endocannabinoid in various 
disease states. Many questions still remain on the regulation of the 
biosynthesis and catabolism of the ECls, however this system 
represents a novel therapeutic target for the treatment of pain, with 
modulators of the system shown to produce analgesic effects both 
clinically and in animal models of pain, reviewed by (Gauldie et a!., 
2001, Huang et a!., 2002, Iversen and Chapman, 2002, Hohmann 
and Suplita, 2006). With insufficient methods allowing the 
simultaneous quantification of ECs and their metabolites, as well as 
sensitivity issues for AEA detection, actual concentrations of ECls 
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and the production of COX-2 metabolites in vitro and also in in vivo 
models of pain are often unclear, thus this new analytical method will 
help provide some further insight into the regulation of ECls in 
various in vivo and in vitro models of pain. 
104 
The role of TRPVl in modulating endocannabinoid levels and neuronal responses 
to TNFa 
Chapter 3. 
The role of TRPV1 in modulating 
endocannabinoid levels and 
neuronal responses to TNFa. 
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3 The role of TRPV1 in 
modulating endocannabinoid 
levels and neuronal 
responses to TNFa. 
3.1 Introduction 
Following the successful development and validation of a lC/MS 
method capable of quantifying ECs and related compounds, we 
wanted to investigate the generation of ECs in sensory neurones. In 
particular, our intention was to address the hypothesis that they act in 
an autocrine fashion such that TRPV1 activation, and subsequent 
increases in cytoslic calcium, could drive ECl synthesis and release. 
The second part was to investigate the role of the pro-inflammatory 
mediator TNFa, which has been shown to sensitise receptors and ion 
channels, including TRPV1 leading to hyperalgesia. Hence, we 
investigated the effects of TNFa on capsaicin-evoked calcium 
responses as a measure of neuronal excitability. 
3.1. 1 Capsaicin and TRPV1 
The activation of TRPV1 channels on sensory fibres and non-
neuronal cells initiates Ca2+ and Na+ influx (Wood et aI., 1988, 
Bleakman et aI., 1990a, Docherty et aI., 1991) and the corresponding 
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release of tachykinin neuropeptides such as substance P (Go and 
Yaksh, 1987, Holzer, 1988, Bevan and Szolcsanyi, 1990), and 
calcitonin-gene-related-peptide (CGRP) (Meng et aI., 2009). Various 
resident immune cells (e.g., macrophages), peripheral target cells 
(endothelia, epithelia), respond to these neuropeptides and mediate 
the tissue response characteristic of inflammation, namely redness, 
swelling, and pain (Richardson and Vasko, 2002). 
Capsaicin also causes the release of endogenous anti nociceptive 
ligands, such as (3-endorphin (Bach and Yaksh, 1995) and 
somatostatin (Szolcsanyi et al., 1998a, Szolcsanyi et aI., 1998b); 
therefore, it is conceivable that capsaicin via the activation of TRPV1 
leads to elevation of cytoplasmic calcium levels and a consequent 
increase in endocannabinoid synthesis, which could attenuate 
neuronal activation via inhibition of Ca2+ channels, opening of K+ 
channels, and inhibiting adenylyl cyclase activity, thereby providing a 
negative feedback system. 
3.1.2 CB1 and TRPV1 
Cannabinoid CB1 receptors and TRPV1 receptors are co-expressed 
in the dorsal horn of the spinal cord, and on primary sensory neurons 
(Szallasi et al., 1995, Szallasi and Blumberg, 1999, Ahluwalia et at, 
2000, Binzen et aI., 2006). The receptors can engage in cross-talk 
when expressed on the same or neighboring cells, such as in the 
striatum, where exogenous AEA application leads to inhibition of 2-
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AG formation, via down regulation of diacylglycerol lipase-a 
(DAGLa). This inhibition of DAGLa activity was prevented by 
inhibition of TRPV1 receptors with I-resinifertoxin (Maccarrone et aI., 
2008), and is thought that AEA, via TRPV1 interferes with 
glutathione-dependant 2-AG synthesis; however the validity of this 
mechanism throughout the brain is still unknown. However, these 
data suggest that AEA might be critically involved in the control of the 
excitability of striatal neurons through a direct depressant action at 
excitatory synapses and an indirect interference with inhibitory inputs 
regulated by 2-AG. Furthermore, the endocannabinoids AEA and 
NADA can also act as endovanilloids (Smart et aI., 2000, Zygmunt et 
aI., 2000, Huang et aI., 2002, Chu et aI., 2003, Van Der Stelt and Di 
Marzo, 2004), with AEA activating the TRPV1 channel via an 
intracellular binding site (De Petrocellis et al., 2001 a). Several 
pieces of evidence suggest that AEA and capsaicin bind to the same 
site on TRPV1. AEA displaces [3H]-RTX from TRPV1 with a Ki of ..... 
2 IJM in transfected (Chinese hamster ovary) CHO cells, which is 
similar to that of capsaiCin (De Petrocellis et aI., 2001b, Ross et aI., 
2001). Although AEA has similar affinity for TRPV1 as capsaicin in 
binding assays, it often shows lower potency in functional assays. In 
heterologous expression systems, such as human embryonic kidney 
(HEK) cells or Xenopus oocytes, the concentrations of AEA required 
to fully activate TRPV1 as assessed by measuring intracellular Ca2+ 
are 1- to 10-fold higher than those required to evoke CB1-mediated 
functional responses (Zygmunt et aI., 1999, De Petrocellis et aI., 
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2000, Smart et aI., 2000, Ross et aI., 2001). In native systems in 
vitro, the potency of AEA ranges between 0.3 and 0.8 IJM in blood 
vessels (relaxation) compared with 6-10 IJM in ORG neurones 
(elevation of intracellular calcium, [Ca2+]j and stimulation of inward 
currents) (Zygmunt et aI., 1999, Smart et aI., 2000, Olah et aI., 2001, 
Ralevic et aI., 2001, Jerman et aI., 2002). The functional activity of 
AEA at TRPV1 can be masked or enhanced by its activity on CB1 
receptors, especially in those cells when the 2 receptors are co-
expressed (Ahluwalia et aI., 2003a), where AEA produces a greater 
increase in CB1ffRPV1 over-expressing cells, compared to TRPV1 
over-expressed cells (Hermann et aI., 2003). Thus, it appears that 
cell and experimental factors such as receptor levels and possibly 
metabolic enzymes can affect the affinity and efficacy of AEA. Given 
that the binding site of AEA is on the intracellular side of TRPV1, and 
that AEA is produced form the hydrolysis of membrane 
phospholipids, via an increase in cytosolic calcium, this makes the 
generation of AEA and other ECs by TRPV1 activation highly likely. 
Furthermore, Oi Marzo's group proposed that AEA acts as an 
intracellular amplifier for Ca2+ and AEA synthesis, where TRPV1 
activation leads to an increase in Ca2+, AEA synthesis, which in turn 
can further activate TRPV1 receptors allowing more AEA synthesis 
(van der Stelt et aI., 2005). This cycle, however, can be interrupted 
by AEA activating extracellular CB1 receptors, and thus inhibiting 
TRPV1 function and calcium release (Millns et aI., 2001). 
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3.1.3 Calcium driven EC synthesis 
The role of calcium in endocannabinoid synthesis is well documented 
(Di Marzo et aI., 1994, Ohno-Shosaku et aI., 2005, Wang and Ueda, 
2008) (see Chapter 1 for more detail). Indeed, in various brain 
regions, it has been demonstrated that postsynaptic depolarization-
induced Ca2+ elevation causes endocannabinoid release, and 
suppresses neurotransmitter release through activation of 
presynaptic CB1 receptors (Kreitzer and Regehr, 2001, Ohno-
Shosaku et aI., 2001, Wilson and Nicoll, 2001, Diana et aI., 2002, 
Yoshida et aI., 2002). However, these studies did not measure 
ECls. To date there is a lack of studies linking capsaicin-induced 
increase in calcium-driven ECl synthesis with direct measurements 
in sensory nerves. Previous studies have reported that DRG 
neurones make AEA by direct measurement using lC/MS (Ahluwalia 
et aI., 2003a, van der Stelt and Di Marzo, 2005, Vellani et aI., 2008), 
either cooperatively with, or independently from, Ca2+-influx, where 
intracellular Ca2+ mobilisation by thapsigargin, or by receptors 
coupled to the PlC/IP3 pathway leads to the formation of intracellular 
anandamide in HEK293 cells and primary sensory neurons, and 
anandamide-induced TRPV1-dependent influx of extracellular Ca2+ in 
these cells (van der Stelt and Oi Marzo, 2005). However, the studies 
did not simultaneously measure levels of the other ECl compounds, 
such as OEA, PEA and 2-AG, which are also reported to be 
produced in a calcium-dependant manner (Hansen et al., 1995, 
Cadas et aI., 1996, Bisogno et aI., 2005). However, levels of OEA, 
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PEA and 2-AG may not be regulated in the same way as levels of 
AEA. In fact, AEA and 2-AG have entirely different biosynthetic 
routes originating from precursors, whose levels in turn depend on 
the amount of arachidonic acid in the sn-1 and 2-position of 
phosphoglycerides, respectively (see review (Oi Marzo and 
Petrosino, 2007». AEA, PEA, and OEA although belonging to the 
same class of lipids, the N-acylethanolamines, are likely to be 
biosynthesised via different enzymes from the corresponding N-acyl-
phosphatidylethanolamine (NAPE) precursors (Liu et aI., 2006, 
Simon and Cravatt, 2006). Therefore, it is possible that neuronal 
AEA, OEA, PEA and 2-AG levels may be regulated via differing 
mechanisms, and it's not definite that the same stimulus would have 
the same effects on all ECl synthesis. 
3.1.4 Endocannabinoid uptake, release and 
degradation 
AEA is inactivated through cellular reuptake and enzymatic 
degradation mechanisms (see Chapter 1 for more detail). It is widely 
accepted that degradation of AEA occurs intracellular; however, the 
mechanisms by which AEA is taken into cells, are yet to be fully 
elucidated. Once inside the cell, actions of AEA are terminated by 
hydrolysis primarily by the enzyme fatty acid amide hydrolase 
(FAAH), which hydrolyzes AEA to arachidonic acid (AA) and 
ethanolamine. 
It still remains unclear as to how Eels are released into the 
postsynaptic plasma membrane and taken into the cell, or even if 
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these are the same mechanisms. ECls are highly lipophillic and so 
are capable of crossing the plasma membrane of cells via passive 
diffusion down concentration gradients (Oi Marzo et aI., 1994, 
Beltramo et al., 1997, Hillard et aI., 1997), but carrier proteins are 
probably required to extrude ECls from the lipid environment of the 
membrane into the aqueous intracellular and extracellular media (Oi 
Marzo et aI., 1994, Piomelli et aI., 1998). AEA uptake has been 
demonstrated in many cell lines (Deutsch and Chin, 1993, Bisogno et 
aI., 1997, Rakhshan et aI., 2000) and in culture from primary neurons 
(Di Marzo et aI., 1994, Hillard et aI., 1997). Uptake is independent of 
sodium (Beltramo et aI., 1997) and ATP (Hillard et aI., 1997), and is 
moderately temperature dependant. However, the suggestion that 
ECls can cross the cell membrane via an endocannabinoid 
membrane transporter remains controversial. Ligand binding studies 
have indicated that the putative carrier protein is stereoselective and 
requires well defined structural requirements (Khanolkar and 
Makriyannis, 1999, Jarrahian et aI., 2000). Furthermore, AEA uptake 
was blocked by the arachidonic acid derivative AM404, which is 
proposed to act as a competitive inhibitor of AEA uptake (Rakhshan 
et al., 2000, Fegley et al., 2004). AM404 has been shown to inhibit 
efflux of accumulated AEA in striatal and endothelial cells (Gerdeman 
et aI., 2002, Maccarrone et aI., 2002), futher supporting the existence 
of a transporter. However it should also be noted that AM404 is also 
a ligand of the TRPV1 receptors, and may be able to modulate ECl 
syntheisis through mobilisation of intracellular calcium (Di Marzo et 
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aI., 1994, Ralevic et aI., 2001, van der Stelt and Di Marzo, 2005). 
Thus, it is probable that an increase in cytosolic calcium via TRPV1 
activation can drive ECl release and uptake via a membrane 
transporter. 
3.1.5 TRPV1 sensitisation by inflammatory mediators 
The ability of TRPV1 to become sensitised by pro-analgesic and 
inflammatory mediators has raised interest in it being a novel drug 
target for the treatment of chronic pain and hyperalgesia 
(see(Gunthorpe and Szallasi, 2008, Gunthorpe and Chizh, 2009). 
There is evidence that the combination of direct and indirect 
mechanisms finely tunes TRPV1 activity (Nagy et aI., 2004), and 
each of the known activators of TRPV1 (heat, protons and vanilloids) 
can sensitise the channel to other stimuli. For example, capsaicin is 
more potent in the presence of sub-threshold concentrations of 
protons as well as slight increases in temperature (Ryu et aI., 2003, 
Ahern et aI., 2005, lee et aI., 2005). Protons induce a leftward shift 
of the capsaicin and temperature response curves of TRPV1 leading 
to a lower ECso and activation threshold, respectively (Tominaga et 
aI., 1998). Thus, proton activation of TRPV1 and sensitisation of 
heat-induced currents is consistent with the dual role of protons as 
nociceptor activator and inflammatory mediator. Thus, a combination 
of otherwise innocuous heat and tissue acidosis may become painful 
(Steen et al., 1995). In addition to protons, other inflammatory 
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agents, such as bradykinin and prostaglandin E2 together in acidic 
solution, can activate TRPV1 in a similar conductance to capsaicin. 
The response is smaller or absent if anyone of the constituents is 
lacking, and is prevented in the presence of capsazepine (Vyklicky et 
aI., 1998). Inflammatory mediators can act as second messengers 
(Dray, 1995, Hingtgen et aI., 1995), by sensitizing TRPV1 to other, 
direct activators, confirming the general hypothesis that, under 
inflammatory circumstances, a 'sensitised' TRPV1 can be activated 
by agonist concentrations much lower than those required under 
conventional experimental conditions. 
3.1.6 Inflammatory mediators and TRPV1 
During inflammation, various cell types, including mast cells and 
immune cells, release pro-inflammatory cytokines (e.g., IL 1 B, IL6, 
and TNFa) (Cunha et aI., 1992, Jonakait, 1993, Davis and Perkins, 
1994), which cause an increase in TRPV1 expression (see Chapter1, 
figure 1.1). For example, in complete Freund's adjuvant-induced 
inflammation in the rat hind paw, TRPV1 protein levels are known to 
increase in the plantar skin (Ji et aI., 2002), DRG and spinal cord 
(Luo et aI., 2004». Additionally, TRPV1 can be indirectly sensitised 
by several inflammatory mediators from the surrounding inflamed 
area, e.g. nerve growth factor (Chuang et aI., 2001) (Ji et aI., 2002), 
bradykinin (Chuang et aI., 2001), and ATP (Tominaga et aI., 2001). 
Inflammatory mediator signaling cascades could, via allosteroc 
modulation, post-translationally modify TRPV1 or increase TRPV1 
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protein expression to produce sensitisation. Increased TRPV1 
expression which has been shown to occur 12-24 h following 
inflammation, appears to be crucial to the development of thermal 
sensitization (Ji et aI., 2002). 
TRPV1 is known to have several phosphorylation sites, and 
sensitisation can occur via modification of several serine and 
threonine residues on the receptor through phosphorylation to 
sensitize receptor activity (Bhave et aI., 2002, Numazaki et aI., 2003, 
Jordt et aI., 2004). In particular, protein kinase A (PKA) (Shave et aI., 
2002) and protein kinase C (PKC) (Cesare et aI., 1999a, Cesare et 
aI., 1999b) appear to have a significant role in TRPV1 
phosphorylation. Mitogen-activated protein kinases (MAPK) have 
also been implicated in nociceptors sensitisation associated with 
inflammation and peripheral neuropathy. P38 MAPK is activated in 
response to inflammation (Ji et aI., 2002), and activation of TRPV1 
by intraplantar injection of capsaicin leads to p38-MAPK dependant 
hyperalgesia (Mizushima et aI., 2005). Inflammation, axotomy and 
spinal nerve ligation also activate p38 MAPK in spinal cord and DRG 
neurones, possibly contributing to neuropathic pain (Kim et aI., 
2002b, Jin and Gereau, 2006). Furthermore, TNFa was reported to 
be central to p38 phosphorylation and mechanical hyperalgesia in 
the spinal nerve ligation model of peripheral neuropathy (Pollock et 
aI., 2002, Schafers et aI., 2003b, Jin and Gereau, 2006). 
Endogenous NGF-dependent p38 activation, leading to an increase 
in TRPV1 expression, has been shown to occur following 
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inflammation (Ji et aI., 2002). Therefore, inflammatory mediators 
such as TNFa, can activate p38MAPK signaling pathway, leading to 
sensitisation and up-regulation or modification of TRPV1 receptors in 
regions of tissue injury, which could play important roles in 
inflammatory nociception. 
3.1.7 TN Fa 
TNFa is a pro-inflammatory cytokine produced in response to injury 
and inflammation and is reported to play a critical role in the 
development and maintenance of neuropathic and inflammatory pain 
states (Woolf et al., 1997, Junger and Sorkin, 2000, Sommer and 
Kress,2004). TNFa has also been implicated in many autoimmune 
diseases including rheumatoid arthritis and multiple sclerosis 
(Feldmann et aI., 1996, Spuler et aI., 1996, Ledeen and Chakraborty, 
1998) and it is involved in nociceptive processes causing 
hyperalgesia (Cunha et aI., 1992, Watkins et aI., 1995, Ignatowski et 
al., 1999, Junger and Sorkin, 2000). Thus, after nerve injury, TNFa 
expression is increased in both ORG (Schafers et aI., 2002, Schafers 
et aI., 2003a) and spinal cord (Hashizume et aI., 2000). 
Two distinct TNF receptor subtypes have been identified, TNFR1 
(type I, p55TNFR) and TNFR2 (type II, p75TNFR), with molecular 
weights of 55 and 75 kOa, respectively (Lewis et al., 1991), and both 
have previously been identified in nociceptive neurones (Shubayev 
and Myers, 2001, Marchand et aI., 2005). Occupation of these 
receptors can activate a number of intracellular signaling pathways 
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including nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF-KB), p38 MAPK and c-jun N-terminal kinase (JNK) resulting 
in a number of responses including inflammation, apoptosis and 
necrosis (Eissner et aI., 2000, Harashima et aI., 2001, Eissner et aI., 
2004, Ware, 2005). TNFR1 appears to be to be particularly 
important in the pain-sensitizing actions of TNFa. Mechanical 
hypersensitivity induced by exogenous TNFa is reduced in TNFR1-
null animals (Cunha et aI., 2005) and antisense knockdown of 
TNFR1 reduces hyperalgesic priming after inflammation in the rat 
(Parada et al., 2003). However, there are conflicting reports as to 
whether activation of these receptors can lead to an increase in 
intracellular calcium. Some reports have shown modulation of Ca2+ 
responses, but not direct Ca2+ mobilisation by TNFa. Moreover, the 
effects that have been observed only occur after long-term exposure 
to TNFa and usually involve TNFa -induced cell death mechanisms 
(Amrani et aI., 1997, Kong et aI., 1997, Parris et aI., 1999, Yorek et 
al., 1999). TNFa, acting via TNFR1, has also been shown to 
increase the frequency of spontaneous miniature synaptic currents in 
cultured rat hippocampal neurones, albeit without increased cytosolic 
Ca2+ concentration (Grassi et al., 1994) and it has also been shown 
to increase the calcium current density in sympathetic neurones 
(Soliven and Albert, 1992). Application of TNFa results in the release 
of Ca2+ via TNFR1 from intracellular stores in rat DRG neurons 
(Pollock et aI., 2002) and human microglia cells (McLarnon et aI., 
2001) which appears to be independent of calcium influx and 
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intracellular IP3 stores. TNFa increases the proportion of DRG 
neurons expressing the TRPV1 receptor 24 hours following 
application (Hensellek et aL, 2007), and studies have revealed that 
p38 MAPK are involved in this increased TRPV1 expression (Ji et aL, 
2002, Bron et aI., 2003). Activation of p38 MAPK has been 
implicated in nociceptor sensitisation associated with inflammation 
(Joseph and Levine, 2004, Wu, 2004). Furthermore, activation of 
TRPV1 leads to p38-dependent hyperalgesia, following injection of 
capsaicin in rats hind paw (Mizushima et aL, 2005), and an up-
regulation of TRPV1 protein expression in cell bodies of DRG 
neurons following intraplanatar administration of Complete Freunds 
adjuvant (CFA), which is mediated by NGF and p38MAP kinase (Ji et 
aI., 2002). Inflammation and spinal nerve ligation similarly activate 
p38 in spinal cord and DRG neurons, contributing to neuropathic pain 
(Kim et al., 2002b, Jin and Gereau, 2006). In the spinal nerve 
ligation model of peripheral neuropathy, TNFa was central to p38 
phosphorylation and mechanical hyperalgesia (Pollock et aI., 2002, 
Schafers et aL, 2003a, Jin and Gereau, 2006). Thus, it is clear that, 
during inflammation, mediators released into the external milieu can 
indirectly sensitize neuronal TRPV1 receptors. 
Collectively these data suggest that it may be possible for TNFa to 
activate the p38MAPK pathway to increase the phosphorylation of 
TRPV1 receptors and allow pronociceptive inflammatory mediators to 
sensitise TRPV1 responses, thus promoting hyperalgesia. 
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3.1.8 The objectives of this chapter are: 
• To determine the effect of capsaicin on intracellular and 
extracellular Eel levels in rat DRG neurons and hTRPV1-
SHSY5Y cells. 
• To determine the effect of FAAH inhibition on the synthesis 
and release of Eels. 
• To examine the effects of TNFa on calcium release from 
sensory neurones. 
• The potential sensitisation of TRPV1 by TNFa in sensory 
neurones and the mechanisms by which it does so. 
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3.2 Materials and Methods 
All chemicals and biochemical were purchased from Sigma, unless 
otherwise stated. 
3.2.1 DRG Preparation 
3.2.1.1 Glass coverslip preparation 
Glass coverslips (19mm diameter) were washed in 10% Decon 
(Decon Sciences) overnight, before being rinsed twice in distilled 
water (dH20) and then in tap water for 2hours. The coverslips were 
rinsed again in dH20, and then soaked in concentrated hydrochloric 
acid (HCI) for 30 minutes. Cover-slips were rinsed again in dH20, 
and then again in tap water for 2 hours, before being rinsed three 
times in dH20. Cover-slips were autoclaved before being stored at 
room temperature in sterile water. 
Cover-slips were coated with 100 ~ I I sterile 0.1 mg/ml poly-L-Iysine 
and left for 90minutes at room temperature. Cover-slips were 
washed once in sterile water and left to dry. Laminin (1 mg/ml) was 
added to the centre of the cover-slip, and left to air dry for a minimum 
of 60 minutes. Cover-slips were washed once with sterile water and 
dried via vacuum before use. 
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3.2.1.2 Dorsal root ganglion (DRG) neurone preparation 
Dorsal root ganglion (DRG) neurones were dissected from adult rats 
using a similar method to that described by Lindsay (1988), with 
minor modifications. 
Adult male Sprague -Dawley rats (180-200g) were killed by 
exposure to CO2. The dorsal surface of the rat was swabbed with 
70% alcohol, and the fur and skin was lifted and cut, to expose the 
underlying vertebral column. Incisions were made close to either 
side of the vertebral column using scissors, and then the spinal 
column lifted out and place into a culture dish containing Dulbecco's 
Ca2+ and Mg2+ -free phosphate-buffered saline (PBS) (Sigma) at 
37°C. Excess back muscle was removed to expose the spinal 
column and cord. The column was held using a pair of rat toothed 
forceps and the bone was removed. Following the midline of the 
ventral plate, the column was halved. The DRGs were exposed in 
their recesses by carefully removing the spinal cord. The DRGs are 
visible as swellings of each spinal nerve that are slightly more 
translucent than the rest of the nerve. The DRGs were carefully 
dissected out by cutting the peripheral and central trunks 
(Approximately 30-40 DRGs can be removed from a single rat). The 
isolated DRGs are placed in a tube containing PBS and washed 
once under gravity, and then incubated (37°C, 5%C02) for 90mins in 
5ml Neurobasal media (Gibco) containing collagenase (2.5 mg/ml) 
supplemented with horse serum (10%). 
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DRGs were then washed three times under gravity in PBS. The PBS 
was removed and 2.5 ml trypsin (1x) was added. Ganglia were 
incubated (37 °C, 5%C02) for 5 minutes, then 1 ml Neurobasal 
medium containing 10% horse serum added. This was triturated up 
and down, approximately 15 times to form a cell suspension using a 
pastette. The suspension was then carefully layered on top of 6ml 
of bovine serum albumin solution (16% in Hanks balanced saline 
solution (HBSS) at pH 7.4) at room temperature. This was then 
centrifuged (1000 x g, 20 °C ) for 5 minutes and the supernatant 
layer removed to leave the cell pellet, which was re-suspended in 
180 ~ I I neurobasal media containing 50 mg/ml glial cell line-derived 
neurotropic factor (GDNF), 2 mM L-glutamine, 1 mg/ml nerve growth 
factor (NGF), 200 units/ml penicillin and 200 ng/ml streptomycin. 20 
~ I I of the cell suspension was pipetted onto sterilised glass cover 
slips, and incubated (37 °C, 5%C02) for 30minutes, (this was to 
produce a densely populated cell area in the centre of the cover-slip 
for ease of imaging) and then the remaining media was added to 
each sterilized cover-slip coated with poly-L-Iysine and laminin and 
incubated (37 °C, 5%C02) overnight before intracellular calcium 
measurements. 
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3.2.1.3 Fura-2AM cell loading 
Intracellular calcium concentrations were visualized by incubating 
cells with the calcium sensitive dye Fura-2AM (L-[2-(carboxyoxazol-
2-yl)-6-amino-benxofuran-5-oxy]-2-(2'-amino-5'methylphenoxy) 
ethane-N, N, N, N-tetraacetic acid pentaacetoxymethylester). 
Cells were washed in Ca2+ buffer (see appendix for recipe), before a 
solution of 5 IJL Fura-2AM (see appendix for recipe) was added to 
the cells, which were incubated in the dark for 30minutes (37°C). 
Cells were washed in Ca2+ to remove extracellular Fura-2AM and 
kept in Ca2+ buffer for use in imaging. 
3.2.1.4 Calcium imaging studies of DRG neurones 
Intracellular Ca2+ concentration ([Ca2+]i) in individual neurones was 
estimated as the ratios of the peak fluorescence emission intensities 
(measured at 500 nm) at excitation wavelengths of 340 and 380 nm 
respectively using an Improvision imaging system. Ratiometric 
imaging is a quantitative fluorescence application that provides a way 
to measure the concentration of intracellular calcium. Fura-2AM 
reversibly binds to cytosolic calcium, shifts its absorption maximum 
towards lower wavelengths upon binding to calcium. In its free form, 
Fura-2 has high excitation efficiency at 380 nm and low excitation 
efficiency at 340 nm. With calcium bound, the reverse is true: at 380 
nm Fura-2 fluoresces with low excitant efficiency and at 340 nm with 
high excitant efficiency. Subsequently, the ratio between the two 
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fluorescence intensities measured at the two excitation wavelengths 
can be calculated. 
The major advantage of ratiometric imaging is the ability to normalise 
for changes in fluorescence intensities that are unrelated to changes 
in dye loading. The temporal and spatial distribution of the measured 
fluorescence intensity can fluctuate, typically due to an unequal 
distribution of the flurophore within the specimen, uneven cell 
thickness, or noise introduced by the imaging system itself, such as 
variations in the illumination intensity. Changes in calcium 
concentration are expressed as changes in ratio units. The 
Grynkiewicz equation (Grynkiewicz at al., 1985) can be used to 
convert the ratio values into absolute calcium concentrations; 
however, the constants required by the equation such as the 
dissociation constant for Fura-2, Rmax and R min, are difficult to 
determine accurately and, as this study was concerned with changes 
in internal calcium levels, we have chosen to quote the fluorescence 
ratios which are directly proportional to the absolute calcium 
concentrations. 
The mean diameter of the neurones studied was 25.7±1.9 ~ m m
(n=537 neurones). This was estimated using Scion Image software 
(Scion Corporation). 
Coverslips were fixed to a Perspex chamber using vacuum grease 
and DRG neurones were suprafused (2 ml/min) with Ca2+ buffer. 
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Drugs were initially dissolved in 100% ethanol to form a stock 
solution of 1mM, except tumor necrosis factor a (TNFa (10 !-Ig/ml) 
which was purchased as a solution in phosphate buffered saline. 
DRG neurones were suprafused (2 ml/min) with either the TRPV1 
receptor agonist capsaicin (1 nM-1 !-1M), or the cytokine TNFa (10, 
30, 50, 100, or 200 ng/ml), or pretreated with TNFa (50 ng/ml) for 4 
min before application of capsaicin (50 nM) for 1 min. Experiments 
were repeated in the presence of the P38 MAPK inhibitor S8706504 
(10 !-1M). Neurones were finally suprafused (2 ml/min) with KCI (60 
mM in Ca2+ buffer; 60s) to cause deploarisation-induced Ca2+ influx. 
All drugs were made up in calcium buffer, and 45 minute washout 
periods with calcium buffer were carried out between applications of 
drugs to ensure drug application did not cause desensitisation. 
Superfusion of neurones with KCI (60 mM) resulted in a 
depolarization-induced calcium influx, which was acted as a control 
response. The stimulated ratio was obtained by subtracting the 
basal conditions, from the ratio obtained during drug addition. 
Neurones with an increase in ratio less than 0.1 units following KCI 
superfusion were considered to be non-responsive and excluded 
from analysis. 
Changes in ([Ca2+]i) were expressed as a percentage of the response 
to KCI. Data are expressed as mean± standard error of the mean 
(SEM). Statistical analysis was carried out using an unpaired 
Student's t-test. P values < 0.05 were deemed significantly different. 
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The Fura-2 pseudo-colour image of DRG neurons shows individual 
neurones under basal and stimulated conditions at excitation 340nm 
and 380nm, emission 510. Neurons fluoresce green at excitation 
wavelengths, and fluorescence appears more intense following 
capsaicin application, due to the increase in cytolsolic calcium. The 
ratio pseudo-image shows neurones appearing red/yellow having an 
increase in [Ca2+]1 (figure3.1). 
3.2.2 Measurement of changes in [Ca2+11 in hTRPV1-
SHSY5Y cells 
A human neuroblastoma cell line SHSY5Y transfected with TRPV1 
receptors was used in this study. The cells were a generous gift from 
Prof Dave lambert (University of leicester). They were originally 
produced by by GlaxoSmithKine (Stevenage, UK) as described in 
(lam et aI, 2007). Whilst it is possible to study neuronal activation in 
vitro, in primary cell cultures, such as DRGs, large cell numbers are 
required to measure endocannabinoid levels. These cultures only 
provide low yields, thus the neuronal cell line was used. 
3.2.2.1 Cell Culture 
Transfected SHSY5Y cells were frown to 80% confluence in t75 
culture flasks and maintained in minimum essential media (MEM), 
supplemented with 10% foetal calf serum, 0.2 mmol/l l-glutamine, 
2.5 J,Jg/ml fungizone, 100 IU/ml penicillin, 100 J,Jg/ml streptomycin and 
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300 jJg/ml hygromycin B at 37°C in 5% C02. The initial transfection 
was sub-cloned in this medium. 
3.2.2.2 Fluorimetric measurement of intracellular free 
calcium 
Assay buffer for intracellular calcium measurements were freshly 
made on the day of experiments. 
Confluent SHSY5Y cells were seeded into black walled clear base 
96-well plates at a density of 30,000 cellslwell over night in 
supplemented MEM excluding hygromycin B (Marshall et ai, 2006). 
Fluo-4AM aliquots (50 I-Ig) were initially prepared as a 1 mM solution 
in DMSO containing 10% pluronic acid. Cells were loaded in 2.3 I-IM 
Fluo-4AM in MEM supplemented with 10% FCS and 2.5 mM 
probenecid (see appendix for recipe) for 30 minutes at 37°C in a 
humidified atmosphere of 5% C02. 
Agonists and antagonists at varying concentrations were incubated 
with Fluo-4AM for 30 minutes (light sensitive). After an incubation 
period, the plate was loaded on the Flexstation (Molecular Devices) 
before the addition of varying concentrations of capsaicin or TNFa 
prepared in loading buffer (for recipe see appendix). 
The Flexstation is a benchtop scanning fluorometer and integrated 
fluid transfer workstation used to measure fluorescence which can 
measure concentrations of free cytoplasmic calcium, ([Ca2+]i) in 
2+ 
cultured cells, using a 96-well plate format. The Ca -insensitive 
fluorescent dye, Fluo-4AM, permeates cell membranes as an ester 
2+ 
and is hydrolyzed in the cell to its Ca -sensitive acidic form. 
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Fluorescence in the adherent cells is measured over time by using a 
bottom read of a 96-well plate. The machine monitors all the wells in 
a column over a time course, during which up to three compounds 
can be added robotically. Multiple columns are read sequentially for 
additional run times. Data are expressed as relative fluorescent units 
(RFU). Intracellular calcium levels were measured at excitation 485 
nm and emission 520 nm. Capsaicin or TNFa was added after 
20seconds. In separate experiments TNFa was added after 20 
seconds, followed by capsaicin addition at 260 seconds. This was 
expressed as relative fluorescence intensity. Note: Fluo-4-AM and 
agonists/antagonists were not washed away before application of 
capsaicin or TNFa. 
3.2.3 Western Blotting 
DRGs were prepared as described earlier; with the exception that 33 
IJI of cell suspension was added to a 6 well plate and incubated 
overnight in supplemented media. The following day, cells were 
washed with PBS, and treated with either TNFa, or buffer for 4 
minutes. In separate experiments, cells were incubated with either 
the p38 MAPK inhibitor SB706504 (10IJM) and TNFa or SB706504 
alone for 4minutes. The supernatant was aspirated and DRGs were 
harvested in ice cold PBS by scraping. The cell suspension was 
centrifuged, supernatant removed and the cell pellet was lysed in 100 
IJI lysis buffer (for composition see appendix a) containing Complete 
Mini protease inhibitor cocktail (from Roche). 1 tablet was added to 
10 ml lysis buffer before use. The cell lysate was shaken for 30 
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minutes at 4°C to ensure complete lysis. 10 IJI cell solution was 
transferred to another Eppendorf tube for protein quantification. The 
remaining solution was stored at -80°C Note: due to the low protein 
yield of DRG cultures, n=3 rats per drug treatment, and DRGs were 
re-suspended in a minimal volume of lysis buffer. 
However, in cell membrane preparations, cells were lysed in 100 IJI 
TRIS/HCI buffer (see appendix for recipe). The cell solution was 
shaken for 30 minutes at 4°C to ensure lysis of cells, and then 
centrifuged at 40,000 x g for 30 minutes to pellet cell membranes. 
The cell supernatant was transferred to another Eppendorf tube, with 
10 IJI of solution used for protein quantification. 
3.2.3.1 hTRPV1-SHSY5Y sample preparation for western 
blot analysis 
Cells were grown in T75 culture flask in supplemented MEM until 
80% confluent. Medium was removed by aspiration, cells were 
washed with PBS, and harvested via scraping using ice cold PBS. 
The cell suspension was centrifuged, the supernatant removed and 
the cell pellet lysed in 200 IJI lysis buffer containing Complete Mini 
protease inhibitor cocktail. Whole cell samples were then prepared 
as described earlier. 
15 IJI of 6x Laemmli solubilisation buffer (for recipe see appendix ) 
were added to samples. Note: 6 x solubilation buffers was used 
instead of 2 x due to low protein content. 
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The cell fraction was often very viscous after addition of solubilisation 
buffer, so samples were boiled at 95°C using a hotplate for 5 
minutes, followed by centrifugation at 15,000 x g at 4°C for 5 
minutes. Samples were used immediately or stored at -20°C for 
immunoblotting analysis. 
3.2.3.2 Lowry protein assay 
In order to compensate for the variation in cell numbers between 
different cell treatments, lysed cell pellets were assayed for total 
protein content using the Lowry method (Lowry at a/., 1951). Serial 
dilutions of standards were prepared as outlined in Table 3.1 using 
Conc. (mg/ml) 0 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 
H20 (JJI) 500 475 450 425 400 375 350 325 300 
BSA (JJI) 0 25 50 75 100 125 150 175 200 
Table 3.1 Protein concentration serial dilutions from esA. 
200 1-11 of each standard concentration and 200 1-11 of diluted samples 
were transferred into a new microfuge tube. 1 ml of Lowry reagent 
(for composition, see appendix) was added to the samples and the 
standards. After 10 minutes, 100 1-11 of FOlin phenol reagent (1:1 
diluted in MiIIi-Q-water) were added to the samples and the 
standards. After 45 minutes, 200 1-11 of samples, blank and standards 
were loaded into a 96-well plate (in triplicate) and absorbance was 
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measured at 750 nm, on a Dynatech Laboratories MRX 
spectrophotometric plate reader, using Dynex Revelation software. 
The correct protein concentration was calculated by multiplying the 
final value by the dilution factor of the samples, and protein 
concentrations were expressed in mg/ml. 
3.2.3.3 Antibodies Used 
Phospho-p38 (p-p38MAPK) primary antibody and p38 MAPK primary 
antibody were supplied by Cell Signalling Technology Inc. (NEW 
ENGLAND BIOLABS, UK). CB1 primary antibody was supplied by 
Calbiochem, TRPV1 primary antibody were supplied by Tocris, 
TNFR1 primary antibody was supplied by Abeam. P-p38 MAPK 
antibody detects p38 MAPK that is dually phosphorylated Thr180 
(threonine 180) and Tyr182 (Tyrosine182). p38 MAPK detects 
endogenous levels of total p38a, -13 or -y MAPK protein. CB1 
antibody detects amino acid sequence 1-77 of rat CB1 receptor, 
TRPV1 detects C-terminal amino acids 822 to 838 of rat TRPV1 with 
a cysteine added at the N-terminus of the peptide for conjugation to 
keyhole limpet haemocyanin (KLH). TNFR1 antibody detects 
SynthetiC peptide sequence: GLVPHLGDREKRDSV, corresponding 
to amino acids 29-43 of Human TNF Receptor I. A polyclonal 
infrared goat anti-rabbit secondary antibody supplied by LiCor 
Bioscieneces (Cambridge, UK) was used to label antibodies at 700-
800nm infrared emission wavelengths for all antibodies except p-p38 
MAPK, where Goat anti-mouse antibody was used. These 
secondary antibodies were used for samples analysed using 
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Odyssey system. For samples quantified using ECl, A polyclonal 
goat anti-rabbit secondary antibody (used for all antibodies, 
excluding p-p38MAPK, where goat anti-mouse secondary antibody 
was used) supplied by Sigma (UK) was used to bind to the primary 
antibodies. GAPOH and ~ - a c t i n n was used to confirm equal protein 
loading of samples. 
3.2.3.4 Running the gels 
10% Sodium dodecyl sulphate (SOS) polyacrylamide gel 
electrophoresis (SOS-PAGE) gels (resolving gel) were prepared 
according to the manufacture's instruction for use with a Sio-Rad 
Mini Protean III apparatus for Western blotting. A 4% SOS-PAGE gel 
(stacking gel) layered on top of the resolving gel was used for loading 
samples. Precision Plus Protein all blue standards (5 1-11) were used 
as markers supplied by Sio-Rad laboratories Ltd (UK). This marker 
contains ten proteins of the following molecular weights: 10, 15, 20, 
25, 37, 50, 75, 100, 150, and 250 kO. Samples containing about 1 
I-Ig protein per lane were loaded (in 10 lane gels). The gels were run 
in loading buffer (for composition, see appendix-A) at 200 V 
(constant) for 45 minutes, or until the dye front ran off the gel. 
The proteins were then transferred onto nitrocellulose membranes in 
transfer buffer (for composition, see appendix-A) using a Sio-Rad Kit 
at 100 V for 60 minutes in a cold room (at 4°C). Nitrocellulose 
membranes (blots) were tested for satisfactory protein transfer with 
Ponceau red stain (supplied by Sio-Rad). The stain was then washed 
away with Milli-Q-water. The blots were then blocked in blocking 
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buffer [5% fat-free dried milk powder in TBST buffer (for composition, 
see Appendix) for 60 minutes at room temperature with gentle 
shaking. The blots were washed twice with TBST buffer and 
incubated with the primary antibody at a 1: 1 000 dilution, made up in 
blocking buffer, overnight at 4°C. Next day, the blots were washed 
three times with TBST buffer, and washed three times with TBST for 
15 minutes. 
The blots were then incubated with secondary antibody at a 1 :2000 
dilution, made up in blocking buffer, for 60 minutes at room 
temperature. The blots were then washed with TBST buffer as 
previously, and finally washed with Milli-Q-water. 
3.2.3.5 Visualislng the protein bands- Eel 
The blots were exposed to ECL detection solution (equal volumes of 
solution 1 (luminal/enhancer solution) & 2 (peroxide buffer solution) 
prepared just prior to the use) for one minute. The blots were dried 
(by placing between two filter papers) and wrapped in SaranWrap® 
cling film. The blots were placed in an X-ray cassette and exposed to 
Hyperfilm EeL autoradiography film (from Amersham Bioscienes, 
U.K.), in dark room for up to 5 minutes. The films were then 
developed and fixed using Kodak GBX developer (from Sigma-
Aldrich, U.K.) and IIford Hypam rapid fixer (From IIford Imaging Ltd, 
U.K.). Proteins bands were detected based on the principle of 
enhanced chemiluminescence. 
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3.2.3.6 Densitometry 
The developed Western blot films were scanned using a GS-710 
Imaging Densitometer (Sio-Rad) on transmission mode using the 
Quantity One software package for image analysis. 
3.2.3.7 Running Gels- Odyssey 
Carried out by Uaque Latif 
Unlike conventional Western blotting, where diffusion is the primary 
means of reagent transport, the SNAP i.d. system applies a vacuum 
to actively drive reagents through the membrane, which is less time 
consuming. The Snap 10 cassettes were soaked in dH20 for 
approximately 1 minute and laid out for immunoblotting. The 
nitrocellulose was placed in the cassette (molecular marker face 
down), and rolled to remove bubbles. The cassette was placed in 
Snap 10 and the nitroce"ulose is blocked with 1.5% concentration of 
fish skin gelatine. (Stock is 45%, so need to dilute 1:30 in TBST). 
The blocking agent was poured over the nitroce"ulose blot and pulled 
through via vacuum. A 1/1000 dilution of primary antibody was used 
in 1.5% fish skin gelatine, antibodies are left on for 1 0 minutes, ran 
through Snap 10 and then washed three times with TBST. 1/2000 
dilution of the 2° antibody was also used in 1.5% fish skin gelatine, 
and was pipetted over nitroce"ulose for a further 1 0 minutes (Note: 
secondary antibodies are light sensitive, thus Snap 10 box was 
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covered). This was then run through Snap ID, washed three times 
with TBST and the nitrocellulose removed and placed in dH20. 
The nitrocellulose blot was placed moist, upside down and analysed 
using Odyssey infrared imaging system. 
3.2.4 Endocannabinoid Measurements 
DRG neurones were prepared in a similar manner to that of the 
Western blot sample analysis. Neurones were treated with capsaicin 
(1 nM, 10 nM, 100 nM, or 1 ~ M ) ) for 1 minute (as in calcium imaging 
experiments). The supernatant was removed and stored at -80°C 
and neurones were removed via scraping. However, due to low cell 
number and sample weight, we were unable to measure 
endocannabinoids in DRG neurones, therefore the effects of various 
agonists and antagonists on endocannabinoid levels were 
investigated in hTRPV1 SHSY5Y. Experiments were designed to 
mimic previous calcium imaging experiments. hTRPV1 SHSY5Y 
cells were grown to approximately 80% confluence in supplemented 
MEM. Cells were washed with PBS before the addition of capsaicin 
(1 nM-1 uM) for 1 minute. The supernatant was removed and stored 
on dry while, while cells were harvested via scrapping in ice cold 
PBS. The effects of IRTX (100 nM) and URB597 (1 ~ M ) ) on 
capsaicin-evoked endocannabinoid release were also investigated. 
Cells were washed in PBS followed by addition of either IRTX (100 
nM) for 1 minute or URB597 (1 ~ M ) ) for 4 minutes (Millns at a', 2006), 
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followed by addition of 10 nM capsaicin (EC50 value) for 1 minute. 
The supernatant was removed and stored on dry while, while cells 
were harvested via scraping in ice cold PBS. Following collection, 
samples were stored at -SOoC until analysis. 
The processing of samples with extraction and analysis of analytes is 
described in detail in Chapter 2. Cells were homogenised in ice-cold 
acetonitrile, samples were shaken twice at 4°C for 1 hour and the 
supernatant collected. Samples were dried under vacuum and 
reconstituted in 100 IJL Acetonitrile. 5 ml Acetonitrile was added was 
added to the supernatant collected from cell treatment. Samples 
were shaken twice at 4°C for 1 hour and the supernatant collected. 
Samples were dried under vacuum and reconstituted in 1 00 ~ L L
acetonitrile. 
The LC-MSIMS method allowed for the quantification of AEA, 2-AG, 
virodhamine, OEA, PEA, 2-LG, and COX-2 metabolites of AEA, and 
2-AG (Le.PG-EA and PG-GE). AEA-d8, 2-AG-d8 and PGF2a-EA-d4 
were used as internal standards. 
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3.3 Results 
The response of DRG neurones to 100nM capsaicin , Figure 3.1 
shows examples of images captured during calcium imaging 
experiments. The DRGs examined had a mean diameter of 25.7±1 .9 
~ m m and are, thus, classified as small diameter neurones. 
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Figure 3.1 Ratiometric calcium pseudocolour images of DRG 
neurones in the presence and absence of capsaicin . 
Fluorescence emission measured at wavelengths: 340nm and 
380nm under basal conditions (A+8) and after capsaicin 
administration (D+E). Fluorescing cells appear green. The 
ratio image shows the ratio between light emitted at 340/500 
nm and 380/500 nm, under basal conditions (C) , and after 
capsaicin (100nM) administration (F). Cells that appear 
yellow/orange after capsaicin administration , compared to 
green under basal conditions, have an increase in intracellular 
calcium. 
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3.3.1 Effects of varying concentrations of capsaicin on 
intracellular calcium responses in adult rat dorsal 
root ganglion neurones in vitro 
In untreated DRG neurones, the 340/380 nm ratio (reflecting basal 
intracellular calcium concentration [Ca2+]i) was 3.4±1.5 % KCI 
response (n =364). 
Capsaicin produced a concentration-dependent increase in [Ca2+]i 
(figure 3.2) (p<O.001) compared to basal, with an estimated EC50 
value of 20±0.2 nM, (n=204) (Figure 3.2). In generating the 
concentration 1 response curve, cells were exposed to a range of 
capsaicin concentrations, with an average of 38% of the neurones 
examined responding to capsaicin at varying concentrations. There 
was a concentration-dependant increase in the number of neurones 
responding to capsaicin (Table 3.2), and little evidence of 
desensitisation. 45 Minutes after an initial exposure to 100nM 
capsaicin, a second exposure of the cells to the same concentration, 
produced a signal that was 81 ± 7% (n=26) of the first response 
(Figure 3.3). 
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Capsaicin concentration (!.1M) % cell responding 
0.001 9.2±3.4 
0.01 24.B±9.6 
0.05 29.7±11.3 
0.1 36.3±14.2 
0.3 49.2±19.1 
1 67.1±23.1 
Table 3.2 percentage of small diameter DRG neurones responding 
to varying concentrations of capsaicin. 
To confirm that this response was TRPV1-mediated, DRG neurones 
were pre-treated with the competitive TRPV1 antagonist IRTX (100 
nM), and then suprafused with varying concentrations of capsaicin. 
Pretreatment with IRTX (100 nM) significantly inhibited capsaicin-
evoked increases in [Ca2+]j causing a rightwards shift in the 
capsaicin concentrationl response curve. This allowed an inhibition 
constant (Ki) of 7 nM to be calculated. 
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Fig 3.2 Effects of capsaicin (closed bars) and capsaicin + IRTX (100 
nM) (open symbols) on [Ca2+]j in DRG neurones, expressed as a 
percentage of KCI response. n=37-61 neurones per concentration 
from 3 rats. 
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Figure 3.3 A representative trace showing changes in 340: 380 nm 
ratios in four individual DRG neurones, in response to capsaicin. 
Recordings of 340:308 ratio were made at various time points, 
where1= 2minute recording, 2 and 3 = 46 minute recording, 4= 3 
minute recording. At point A, the cell was exposed to capsaicin (50 
nM) for 60 s. Forty-five minutes later, at point 8, capsaicin (50 nM) 
was reapplied with no evidence of desensitisation. After another 45 
min (C) KCI (60 mM) was applied to depolarize neurones. 
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3.3.2 The role of CB1 receptors in modulation of 
intracellular calcium responses 
We have previously shown that CB1 receptor agonists can modulate 
capsaicin-evoked calcium responses (Millns et aI., 2001). In the 
presence of the CB1I2 receptor agonist HU210 (1 ~ M ) , , peak 
responses to capsaicin (100 nM) were significantly reduced to 
44.4±2.7% of the control capsaicin response (Figure 3.4; P<0.001, 
n=58). Pre-incubation with the CB1 receptor antagonist AM251 (1 
~ M ) ) partly reversed the inhibitory effect of HU210 (1 ~ M ) ) on the 
capsaicin (100 nM)-evoked response (67.9±2.8% of control 
response, n=48 neurones, Figure 3.4). AM251 alone had no 
significant effect on capsaicin-evoked responses (92+2% of control 
capsaicin response, n=37 neurones). 
*** 
HU210+ AM251 
Figure 3.4 Inhibition of capsaicin-evoked calcium responses in the 
presence of HU210 and reversal by AM251 in DRG neurones. 
Results are expressed as percentages of the responses to 100 nM 
capsaicin alone. In the presence of HU210 (1 ~ M ) ) the capsaicin 
response was reduced to 44.4±2.7% of control (P<0.001, n=58). Co-
administration of AM251(1 ~ M ) ) partially reversed this to 67.9±2.8% of 
control (***P<0.001, Mann Whitney, compared with HU210). 
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3.3.3 Effects of capsaicin on endocannabinoid levels in 
rat DRG neurones 
The effects of varying concentrations of capsaicin on levels of 
endocannabinoids (ECs) in rat DRG neurons were investigated. 
Levels of OEA were significantly reduced following capsaicin 
application, while levels of PEA and 2-AG were unaltered following 
capsaicin application; however, levels of AEA were below the limit of 
quantification (Table 3.3), due to the small cell yield from DRG 
cultures. Therefore, as an appropriate alternative, a neuronal cell 
line was used to investigate the role of TRPV1 activation in EC 
synthesis. 
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Treabnent AEA pmoVg OEA nmollg PEA nmol/g 2-AG nmol/g 
Cell Super Cell Super Cell Super Cell Super 
Capsaicin NO NO 6.45±O.89** 5.28±O.16** 15.49±3.57 38.77±8.45 NO NO 
Vehicle NO NO 13.39±1.75 14.02±1.46 14.50±O.73 89.20±65.38 NO NO 
-- -- - ---
Table 3.3 Levels of ECs in rat ORG neurone cultures expressed as 9 wet weight, following treatment for 1 minute with 100nM 
capsaicin or vehicle. Oata were analysed using Mann-Whitney non-parametric testing, **P<O.01 vs vehicle treated cells. 
Abbreviations; NO=not detected (below level of quantification; AEA=2.5pmol/g, 2-AG=10nmol/g), super-supernatant. 
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3.3.4 hTRPV1 SHSY5Y 
Primary neuronal cell culture produces low cell yields, which proved 
to be insufficient for the routine measurement of ECs. Currently, 
there is a lack of neuronal models available that natively express 
TRPV1 receptors, TRPV1 have been studied in heterologous 
expression systems such as HEK cells and CHO cells (Caterina et 
aI., 1997, Hayes et aI., 2000, Lam et aI., 2005); however, these do 
not provide a neuronal environment that models the situation in 
sensory nerves. It has proved to be difficult to obtain stable TRPV1 
transfects in neuronal host cells but we have been fortunate to obtain 
SHSY5Y human neuroblastoma cells that stably express TRPV1 
receptors from Prof David Lambert (University of Leicester). The cells 
exhibit a pharmacological profile consistent with endogenous TRPV1 
receptor expression in neurones (Lam et aI., 2007) . 
3.3.5 Capsaicin concentration/response in hTRPV1 
transfected SHSY5Y cells 
Capsaicin produced a statistically significant, concentration-related 
increase in [Ca2+]i (p<0.001), compared to basal, with an estimated 
EC50 value of 9 nM, (n=4) (Figure 3.5). This was similar to the EC50 
of 20nM in primary DRGs (Figure 3.2). To confirm that this response 
was TRPV1-mediated, SHSY5Ys were pre-treated with the TRPV1 
selective antagonist IRTX (100 nM), and then suprafused with 
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increasing concentrations of capsaicin. IRTX treatment significantly 
inhibited capsaicin-evoked increases in [Ca2+]j causing a rightwards 
shift in the capsaicin concentration! response curve, allowing 
calculation of a Kj value of 30 nM for IRTX (compared with 7 nM in 
DRGs; Figure 3.2). 
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Figure 3.5 Effects of capsaicin (closed symbols) and capsaicin + 
IRTX (10nM) (open symbols) on [Ca2+]j in hTRPV1 SHSY5Y cells, 
expressed as a percentage of the maximum capsaicin response. n=3 
separate experiments carried out on Flexstation. 
We and others have shown that CB1 receptors present on rat DRGs 
are functional and that they can modulate nociceptive responses 
(Hohmann and Herkenham, 1999, Ahluwalia et aI., 2000, Millns et 
aI., 2001, Sagar et aI., 2005, Millns et aI., 2006). Therefore, the 
effects of CB1 agonists and antagonists in SHSY5Ys were 
investigated. 
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3.3.6 Cannbinoid response in hTRPV1-SHSY5Y cells 
Cells were incubated with either the CB1/2 receptor agonist HU210 (1 
IJM), the CB1 receptor antagonist AM251 (1 IJM) or a combination of 
both for 30 minutes prior to exposure to 10 nM capsaicin 
(approximate ECso value). Neither HU210 (1 IJM) nor AM251 (1 IJM) 
had any effect alone on [Ca2+Jj. HU210 significantly reduced calcium 
responses to capsaicin to 49±4% of the response to capsaicin alone. 
Surprisingly, AM251, also significantly reduced the capsaicin-evoked 
response to 71±3% and co-application of AM251 and HU210 further 
reduced the capsaicin-evoked responses to 21±3%. The 
combination of HU210 and AM251 may be toxic to these cells; 
however, for this to be the case AM251 alone would have to be toxic, 
which was not observed (Figure 3.6). It is also worthy of note that 
AM251 alone had no effect on [Ca2+11 in DRG neurones. 
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Figure 3.6 Inhibition of capsaiCin responses in the presence of 
HU210 or AM251 separately and in combination. Results are 
expressed as percentages of the responses to 10 nM capsaicin 
alone. In the presence of HU210 (1 I-IM) the capsaicin response was 
reduced to 49±4% of control (P<O.001, n=3). AM251 also reduced 
the capsaicin response to 71±3% (P<O.05, n=3). Co-administration 
of AM251 (1 I-IM) further reduced this response to 21±3% of control 
(**P<O.005), compared with HU210 plus capsaicin. 
The potential function of CB2 receptors in SHSY5Y was also 
investigated to see if activation could modulate calcium responses. 
The CB2 receptor agonist JWH-133 (1 I-IM) and CB2 antagonist 
SR144528 (1 I-IM) were, however, without effect on capsaiCin 
responses (Figure 3.7). 
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Figure 3.7 Capsaicin responses in the presence of SR144528, JWH-
133 separately and in combination. Results are expressed as 
percentages of the responses to 10 nM capsaicin alone. 
CB1 receptor expression in TRPV1-transfected SHSY5Y cells was 
compared to CB1 receptor expression in rat ORG neurones and 
untransfected SHSY5Y cells. Due to the lack of effect of CB2 
receptor ligands in modulating capsaicin-evoked calcium responses, 
it was decided only to investigate CB1 receptor expression. 
CB1 receptor protein appeared to be expressed by rat DRG 
neurones; in immunoblots; a faint band was detected at approx 60 
kOa, (Figure 3.8), consistent with previous reports (Song and 
Howlett, 1995, Matias et aI., 2002, Porcella et aI., 2002, Wager-Miller 
et aI., 2002). 
Both hTRPV1 and native SHSY5Y stained positive for the CB1 
receptor protein, although the bands were detected at a slightly lower 
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mass than the rat C8 1 band , which may be due to species 
differences in post-translational modification (Figure 3.8) . 
On the basis of desitometric analysis , C81 bands from the native and 
transfected SHSY5Ycelis and rat DRG neurones appeared to show 
equal levels of expression when normalised to GAPDH. 
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Figure 3.8 Quantification of C81 receptor protein expression in rat 
DRG neurones (8) , hTRPV1 SHSY5Y (A) , and SHSY5Y (C) cells 
detected by Western blotting and quantified using Odyssey. Rat 
DRG primary neuronal cultures were prepared from 3 rats. SHSY5Y 
cells were from 1 flask 70% confluent at passage numbers 14-23. 
Data are expressed as percentages of GapDH intensity mean±SEM 
(n=3 separate experiments) . 
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3.4 Endocannabinoid levels in htrpv1-SHSY5Ys 
cells and supernatant 
It is well documented that ECl synthesis is stimulated by increases 
in intracellular calcium and previous authors have suggested that 
TRPV1 might be a key player in controlling synthesis via intracellular 
AEA activation of the receptor channel. To investigate this further, we 
measured ECl levels in hTRPV1-SHSY5Y cells, and in the cell 
supernatant following stimulation with a range of concentrations of 
capsaicin, and determined whether levels were altered with 
URB597(1 IJM) or IRTX (100 nM) treatment. 
3.4.1.1 Effects of varying concentrations of capsaicin on 
Eel levels 
levels of AEA, OEA, PEA and 2-AG in hTRPV1-SHSY5Ys were 
measured following incubation with varying concentrations of 
capsaicin (1 nM, 10 nM, 0.1 IJM, and 1 IJM). levels of AEA were 
significantly increased in cells treated with 1 nM capsaicin compared 
to control cells (Figure 3.9). There was a trend towards an increase 
in 10 nM, 0.1 IJM, and 1 IJM capsaicin-treated cells; although 
significance was not reached. levels of 2-AG were significantly 
higher only in cells treated with 0.11JM capsaicin compared to control 
cells. Interestingly, there was a decrease in levels of PEA following 
capsaicin treatment (1 nM, 10 nM, 0.1 IJM, and 1 IJM), whereas 
levels of OEA were not significantly altered by capsaicin (Figure 3.9). 
Given the concentration-dependent effects of capsaicin on [Ca2+]1 
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shown earlier, it is, therefore, clear that there was no correlation 
between whole cell endocannabinoid levels and [Ca2+];. 
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Figure 3.9 Effects of varying concentrations of capsaicin or PBS 
(control) on the levels of endocannabinoids in hTRPV1 SHSY5Y 
cells. Data were analysed using the Mann-Whitney non-parametric 
test and expressed as the median and range, (n=4-5 separate 
experiments). ·P<0.05, ··P<0.01 vs. control treated cells. 
Levels of ECs in the supernatant followed a similar trend to that 
observed in the whole cells after capsaicin treatment. Levels of AEA 
in the supernatant appeared, if anything, to decrease with increasing 
capsaicin concentration and were undetectablelbelow the limit of 
detection in control and 1 uM capsaicin-treated cells. Capsaicin 
treatment had no clear effect on levels of PEA and OEA, with levels 
significantly lower following 10 nM and 1 IJM capsaicin treatment, 
compared to control supernatants (Figure 3.10). 
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Interestingly, levels of 2-AG were elevated following treatment with 
capsaicin, with levels of 2-AG at their highest following 0.1 ~ M M and 
1 ~ M M capsaicin treatment (Figure 3.10) . 
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Figure 3.10 Effects varying concentrations of capsaicin or PBS 
(control) on the levels of endocannabinoids in hTRPV1 SHSY5Y cell 
supernatant. Data were analysed using the Mann-Whitney non-
parametric test and are expressed as the median and range, (n=4-5 
separate experiments). ·P<O.05, ··P<O.01 vs. control cell 
supernatant. 
A correlation analysis of the levels of Eels in the whole cells and cell 
supernatants was undertaken to investigate the relationship between 
cell and released Eels. Spearman rank correlation coefficients (R2) 
were calculated and demonstrated that there was no correlation 
between intracellular and extracellular levels of Eels, regardless of 
the concentration of capsaicin (data not shown). 
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3.4.1.2 Effects of IRTX (100nM) and capsaicin (10nM) on 
Eel levels 
It is apparent from the data shown above that there is no 
straightforward relationship between intracellular calcium 
concentrations and ECl levels. To examine this further, the effects 
of the TRPV1 antagonist IRTX (100 nM), which significantly inhibited 
capsaicin-evoked increases in intracellular calcium (Figure 3.S) were 
determined. Surprisingly, IRTX in the presence of capsaicin, 
significantly increased levels of OEA, PEA, and 2-AG (P<O.OS) and 
there was a trend towards an increase in AEA, although significance 
was not reached (Figure 3.11), levels of PEA were significantly 
elevated, compared to those in control cells, following application of 
IRTX alone, while levels of AEA, OEA, and 2-AG were unaltered 
(Figure 3.11). These data suggest that the synthesis of ECls is not 
simply enhanced by increasing [Ca2+], at least via TRPV1 activation. 
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Figure 3.11 Effects capsaicin (10 nM) and I RTX( 100 nM) on the 
levels of endocannabinoids in hTRPV1 SHSY5Y cells. Data were 
analysed using Mann-Whitney non-parametric testing and are 
expressed as the median and range, (n=4-5 separate experiments). 
·P<0.05 vs. c antral treated cells, $P<0.05 vs. IRTX (100 nM) + 
capsaicin (10 nM). The control and 10nm EC levels were taken from 
the previous set of experiments. 
However, in the extracellular medium, levels of PEA, OEA and 2-AG 
were decreased following pre-treatment with IRTX (10 nM) compared 
to contral (Figure 3,12). Treatment with capsaicin and IRTX did not 
further alter levels of PEA, OEA or 2-AG; levels of AEA were 
unaltered following IRTX treatment, in the presence and absence of 
capsaicin (Figure 3.12). 
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Figure 3.12 Effects of capsaicin (10 nM) and IRTX (100 nM) on the 
levels of endocannabinoids in hTRPV1 SHSY5Y cell supernatants. 
Data were analysed using Mann-Whitney non-parametric testing and 
are expressed as the median and range, (n=4-5 separate 
experiments). ·P<0.05, **P<0.01 vs. control treated cell 
supernatant, $$P<0.01 vs. IRTX (100nM) + capsaicin (10nM). The 
control and 10nm EC levels were taken from the previous set of 
experiments. 
3.4.1.3 Effects of URB597 (1 J,lM) and capsaicin (10 nM) on 
Eel levels 
It was expected that capsaicin-induced increases in [Ca2+]1 would 
enhance ECl synthesis. However, this was not reflected in increased 
levels of ECls in the cells or supernatants. Given that extracellular 
levels were unaltered, it is unlikely that the effects of any increased 
synthesis were masked by transport out of the cells. Another 
possibility is that capsaicin also increased ECl metabolism, thereby 
blunting any increases in parent ECl levels. To investigate the 
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potential role of increased metabolism in altering levels of Eels, the 
effects of the FAAH inhibitor URB597 (1 !-1M) were investigated on 
levels of both intracellular and extracellular Eels. 
Neither URB597 (1 !-1M) alone nor the combination of capsaicin and 
URB597 altered levels of AEA, OEA or PEA in the whole cell (Figure 
3.13). Interestingly, URB597 treatment increased levels of 2-AG but 
these were not elevated further in the presence of capsaicin. 
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Figure 3.13 Effects of capsaicin (10 nM) and URB597 (1 !-1m) on the 
levels of endocannabinoids in hTRPV1 SHSY5Y cells. Data were 
analysed using the Mann-Whitney non-parametric test and are 
expressed as the median and r a n ~ e , , (n=4-5 separate experiments). 
··P<0.01 vs. control treated cells, P<0.05 vs. URB597 + capsaicin 
(10 nM). The control and 10 nm Eel levels were taken from the 
previous set of experiments. 
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In relation to the cell supernatants, neither URB597 (1 IJM) alone nor 
the combination of capsaicin and URB597 altered the levels of AEA, 
PEA and OEA compared to control (Figure 3.14). The effects on 2-
AG supernatant levels mirrored those in the whole cells; URB597 
alone increased 2-AG but this was not enhanced further in the 
presence of capsaicin. 
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Figure 3.14 Effects of capsaicin (10 nM) and URB597 (1 IJM) on the 
levels of endocannabinoids in hTRPV1 SHSY5Y cell supernatant. 
Data were analysed using Mann-Whitney non-parametric testing and 
are expressed as the median and range, (n=4-5 separate 
experiments). ·P<0.05, **P<0.01 vs. control treated cell supernatant, 
$P<0.05 vs. URB597 (1 IJM) + capsaicin (10 nM). The control and 10 
nm ECl levels were taken from the previous set of experiments. 
A correlation analysis of the levels of ECls in the cell and cell 
supernatant was also undertaken following URB597 application in 
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the presence and absence of capsaicin (10 nM). Spearman rank 
correlation coefficient (R2) analysis demonstrated that there was no 
correlation between levels of intracellular and extracellular, ECLs 
following URB597 treatment (data not shown). 
3.5 Modulation of TRPV1 function by TNFa 
Pro-inflammatory mediators such as TNFa are known to increase the 
sensitivity and excitability of nociceptors by enhancing the activity of 
receptors and ion-channels such as TRPV1. To investigate this 
further, the effects of the pro-inflammatory cytokine TNFa in 
modulating intracellular calcium levels and TRPV1 expression were 
examined. 
3.5.1 Effects of varying concentrations of TNFa on 
intracellular calcium responses in adult rat dorsal 
root ganglion neurones in vitro 
The mean diameter of DRG neurones examined in this study was 
28.3±2.1 ~ m . . In untreated DRG neurones, the 340/380 nm ratio 
(reflecting basal [Ca2+]i) was 2.5±0.7% KCI response (n =81). 
Neurones were exposed to increasing concentrations of TNFa (3 
ng/ml-200 ng/ml); this produced an increase in [Ca2+]i (p<0.005) 
compared to basal, with a maximal effect seen at 100 ng/ml (Figure 
3.15). In this case, TNFa was applied via Pasteur pipette, rather 
than suprafusion (to save on material costs) and left in contact with 
neurones for 4 minutes before removal via aspiration. A 
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representative trace of TN Fa-induced increases in [Ca2+]1 is shown in 
Figure 3.16. An estimated EC50 value of 72 ng/ml was calculated for 
TNFa. An average of only 6% of the neurones examined responded 
directly to TNFa at varying concentrations, with a maximum of 9% 
responding at 100 ng/ml. The increase in [Ca2+]j that was observed 
following 50ng/ml TNFa was abolished in experiments that were 
performed without extra-cellular calcium (Figure 3.15b) showing that 
the increases were due to mobilisation of intra-cellular calcium. We 
were unable to record from neurones treated with concentrations of 
TNFa above 200 ng/ml at which concentration neurones were 
washed off the cover slip, suggesting cell toxicity. 
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Figure 3.15 (A+B) Effects of TNFo on [Ca2+]i in DRG neurones. 
(A)This concentrationl response curve shows the change in [Ca2+]10 
expressed as a percentage of a control KCI, response, evoked by 
increasing concentrations of TNFo. n=7-21neurones per 
concentration from 4 rats (B).The effects of calcium and calcium free 
buffer on changes in [Ca2+]" expressed as a percentage of a control 
KCI, response, evoked by 50ng/ml TNFo. n=9-47neurones from 3 
rats. 
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Figure 3.16 A representative trace showing changes in 340: 380 nm 
ratios in two individual DRG neurones, in response to TNFa 50 
ng/ml. Recordings of 340:308 ratio were made at various time points, 
where 1= 2minute recording, 2 and 3 = 46 minute recording, 4= 3 
minute recording. At point A, the cell was exposed to TNFa (50 
ng/ml) for 4minutes. Forty-five minutes later, at point B, TNFa (50 
ng/ml) was reapplied with no evidence of desensitisation. After 
another 45 min (C) KCI (60 mM) was applied to depolarize neurones. 
3.6 Effects of TNFa on capsaicin-evoked changes 
in intracellular calcium concentrations in DRG 
neurons 
To determine whether exposure to TNFa affected the capsaicin 
response in DRG cells, neurones were treated with TNFa (50ng/m)1 
for 4 minutes; 50ng/ml was used at it produced approximately 50% of 
the maximal effect and 4 minutes was the optimum time to induce an 
increase in [Ca2+]1 without washing neurones off the cover slip. SOnM 
capsaicin was used as this was the approximate EC50 value for the 
calcium response (figure 3.17). 50nM capsaicin alone produced a 
peak [Ca2+], response of 34.3±S.9% KCI which was increased to 
42.1±6.9% in the presence of TNFa (P<O.05; Student's t -test). 
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Figure 3.17 A representative trace showing changes in [Ca2+]i 
(340:380nm ratios) in response to TNFa 50 ng/ml (A), exposure to 50 
nM capsaicin(B), and following KCI (60 mM) (C) to depolarize 
neurones. Recordings of 340:308 ratio were made at various time 
points, where1 = 2minute recording, 2 and 3 = 46 minute recording, 
4= 3 minute recording. Following each application of drug there was 
a 45 minute washout period. 
To see if this effect was simply additive, in further experiments, TNFa 
was applied to neurones for 4 minutes, before removal by aspiration, 
followed by capsaicin supra-fusion for 60 seconds. 
Pre-treatment with TNFa for 4 minutes, significantly increased 
capsaicin-evoked [Ca2+]j from 46.6±5.4% with capsaicin to 
58.67±1.9% (P<0.05) (Figure 3.18). TNFa pre-treatment also 
increased the percentage of neurones responding to 50nM capsaicin 
from 27.5±1.9% to 35.1±1.1% for TNFa and capsaicin-treated 
neurones (Figure 3.19) (P<0.01 ;t- test) 
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Figure 3.18 Effects of pre-treatment with TNFa (50 ng/ml) on 
capsaicin-evoked calcium responses in DRG neurones. Pre-
treatment with TNFa significantly increased capsaicin-evoked [Ca2+] j 
responses (n=59-88 neurones, p<0.05). 
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Figure 3.19.Effects of pre-treatment with TNFa on the number of 
neurones responding to capsaicin . TNFa significantly increased the 
percentage of neurones that responded to capsaicin , compared to 
neurones treated with capsaicin alone, (n=59-88 neurones; p<0.01). 
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A representative trace of the increase in percentage of cells 
responding to capsaicin following TNFa treatment is shown in figure 
3.20. This shows that neurones initially unresponsive to capsaicin, 
responded to capsaicin following TNFa treatment, suggesting a role 
for TNFa in neuronal sensitisation. 
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Figure 3.20 A representative trace showing changes in [Ca2+]i 
(340:380nm ratios) in initially capsaicin - unresponsive DRG 
neurones following exposure to 50nM capsaicin, with or without pre-
treatment with TNFa (50 ng/ml). Recordings of 340:308 ratio were 
made at various time points, where1= 2minute recording, 2= 46 
minute recording, 3=4 minute recording, 4= 46 minute recording, and 
5= 3 minute recording. The percentage of neurones responding to 
capsaicin significantly increased from 27.5±1 .9% to 35.1 ±1 .1 % after 
pre-treatment with TNFa (*** p<0.001 ; n=84-103 neurones, from 4 
rats). 
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3.7 Effects of 88706504 on TNFa and capsaicin-
evoked changes in intracellular calcium 
concentrations in DRG neurones 
To investigate the mechanism underlying the TNFa sensitisation of 
DRG neurones to capsaicin, experiments were performed in the 
presence of a phospho-38 mitogen-activated protein kinase 
(p38MAPK) inhibitor 5B706504 (10 IJM); this concentration has been 
reported to inhibit TNFa regulation of p38MAPK (Vanden 8erghe et 
al., 1998, Jin and Gereau, 2006). 
Pretreatment with 5B706504 (10 IJM) for 1 minute, followed by TNFa 
application (50 ng/ml) for 4 minutes, removal of TNFa and supra-
fusion of 50nM capsaicin, did not significantly alter TNFa facilitated 
capsaicin-evoked [Ca2+]j responses (58.1 ±1.8%, compared to 
65.0±4.1% in the absence of 5B706504) (Figure 3.21 a) 
However, pre-exposure to 58706504 did significantly reduce the 
percentage of neurones responding to the combination of TNFa and 
capsaicin (14.6±2.3% compared with 35.3±1.1% in the absence of 
58706504, (p<0.05 Figure 3.21b). 
Pretreatment with 5B 706504 alone, or in combination with either 
TNFa or capsaicin did not alter the capsaicin or TNFa -evoked [Ca2+]j 
responses or the percentage of neurones responding to either TNFa 
or capsaicin alone (data not shown). 
165 
The role of TRPVl in modulating endocannabinoid levels and neuronal responses 
to TNFa 
TNFa + capsaicin TNFa + capsaicin 
S9706504 
a 
u ~ ~
~ ~ Q) 
~ I I I I
o c: 
:::"0 
~ ~ Co 
+ III 
N Q) 
co a:: 
~ ~
TNFa + capsaicin 
b 
TNFa + capsaicin 
58706504 
Figure3.21 a+b Effects of pre-exposure or ~ B 7 0 6 5 0 4 4 and pre-
treatment with TNFa on the responsiveness of DRG neurones to 
capsaicin . 
a) Pre-exposure of DRG neurones to SB706504 significantly reduced 
the percentage of neurones responding to capsaicin following pre-
incubation with TNFa (14 .6±2.3%compared to 35.3±1.1 %) (n=72-101 
neurones from 4 rats) 
b) Pre-exposure to SB706504 did not alter TNFa facilitated 
capsaicin-evoked [Ca2+]j responses(58.1 ±1.8%, compared to 
65.0±4.1 % in the absence of SB706504) (n=49-91 neurones from 4 
rats) . 
3.7.1 Effect of TNFa on P38 MAPK phosphorylation and 
TRPV1 receptor expression 
To investigate whether TNFa stimulates p38 MAPK phosphorylation , 
Western blot analysis using phosphospecific antibodies was carried 
out to asses MAP kinase activation in whole cell Iysates of DRG 
neurones exposed (or not) to TNF for 4 minutes. 
DRGs were prepared following the same protocol used in calcium 
imaging experiments. The cells were harvested via scraping from 6 
well plates, instead of mounting on cover-slips, and levels of phospho 
p38MAPK were normalized to the amount of ~ - a c t i n n present in the 
DRG neurone Iysates. 
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Immunoblotting for phospho p38 MAPK expression in DRG neurons 
detected a major band at 40 kDa consistent with previous reports 
(Clerk and Sugden , 1998, Morrison et aI. , 2000, Ji et aI. , 2002). 
Densitometric analysis showed that p38 MAPK phosphorylation in 
the whole DRG lysate was significantly increased (P<0.01) after 
TNFa treatment, (Figure 3.22). 
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Figure 3.22 Expression of phosphoP38 MAPK protein expression in 
DRG neurones treated with either TNFa (50 ng/ml) or buffer for 4 
mins detected by Western blotting and quantified by densitometry. 
Protein expression was calculated as percentage of expression of 
the internal control , ~ - a c t i i . . Data are shown as means±SEM of the 
expression of phosphoP38MAPK assessed in 3 separate 
experiments. (n=4 rats per treatment) . 
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The levels of TRPV1 expression following TNFa treatment were 
measured in DRG neurones treated with either 50 ng/ml TNF a or 
PBS (control) by Western blot analysis. A band at approximately 103 
kDa was detected consistent with the antibody manufacturer's 
specification . TNFa significantly increased TRPV1 expression in 
whole ceillysates compared to control cells (Figure 3.23). 
1()(J([)a - TRPV1 
* 
Figure 3.23 TRPV1 protein expression in DRG neurones treated with 
either TNFa (50ng/ml) or buffer for 4 mins detected by Western 
blotting and quantified by densitometry. Protein expression was 
calculated as percentage of expression of the internal control , ~ ­
actin . Data are means±SEM of the expression of TRPV1 assessed 
in 3 separate experiments. 
The effect of the p38 MAPK inhibitor SB706504 on TNFa induced 
TRPV1 expression was also investigated, and SB706504 (1 O M ~ M ) )
significantly (P<O.01) inhibited TN Fa-induced increase in TRPV1 
expression (Figure 3.24). Note: The expression of TRPV1 receptors 
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in DRG neurones in the presence or absence of TNFa and 
SB706504 was analyzed using Odyssey software, unlike previous 
experiments wh ich were analysed using ECL. 
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Figure 3.24 TRPV1 protein expression in DRG neurons treated with 
PBS (lane A) , SB706504 (1 0 ~ M ) ) (Lane B), TNFa (50ng/ml) (lane C) , 
or S8706504 (1 0 ~ M ) ) + TNFo (50 ng/ml) (lane D) for 4 mins detected 
by western blotting and quantified by densitometry. Protein 
expression was calculated as percentage of expression of the 
internal control , GAPDH. Data are means±SEM of the expression of 
TRPV1 assessed in 3 separate experiments. 
The effects of TNFo (50ng/ml) in the SHSY5Y cells were investigated 
to see if responses were modulated as was the case for DRG 
neurones. 
Exposure of SHSY5Ys to varying concentrations of TNFa did not 
cause an increase in [Ca2+Ji, Cells were then exposed to capsaicin 
following a 4 minute pre-incubation with 50 ng/ml TNFo (as 
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previously used in DRG neurones). However, TNFa did not alter 
capsaicin-evoked calcium responses (capsaicin + TNFa=104.2±0.4% 
capsaicin response. 
Data presented earlier in this chapter suggested that TNFa increases 
[Ca2+]j via TNFR1 in rat DRG neurones. To investigate this 
hypothesis, TNFR1 expression in DRG neurones and TRPV1-
transfected SHSY5Y cells was investigated (there are no specific 
TNFR1 antagonists). There was a strong protein band detected at 
55 kDa in rat DRG neurones which corresponded to the predicted 
molecular mass of TNFR1 (Figure 3.25). This band was much 
weaker in TRPV1-SHSY5Y cells, suggesting lower levels of TNFR1 
expression. The TNFR1 protein level was higher in native SHSYSY 
cells compared to hTRPV1 cells suggesting that during cloning of the 
transfects TNFR1 may have selected out (Figure 3.2S). 
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Figure 3.25 Quantification and expression of TNFR 1 protein in rat 
primary DRG neurones (n=3 rats) (C), hTRPV1 SHSY5Y cells (A), 
and untransfected SHSY5Y cells (8) detected by Western blotting 
and quantified using Odyssey. Data are expressed as percentages 
of GAPDH intensity (means±SEM) in triplicate determinations. There 
was equal loading of protein as confirmed by GAPDH expression. 
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3.8 Discussion 
In this study, capsaicin-evoked increases in [Ca2+]j in adult DRG 
neurones and hTRPV1 SHSY5Ys have been employed to investigate 
interactions between TRPV1 and CB1 receptors in sensory nerves. 
Our results corroborate previous electrophysiological studies of 
capsaicin-evoked responses (Helliwell et al., 1998), showing 
mediation by TRPV1 (Caterina et aI., 1997). 
Here, we have shown that both DRG neurones and hTRPV1-
SHSY5Y cells express active and functional TRPV1 receptors. The 
excitatory effects of capsaicin and the presence of TRPV1 receptors 
on DRG neurones reported here are in agreement with previous 
studies (Helliwell et ai, 1988, Caterina et ai, 1997), and calcium 
imaging of these small diameter neurones with the TRPV1 agonist 
capsaicin provided a robust and concentration-dependant increase in 
intracellular calcium, which was attenuated with the TRPV1 speCific 
antagonist IRTX. Capsaicin application in DRG neurones can 
desensitize TRPV1 channels via a rapid influx of Ca2+ and activation 
of voltage-sensitive ion channels (Bevan and Szolcsanyi, 1990, 
Koplas et aI., 1997). Thus, the experimental protocols were 
designed so that multiple additions of capsaicin could be applied 
without desensitisation. Effects of capsaicin were readily reversible 
on washout, further suggesting that desensitisation does not 
markedly affect responses; however desensitisation can be 
dependant on the dose and time intervals of capsaicin exposure 
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(Winter et aI., 1988, Maggi et aI., 1990, Craft and Porreca, 1992). It 
is also well known that CB1 receptor and TRPV1 are co-expressed 
on primary sensory neurons see reviews (Szallasi et aI., 1995, 
Szallasi and Blumberg, 1999, Hohmann, 2002, Rice et aI., 2002) and 
in small diameter DRGs (Ahluwalia et aI., 2002, Bridges et al., 2003, 
Price et aI., 2003, Binzen et aI., 2006). As reported by Millns et al., 
(2001) we found that the synthetic cannabinoid agonist HU210 
inhibited capsaicin-evoked Ca2+ responses in DRG neurones. This 
effect of HU210 was reversed by the cannabinoid CB1 receptor 
antagonist AM251(Milins et aI., 2001). Thus, HU210 appears to 
modify TRPV1 responses through CB1 receptor activation and it is 
unlikely that HU210 inhibition of capsaicin-evoked responses is via 
interaction with the TRVR1, as HU210 alone had no effect on 
capsaicin-evoked responses. 
To investigate the relationship between calcium-driven 
endocannabinoid synthesis and TRPV1 activation, levels of ECls in 
rat DRG neurons were investigated following stimulation with 
capsaicin. However, due to the low yield of DRG neurones in 
primary culture preparations, we were unable to quantify ECls in the 
rat DRG. Some groups have quantified ECls in both control and 
stimulated DRGs (Ahluwalia et aI., 2003b, van der Stelt et aI., 2005, 
Vellani et aI., 2008); however, the limits of quantification (lOa) of the 
analytical instruments used in these studies were not given, although 
very low levels of AEA have been reported (0.05pmol in some cases, 
e.g. (van der Stelt et aI., 2005), whereas the lOa used in the present 
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experiments is 0.5pmol/g for AEA. The ORG cell number observed 
following our culture is approximately 10,000 to 20,000 cells per rat 
(observation), however for the quantification of AEA, cell number was 
approximately 10 times this (Vellani et aI., 2008). Therefore, 
excessive numbers of animals would be needed to produce such cell 
numbers. Some of the other experiments were also performed in the 
presence of MAFP, to prevent AEA and 2-AG hydrolysis by FAAH 
(Ahluwalia et al., 2003b), which complicates interpretation, or using 
atmospheric pressure chemical ionization (Vellani et al., 2008), 
instead of electrospray ionisation, as used in the present studies 
which may increase sensitivity. In all cases, samples were analysed 
using lC/MS, and monitored using selected ion monitoring (SIM), 
which is less specifiC compared to multiple reaction monitoring 
(MRM): however, an advantage of SIM is that the detection limit is 
lower since the MS instrument is only looking at a small number of 
fragments (see Chapter 2). 
In order to investigate the roles of calcium and TRPV1 in neuronal 
endocannabinoid synthesis and release, we needed an appropriate 
cell model expressing the receptor channel that would generate large 
enough cell yields to enable quantification of ECls. Previous studies 
have used TRPV1-transfected HEK cells (van der Stelt et aI., 2005, 
Vellani et aI., 2008), mouse neuroblastoma cells (Bisogno et aI., 
1997), rat cortical neurones (Stella and Piomelli, 2001) to investigate 
ECl levels in vitro. However, to date, there is only one stable 
neuronal cell line available that expresses the hTRPV1 receptor 
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(Lam et aI., 2007), with previous studies using recombinant TRPV1 
receptors in non-neuronal cell lines, such as HEK and CHO Thus, 
the SHSY5Y neuroblastoma cell line transfected with TRPV1 (Lam et 
aI., 2007) was used to investigate the relationship between TRPV1-
mediated modulations of cell calcium and endocannabinoid 
synthesis. 
SHSY5Y cells transfected with TRPV1 receptors responded to the 
TRPV1 agonist capsaicin, with increases in intracellular calcium, 
which were attenuated by the antagonist IRTX (figure 3.5), and there 
was good agreement in terms of agonist and antagonist potencies 
compared to primary neuronal DRG cultures. HU210 in the presence 
of capsaicin, significantly decreased the capsaicin response, 
consistent with previous studies (Millns et aI., 2001). Unexpectedly 
however, AM251 alone reduced the capsaicin response, and the 
combination of AM251 and HU210 appeared to have an additive 
effect. The mechanisms behind this inhibition remain unclear. 
However it is surprising that AM251 did not have the same effect as 
SR141716A as seen in DRG neurones (Millns et aI., 2001), 
suggesting that there is a difference in the selectivity or specificity of 
these CB1 antagonists. Indeed, a recent report indicated that 
SR141716A may also antagonize TRPV1 (De Petrocellis et al., 
2001a) therefore, one might conclude that in TRPV1expressing 
SHSY5Y cells AM251 may act as a TRPV1 antagonist although there 
is no existing evidence to support this hypothesis and the antagonist 
had no such effect in DRG neurones. Further pharmacological 
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studies are required to address this unexpected finding, starting with 
an examination of the effects of SR141716A on capsaicin-evoked 
calcium responses in TRPV1-SHSY5Y cells. The existing literature 
reports that treatment of cells co-expressing CB1 and TRPV1 
receptors with CB1 receptor agonists leads to either an inhibition or 
enhancement of TRPV1 activity, depending on the state of activation 
of the cAMP-signalling pathway (Hermann et aI., 2003). Thus, there 
is the possibility that in TRPV1 transfected SHSY5Y cells, AM251 
could inhibit cAMP formation, thereby attenuating capsaicin-evoked 
increases in calcium. Another possibility is that the combination of 
AM251 and HU210 is toxic to these cells, although for this to be a 
viable explanation; AM251 alone would have to be toxic, which was 
not observed. 
Western blot analysis of TRPV1-transfected SHSY5Y cells was 
consistent with the presence of CB1 receptors in both rat DRG 
neurones (Hohmann and Herkenham, 1999, Ahluwalia et aI., 2000) 
and native SHSY5Y cells (Klegeris et aI., 2003) (Marini et aI., 2009). 
The protein band appearing to correspond with CB1 for human 
SHSY5Y cells exhibited a slightly lower molecular weight than the 
CB1 band in rat DRG, which could be due to a difference in post-
translational modification of the protein between the species. Thus, 
the effects of HU210 in attenuating the response to capsaicin are 
largely consistent with CB1 mediation in DRG neurones (albeit with 
the uncertainty over AM251 's effects in SHSY5Y cells). 
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Having confirmed the role of TRPV1 receptors in mediating 
capsaicin-evoked increases in intracellular calcium and the presence 
of CB1 receptors in SHSY5Y cells, we investigated the roles of 
calcium and TRPV1 receptors in controlling endogenous 
endocannabinoid levels. The measurement of ECls provides a snap 
shot in time, and estimates an uncertain balance between synthesis, 
catabolism and export of ECls, and mechanisms governing these 
relationships are unclear. Endocannabinoid generation is reported to 
be triggered by two well known pathways, depolarization-induced 
elevation of Ca2+ (Kreitzer and Regehr, 2001, Ohno-Shosaku et aI., 
2001, Wilson and Nicoll, 2001) and activation of Gq-coupled 
receptors, including group I metabotropic glutamate receptors 
(mGluRs) (Maejima et al., 2001a, Varma et aI., 2001). levels of 
Eels varied following capsaicin application in both whole cell, and 
cell supernatant, and there appeared to be no clear relationship 
between an increase in intracellular calcium, and endocannabinoid 
synthesis and release. levels of AEA were Significantly higher 
following treatment with 1 nM capsaicin, while levels were unaltered 
following higher concentrations of capsaicin. Further experiments 
are required to generate more statistical confidence in these 
observations. It has previously been suggested that receptor 
activation with weak depolarization enhances endocannabinoid 
release (Varma et aI., 2001, Kim et aI., 2002a, Ohno-Shosaku et aI., 
2002) (Ohno-Shosaku et al., 2003). This can be related to the 
capsaicin concentration response curve, where 1 nM capsaicin, 
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produced the lowest response to intracellular calcium elevation, but 
significantly elevated AEA levels. levels of OEA were unaltered at 
all capsaicin concentrations, while capsaicin caused a significant 
decrease in PEA levels. A higher concentration (0.1 ~ M ) ) of capsaicin 
was required to elevate levels of 2-AG. levels of individual ECls 
may vary depending on intracellular calcium levels, with some 
compounds, such as AEA requiring lower calcium levels for their 
synthesis, and others such as 2-AG, requiring higher calcium levels. 
However, it is not surprising that AEA and 2-AG levels are not 
comparable, with AEA and 2-AG belonging to two different classes of 
lipids, although AEA, OEA and PEA belong to the same class, the N-
acylethanolamines, and are synthesied via their corresponding N-
acyl phosphatidyl ethanolamine (NAPE) precursors; thus, it is 
possible that other pathways may contribute to the synthesis of each 
compound, due to their difference in structure (namely the number of 
carbon atoms). Indeed, disruption of NAPE-PlD gene in mice 
increased levels of the precursor NAPE, and decreased brain levels 
of longer chain NAEs, specifically saturated N-acyl chains with 20 or 
more carbon atoms (OEA and PEA) (leung at al., 2006). By contrast, 
levels of longer chain polyunsaturated NAEs, including AEA (C20:4) 
were unaltered in knock-out mice, compared to NAPE-PlD+1+ mice 
(leung et aI., 2006, Liu et aI., 2006, Simon and Cravatt, 2006, Liu et 
aI., 2008). These data further highlight the differences in ECls, and 
differing unknown pathways potentially involved in ECl synthesis 
and metabolism for AEA, OEA PEA and 2-AG which warrants further 
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investigation. In the present study we have found little evidence for 
capsaicin-induced Ca2+ mobilisation elevating levels of ECls, which 
does not support a recent study by Van der Stelt (2005). In the latter 
study it was proposed that AEA acts as an intracellular agonist of 
TRPV1, providing an amplification system for increasing cell calcium, 
whereby activation of TRPV1 leads to an elevation of cytosolic 
calcium, which increases AEA levels, thus providing a positive 
feedback mechanism. Release of AEA is then suggested to act on 
extracellular facing CB1 receptors, to inhibit TRPV1 function (Millns et 
al., 2001). Other 'entourage compounds' such as OEA and PEA 
could, potentially, potentiate these effects. Furthermore, TRPV1 
receptors are activated/sensitised by activation of PKC, leading to an 
increase in AEA levels, but not 2-AG and PEA (Vellani et aI., 2008). 
This suggests that the generation of second messengers, following 
TRPV1 activation has the potential to modulate ECl levels, and to 
potentiate AEA activity at either CB1 or TRPV1 receptors. 
There was no clear relationship between intra- and extracellular 
levels of ECLs and capsaicin concentration. However, it does 
suggest that ECls are released into the extracellular medium, 
possibly via the proposed endocannabinoid membrane transporter 
(EMT), (see reviews (Glaser et aI., 2005, Ho and Hillard, 2005, 
Hermann et aI., 2006). Surprisingly, the TRPV1 antagonist, IRTX 
appeared to elevate intracellular levels of AEA, 2-AG, PEA and OEA 
in the presence of capsaicin. This puzzling observation, may 
suggest other unknown properties of IRTX, such as inhibition of 
179 
The role of TRPVl in modulating endocannabinoid levels and neuronal responses 
to TNFa 
endocannabinoid membrane transporter (EMT); however, further 
studies, such as the use of the EMT inhibitor, AM404 are required to 
test this hypothesis. The effects of FAAH inhibition and increases in 
levels of ECls are well documented (Cravatt et aI., 2001, Maione et 
aI., 2006, Piomelli et aI., 2006, Jhaveri et aI., 2007a, Jhaveri et aI., 
2008b); however, following incubation with URB597 (1 IJM) for 30 
minutes, followed by capsaicin (10 nM) for 1 minute, there were no 
changes in the levels of AEA, PEA and OEA, although 2-AG levels 
were significantly increased both in the presence and absence of 
URB597, suggesting that this increase is via a mechanism 
independent of FAAH inhibition, as 2-AG is not a good substrate for 
FAAH. However, some evidence suggests that 2-AG can also be 
metabolized by FAAH (Goparaju et aI., 1998) and microinjection of 
an FAAH inhibitor into the peri-aqueductal grey increases 2-AG 
levels in that region (Maione et aI., 2006) A cautious interpretation is 
that both FAAH and MAGl partiCipate in 2-AG inactivation to an 
extent depending on the tissue or cell type, although 2-AG levels, 
unlike those of AEA, are not increased in FAAH "knockout" mice 
(Lichtman et aI., 2002). 
Collectively, these puzzling data suggest that increasing cell calcium 
via TRPV1 does not elevate ECl levels, and there is no correlation 
with intracellular and extracellular levels. However, the possibility of 
calcium-independent ECl synthesis must not rule out. Indeed, most 
of the enzymes identified to date that catalyse endocannabinoid 
formation are Ca2+ -sensitive, however Ca2+ -independent 
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endocannabinoid biosynthesis has been suggested to occur during 
certain types of synaptic plasticity (Brenowitz and Regehr, 2003), 
furthermore Oi Marzo's group have shown that AEA levels can be 
elevated in intact neurons independent from elevation of intracellular 
Ca2+ (Vellani et aI., 2008). 
In the second part of this study, we showed that TNFa facilitates 
capsaicin-evoked calcium responses via the activation of p38 MAPK, 
and that inhibition of this pathway may prevent sensitisation of 
sensory neurones to inflammatory mediators. 
The pro-inflammatory cytokine TNFa, increased intracellular calcium 
levels in adult rat ORG neurones; however, the mechanism 
underlying this increase remains unclear. TNFa, acts either on TNF 
receptor 1 (TNFR1), or TNF receptor 2 (TNFR2). Most TNFa effects 
including cell growth and death, development, oncogenesis, and 
immune, inflammatory, and stress responses (for review see (Chen 
and Goeddel, 2002) are mediated through TNFR1, although both 
TNFR1 and TNFR2 have been localised in rat DRG neurones 
(Pollock et aI., 2002, Schafers et al., 2002, Schicho et aI., 2004). 
TNF receptor activation can lead to the mobilisation of intracellular 
stores of calcium (Amrani et al., 1996, Bick et aI., 1997, Parris et aI., 
1999) but, due to the lack of selective TNFR1 antagonists, we were 
unable to investigate if the mobilisation of intracellular calcium was 
TNFR1-mediated. Other reports have shown an increase in 
intracellular calcium levels in human microglia following TNFa 
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application (McLarnon et al., 2001), which appeared to be 
independent of Ca2+ influx and intracellular IP3 stores. However, in 
astrocytes (Koller et al., 1996), and hen granulosa cells (Sobloff et 
aI., 1995), TNFo induced an increase in intracellular calcium which 
was dependant on extracellular calcium, which concurs with our 
findings. The inhibition of increased [Ca2+]1 via TNFo, in the absence 
of extracellular calcium suggests that the increase in [Ca2+]1 is via 
influx through ion channels, however, further work with calcium ion 
channel antagonists is required to investigate this. It appears that 
depending on the cell type, multiple mechanisms contribute to TNFo-
induced increases in intracellular calcium. 
Pre-treatment of DRG neurones with TNFo, prior to capsaicin 
administration, increased both the percentage of neurones 
responding to capsaicin, and the evoked changes in intracellular 
calcium. These data are supported by previous studies showing the 
ability of TNFo to sensitise neurones to capsaicin (Nicol et al., 1997, 
Hensellek et aI., 2007) via TRPV1. Analysis of TNFo (50ng/ml) pre-
treated DRG neurones prior to capsaicin application, revealed an 
increase in TRPV1 protein levels, indicating an increase in TRPV1 
receptor expression. Increases in TRPV1 receptor expression in vivo 
(Carlton and Coggeshall, 2001, Ji et aI., 2002, Amaya et aI., 2003, 
Bron et aI., 2003) and in vitro (Ji et aI., 2002, Hensellek et aI., 2007, 
Constantin et aI., 2008) under inflammatory conditions are well 
documented and consistent with our findings that TNFo application 
caused an increase in TRPV1 protein levels in whole cells, while 
182 
The role ofTRPVl in modulating endocannabinoid levels and neuronal responses 
to TNFa 
levels were undetectable in membrane Iysates, due to insufficient 
samples being available for reliable measurements. 
There are reports of increases in TRPV1 protein levels but not 
TRPV1 mRNA levels in the DRG after complete Freund's adjuvant-
induced inflammation (Ji et aI., 2002b) suggesting a translational 
regulation, however, the short time frame (4 minutes) of TNFo 
application and associated increase in TRPV1 suggests that this is 
not a translational effect; but possibly liberation of a protein 
recognised by the TRPV1 antibody resulting from p38MAPK 
activation. The increase in TRPV1 protein levels occurred in 
conjunction with an increase in the activity of phospho-p38 MAPK in 
DRG Iysates, and inhibition with the p38 MAPK inhibitor, 58706504 
caused a significant reduction in the percentage of cells that 
responded to capsaicin, while having no effect on intracellular 
calcium levels. Previous studies conducted by Pollock et al. 2002 
demonstrated a significantly increased level of phospho p38 MAPK 
activity after five minutes (Pollock et aI., 2002): however, to date 
there are no other studies that have investigated TRPV1 protein 
levels after short exposure to TNFo. The involvement of p38 MAPK 
in mediating heat hyperalgesia after peripheral inflammation is well 
documented (Ji et aI., 2002, Boyle et aI., 2006, Jin and Gereau, 
2006). Furthermore, p38 MAPK is activated in spinal cord by 
injection of carrageenan or formalin into the paw, and inhibition of 
p38MAPK reduces pain behaviour associated with peripheral 
inflammation (Kim et al., 2002b, Svensson et aI., 2003). TNFo 
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activates p38 MAPK in vitro (5chafers at al., 2002) while neurones 
treated with anti-TNFa antibodies exhibited an attenuation of 
mechanical hypersensitivity, an effect mimicked by treatment with 
58706504, (the inhibitor of p38 MAPK; (5chafers et aI., 2003b). This 
presents the possibility that the effects observed in these studies 
were due to TNFa, via p38 MAPK activation, inducing 
phosphorylation of TRPV1 receptors, and subsequently sensitising 
nociceptive neurones to capsaicin. 
Another possible explanation is TNFa, via p38 MAPK, causes a 
release or an activation of an inactive form of TRPV1 receptor protein 
translocated to the DRG membrane, which is detectable by our 
antibody, however to further investigate this, protein levels in DRG 
membrane Iysates need to be higher, demanding the use of large 
numbers of experimental animals. The increase in the number of 
neurones responding to capsaicin following TNFa application 
corresponds to an increase in TRPV1 expression, however for this to 
be viable, TRPV1 would have to be functional TRPV1 in the cell 
membrane, and due to low protein levels is immeasurable. These 
data imply that TNFa increases the percentage of neurones, and 
increases levels of [Ca2+]10 via a phosphorylation of p38MAPK and 
subsequent sensitisation of TRPV1. It is unknown as to whether 
TNFa phophorylates TRPV1, as unlike other protein kinases, there is 
a lack of specific phosphorylated TRPV1 antibodies. 
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To determine a link between TNFa and ECl release we were 
interested in measuring EC release following TNFa treatment, 
however the TRPV1-SHSY5Y cells used for the quantification of 
ECls did not express TNFR1, and thus unsurprisingly the 
potentiating effects of TNFa on capsaicin-evoked increases in 
calcium observed in DRG were not seen in SHSY5Y cells. 
In conclusion we have shown the inflammatory cytokine TNFa has 
the potential directly, and indirectly, perhaps by way of a p38 MAPK-
mediated phosphorylation and sensitisation of TRPV1 receptors, to 
augment inflammatory nociceptive states. 
Developing inhibitors of TN Fa-mediated sensitisation of nociceptive 
neurones represents a potential therapeutic avenue for treating 
inflammatory pain states. 
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Chapter 4 
Effects of inhibition of fatty acid 
amide hydrolase in the 
carrageenan model of 
inflammation. 
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4 Effects of inhibition of fatty acid 
amide hydrolase in the 
carrageenan model of 
inflammation 
4.1 Introduction 
Following the development of a LC-MS-MS method capable of 
quantifying the ECs and the COX-2 metabolites of AEA and 2-AG in 
the rat brain and neuronal cell line, the effects of acute noxious 
stimulation on levels of ECs were investigated, alongside 
measurement of pain related behaviour in the rat. The effects of 
carrageenan-induced inflammation on nociceptive behaviour and on 
levels of ECs in the hindpaw and spinal cord were investigated along 
with the effects of a FAAH inhibitor in this model of inflammation. 
4.1.1 FAAH inhibitors in inflammatory pain 
The analgesic effects of cannabinoid agonists acting at CB1 and CB2 
have been widely documentaed and reviewed (Pertwee, 2001, 
Walker and Huang, 2002b, Hohmann and Suplita, 2006). One of the 
major drawbacks of this approach to analgesia is the wide spread 
distribution of CB1 receptor in the brain and the associated side 
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effects of CB1 receptor activation, including sedation, dependence 
and psychosis (Thomas, 1996, Kalant, 2004, Pacher et aI., 2006). 
The endocannabinoids AEA (Devane et aI., 1992c) and 2-AG 
(Sugiura et aI., 1995) act at CB1 and CB2 receptors to modulate 
many physiological responses, including nociception (see review 
(Fowler et aI., 2005, Pacher et aI., 2006). Recent studies have 
investigated targeting the ECls, rather than the receptors as an 
alternative mechanism to achieve analgesia without the unwanted 
associated side effects. The rapid termination of the biological 
actions of the Eels, via metabolism and transport, does limit their 
analgesic effects. Nevertheless, systemic administration of 
anandamide produces analgesia in a number of animal models of 
inflammatory pain (Devane et ai, 1992, Jaggar et ai, 1998, 
Richardson et ai, 1998), thus supporting the targeting of the 
endocannabinoid system as an alternative approach to achieving 
analgesia. 
As discussed in Chapter 1, a number of studies have shown that 
FAAH is the predominent enzyme responsible for the hydrolysis of 
fatty acid amides (FAAs) including AEA (Cravatt et aI., 2001, 
Lichtman et aI., 2002, Cravatt et aI., 2004). 2-AG is predominantly 
metabolised by MAGl (Oinh et aL, 2002). There is, however, 
evidence that 2-AG is also metabolised by FAAH (Oi Marzo et aL, 
1998) and both 2-AG and AEA can be metabolised by COX-2 (Yu et 
al" 1997, Kozak et aI., 2002a, Kozak et aI., 2004). 
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4.1.2 Effects of inhibiting FAAH on pain responses 
Deletion of the gene encoding F AAH results in the endogenous 
levels of anandamide and other fatty acid amides being elevated 
over 10- fold throughout the nervous system (Cravatt et aI., 2001). 
These data strongly support the notion that FAAH is the primary 
enzyme responsible for the hydrolytic degradation of these lipids in 
vivo (Cravatt et aI., 2001). Deletion of FAAH attenuates inflammation 
in the carrageenan-induced paw edema model (Cravatt et aI., 2004, 
Lichtman et aI., 2004 (b)), allergic contact dermatitis model (Karsak 
et aI., 2007) and dinitrobenzene sulfonic (DBNS) model of colitis 
(Massa et al., 2004). FAAH (-1-) mice do not, however, display a 
reduction of thermal hyperalgesia in the CCI model (Lichtman et aI., 
2004b). Consistent with the crucial role of FAAH in the catabolism of 
anandamide, exogenous administration of anandamide in FAAH (-1-) 
mice produced exaggerated behavioural effects including 
hypomotility, analgesia, hypothermia, and catalepsy. The effects of 
AEA in FAAH (-1-) mice were blocked by a CB1 antagonist (Cravatt et 
ai, 2001, Cravatt et ai, 2004, Litchman et al 2004b. 
The analgesic phenotype of FAAH inhibition is thought to be 
mediated through an increase in ECs in both central and peripheral 
tissues. Comparison of CNS-spared FAAH knockout mice (FAAH 
present in CNS, however not in peripheral tissue) with complete 
FAAH knockout mice, showed that analgesic effects in tests of acute 
pain (tail immersion & hot plate tests) were only noted in the 
complete FAAH knockout mice, whereas both CNS-spared and 
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complete FAAH knockout mice displayed reduced oedema in the 
carrageenan-inflammation model. levels of ECs in the brain and 
spinal cord of CNS-spared FAAH knockout mice were similar to wild-
type levels off ECls in the brain and spinal cord, but levels were 
significantly elevated in peripheral tissues (Cravatt et aI., 2004). 
These data indicate a role of peripheral FAAH in modulating oedema, 
whereas acute pain responses are modulated by FAAH through the 
central elevation of ECls. The outcomes of these knockout studies 
has resulted in considerable interest in the potential analgesic effects 
of the pharmacological manipulation of FAAH, which has clear 
therapeutic potential for the treatment of pain. Inhibition of FAAH 
with compounds such as URB597 elevates levels of AEA both in vivo 
and in vitro (Cravatt et aI., 2001, Kathuria et aI., 2003b, Fegley et aI., 
2005), and produces similar effects to that seen with FAAH gene 
deletion (Table4.1) 
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Potential CB1 FAAHr) Mice· Chemical 
Therapeutic Agonist* FAAH 
Effects inhibition· 
Analgesia Yes Yes Yes 
Anxiolysis Yes/No Unknown Yes 
Anti-inflammatory Yes Yes Unknown 
Anti-spasticity Yes Unknown Unknown 
Anti-emesis Yes Unknown Unknown 
Side effects 
Hypermotility Yes No No 
Hypothermia Yes No No 
Catalepsy Yes No No 
Table4.1 Comparison of the behavioral effects of CB1 agonists 
versus genetic deletion of FAAH gene, and chemical inhibition of 
FAAH using FAAH inhibitor. 
·For a comprehensive review see (Kumar et aI., 2001, Lichtman et 
al.,2002) 
4.1.3 Inhibition of FAAH in animals models of pain 
A number of studies have investigated the effects of FAAH inhibition 
on pain behavior, as is often the case, there are inconsistencies in 
the reported effects. Inhibition of FAAH has been consistently 
reported to produce analgesia and reduce inflammation in models of 
acute inflammatory pain (Lichtman et aI., 2004 (a), Holt et aI., 2005b, 
Chang et al., 2006, Jayamanne et aI., 2006b, Maione et aI., 2006, de 
Novellis et al., 2008, Jhaveri et aI., 2008b, Sagar et aI., 2008a, Ahn 
et aI., 2009) (Table4.2). By contrast, inconsistent effects of inhibition 
of FAAH have been reported in models of neuropathic pain 
(Jayamanne et aI., 2006b) or anti-nociceptive effects (Chang et aI., 
2006, Maione et aI., 2006, Russo et aI., 2007b, Karbarz et aI., 2009) 
191 
Effects of inhibition of fatty acid amide hydrolase in the carrageenan model of 
inflammation 
in models of neuropathic pain. In mice, repeated oral administration 
of URB597 attenuated CCI-induced thermal hyperalgesia and 
mechanical allodynia (Russo et aI., 2007a). These effects were 
blocked by CB1 and CB2 receptor antagonists. Local injection of 
URB597 and URB602, which inhibits both FAAH and MAGL, into rat 
paws ipsilateral to the ligated nerve, also attenuated thermal 
hyperalgesia and mechanical allodynia (Desroches et aI., 2008). 
Similarly, the reversible FAAH inhibitor, OL-135, reversed 
mechanical allodynia in a rat spinal nerve ligation model (Chang et 
aI., 2006). This anti-allodynic effect was blocked by the CB2 receptor 
antagonist, SR144528. In contrast to mice treated with FAAH 
inhibitors, FAAH (-1-) mice do not to display a phenotypic reduction of 
thermal hyperalgesia in the CCI model (Lichtman et aI., 2004b). 
Collectively, these studies indicate FAAH inhibitors are efficacious in 
animal models of inflammatory and neuropathic pain. 
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Model 
Carra 
(Mouse) 
Carra 
(Rat) 
Carra 
(Rat) 
CFA 
(Rat) 
CFA 
(Rat) 
Formalin 
(Mouse) 
Formalin 
(Rat) 
Formalin 
(Mouse) 
Formalin 
(Rat) 
FAAH I Route of I Analgesic 
Inhibitor Administration 
URB597 
Pre-carra 
0.3, 1 and 3mgkg" i.p. 
SYSTEMIC 
Dose dependent 
reduction in 
oedema 
Effects of inhibition of fatty acid amide hydrolase in the carrageenan model of inflammation 
Suggested Mechanism Endogenous 
Cannabinoid levels 
~ ! = C B ~ 1 ~ - - - - - - - - ~ I ~ C = B = 2 - - - - - - - - ~ \ ~ ~ ~ - r - - - - - - - - - - - - ~ 1 1
Not inhibited by Prevented with 1 Not inhibited by co-ad 
pretreatment pretreatment BADGE 3Omgkg' 
SR141716A, 1mgkg" SR144528, 1mgkg' '/capsazepine 1Omgkg" 
i.p., 1 i.p., 
Not measured 
Reference 
(Holt et aI., 
2oo5a) 
URB597 
Pre-carra 2 5 & 1 ~ g i . p l , ,
LOCAL 
Yes-MH (WB) 
No effect 
inflammation 
on • -
Not inhibited by co-ad 
PPARy agonist GW9662 
(301.19, i.pl,), prevented by 
PPARa agonist GW6471 
(301.19, i.pl,) 
tAEA and 2-AG in URB \ (Jhaveri et aI., 
inflamed HP with 251.1g. 2oo8b) 
tspinal AEA and OEA 
URB597 
Pre-carra 
PF-3845 
URB597 
Post-
CFA 
25IJg i.pI, 
LOCAL 
1-3OmgIkg p.o 
ORAL 
O.3mgkg·', i.p., 
SYSTEMIC 
No effect on 
evoked responses 
or inflammation 
Yes- MA (PWT) 
Yes-MA, TH 
Ol-135 13, 10, & 3OmgkgO' , I Yes-both phases 
Pre- i.p., 
Formalin SYSTEMIC 
M-5-HT 
Pre-
Formalin 
AA-5-HT 
Pre-
Formalin 
1mg, i.pl., 
LOCAL 
5mgkgO ', i.p., 
SYSTEMIC 
5mgkgO ', i.p., 
SYSTEMIC 
O.5nmol, i.VL-PAG, 
LOCAL 
Yes - 2"" phase 
Yes - 2"" phase 
Yes - both phases 
Yes - Z""phase 
Not inhibited by co-ad ' -
with AM251 , 30IJg, 
Prevented by PPARa agonist 
GW6471, 30IJg, Lpl, 
Prevented with co-ad 
SR141716A 1Omg/kg 
Reduced with co- ' -
adSR144528 
3Omg/kg 
Reduced bl 
SR141716A, 1mgkgO , 
i.p. Co-ad 
Reduced by co-ad \ Prevented by co-ad of both 
SR144528, 1mgkg' antagonists 
I, i.p 
Prevented with pre-I Not inhibited by'-
treatment ip pretreatment i.p 
SR141716A,3mgkgO SR144528,3mgkg' 
Prevented with c0-
administration of . -
AM251, 0.35mg, s.C., 
Prevented with c0-
administration 
AM251, 3mgkgol , i.p 
Prevented by co-ad 
AM251, 3mgkgo \ i.p. 
Blocked by co-ad 
Not inhibited by c0-
administration 
AM630, 3mgkgo" 
i.p., 
AM251, O.5nmol, i.VL- , -
PAG 
Prevented by c0-
administration with TRPV1 
antagonist capsazepine, 
5 O ~ s . c c
Prevented by co-ad i.p of 
TRPV1 a n ~ o n i s t t
capsazepine, 2.5mgkgo , and 
by I-RTX, 0.1 & 0.2mgkgo l 
Not inhibited by TRPV1 
antagonist capsazepine 2.5 
or 1OmgkgO ', or by I-RTX, 0.1 
& O.2rngJ(g·',_hp., C 
Prevented with co-ad TRPV1 
antagonist I-RTX, a.5nmol, 
iVL-PAG, 
following 1ool.lg 
URB597 
Not measured I (Sagar et aI., 
2oo8b) 
tbrain and liver levels of I (Ahn et al., 
AEA, PEA and OEA 2009) 
Not Measured I (Jayamanne 
Not Measured 
tAEA and 2AG in 
formalin treated hindpaw 
receiving M-5-HT 
compared to vehide 
No change in AEA, PEA 
or 2AG in Spinal tissue 
orPAG. 
tAEA, PEA and 2AG in 
formalin treated hindpaw 
receiving AA-5-HT 
t2AG and PEA in PAG 
in 1st stage f AEA in 
PAG at 2nd stage 
et al., 2006) 
(Lichtman et 
al.,2004a) 
(Maione et al., 
2007) 
(de Novellis et 
al.,2008) 
Table 4.2.Comparsion of the effects of inhibition of FAAH on inflammatory pain responses and levels of endocannabinoids. 
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Overall, these studies demonstrate that the analgesic effects of FAAH 
inhibition are mediated by the endocannabinoid system; however the 
contribution of peripheral versus central FAAH to these effects has been 
less widely studied and warrants further investigation (Table4.3). An 
interesting observation from these previous studies is that the duration 
of analgesia produced by pharmacological inhibition of FAAH is shorter 
than the period over which FAAH activity is inhibited, however ECls are 
remain elevated during enzyme inhibition. The consequence of this, in 
terms of the application of FAAH inhibition to a clinically relevant 
therapeutic treatment for pain, is unknown. One question that remains 
to be addressed is whether the effects of pharmacological inhibition of 
FAAH are sustained over longer periods of time treatment (repeated 
dosing). Indeed, it could be envisaged that alternative metabolising 
pathways for ECs play, such as MAG lipase and COX-2, may have 
increased prominence when FAAH is inhibited over a number of days. 
FAAH Inhibitor Model EC Levels Reference: 
Single Repeated 
10mg/kg Neuropathic Pain Increase in spinal levels of (Russo et aI., 
-
Oral Chronic AEA, OEA and PEA in 2007) 
Once daily Constrictive URB597 treated animals 
4 days Injury versus vehicle CCI 
URB597 
Mouse 
0.3mg/kg NaIve tissue Increase in rat brain AEA (Fegley et aI., 
i.p - Levels measured levels 30min, 1 hr and 2 hr 2005) 
URB597 30min, 1, 2, 6, post URB597. Increase in 
Rat and 24 hr post PEA and OEA up to 6 hrs 
URB597 following URB597. No 
change in duodenum levels 
compared to vehicle 
5mg/kg Lp NaIve Tissue Increase in AEA and 2AG (de Lago et aI., 
-
Once every Levels measured levels in rat brain 1, 6, 12 2005) 
12 hrs for 1, 5, and 12 hr hours post AA-5-HT 
48 hrs post AA-5-HT compared to vehicle at 
AA-5-HT each time paint 
Rat 
0.3mg/kg - Anti-anxiety Increase in brain levels of (Kathuria et aI., 
i.p NaIve tissue AEA, no change in 2-AG 2003b) 
URB597 Levels measured levels compared to vehicle. 
Rat 2 hours post 
URB597 
194 
Effects of inhibition of fatty acid amide hydrolase in the carrageenan model of 
inflammation 
0.3mg/kg Chronic Mild Increase in AEA levels in (Bortolato et aI., 
Lp Stress Midbrain, thalamus and 2007) 
Once daily EC levels striatum, not hippocampus 
for 5 weeks measured in and prefrontal cortex. 
midbrain, Levels of OEA and PEA 
straitum, increased in all 5 areas 
hippocampus, compared to vehicle. 
prefrontal cortex 
and thalamus 
0.1mg/kg 0.1mg/kg Anti-depressant Increase in AEA 2 hours (Gobbi et aI., 
Lp Lp ECs measured in following single 2005) 
URB597 Once daily Hippocampus, administration of URB597 
4 days cortex and in all 3 brain regions. 
URB597 midbrain. Increase in AEA levels 
following repeated 
administration, although 
levels were approx 3 times 
lower than sinale URB597. 
10mglkg CFA model of Increase in brain and liver (Ahn et aI., 
oral Inflammatory levels of AEA, PEA and 2009) 
PF-3845 Pain OEA. Levels peaked at 
Rat ECs measured in approx 3 hours, and 
brain maintained for up to 7-12 
hrs post PF-3845. 
Table 4.3 Effects of systemic administration of FAAH Inhibitors and on 
the levels of ECs in peripheral and brain tissue 
4.1.4 COX-2 metabolism of ECs and its role in 
inflammatory pain 
Both AEA and 2-AG can be oxidised by COX-2 in vitro (Kozak et aI., 
2001a, Kozak et aI., 2001b, Kozak et aI., 2003) to prostaglandin 
ethanolamides (PG-EA), and prostaglandin glycerol esters (PG-GE), 
respectively, see figure 4.1. There is some evidence that this route of 
metabolism has physiological I pathophysiological relevance. 
Bimatropast, a structural analogue of PGF2a-EA, has anti-glaucoma 
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properties (Woodward et aI., 2004) and PGE2-GE modulates inhibitory 
synaptic transmission in hippocampal neurones (Sang et aI., 2006). 
COX-2 is constitutively expressed in some areas of the CNS (Yamagata 
et aI., 1993, Ghilardi et aI., 2004), reproductive tissues (Kniss, 1999), 
and kidneys (Harris et aI., 1994). Constitutive levels of COX-2 are high 
in the spinal cord. Expression is up-regulated spinally following 
peripheral inflammation (Ichitani et aI., 1997, Tonai et aI., 1999, Samad 
et aI., 2001) and neuropathic pain states (Zhao et aI., 2000). Inhibition 
of COX-2 has well described analgesic effects in models of 
inflammatory pain (Zhang et aI., 1997, Yaksh et aI., 2001, Francischi et 
aI., 2002). Synergistic analgesic actions of ECls and COX2 inhibitors 
have been reported (Guindon et aI., 2006) and a number of in vivo 
studies have provided evidence for a role of COX-2 in modulating levels 
of AEA and 2-AG. Intraplantar administration of the COX-2 inhibitor 
nimesulide, increased levels of AEA and PEA in the hindpaw, and 
reduced hindpaw inflammation (Jhaveri et aI., 2008b), thus suggesting 
that there is a role for COX-2 metabolism of AEA under inflammatory 
conditions. By contrast, peripheral administration of another COX-2 
inhibitor (rofecoxib) did not alter levels of AEA or PEA in the formalin 
model of pain (Guindon et aI., 2006). The selectivity of the compounds 
used is an important issue. Several non-selective cyclooxygenase 
inhibitors also inhibit the activity of FAAH in a pH-dependent manner 
(Holt et aI., 2001, Fowler et aI., 2003a), whereas nimesulide is selective 
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for COX-2 (Fowler et aI., 2003b), rofecoxib is also a weak inhibitor of 
FAAH (Holt et aI., 2007). Interestingly, ECs are able to modulate COX2 
activity, AEA and 2AG increase cyclooxygenase and 5-lOX activity in 
intact human neuroblastoma CHP100 cells (Maccarrone et aI., 2000) 
and AEA produced a concentration-dependent increase in the 
expression of COX-2 in cerebral microvascular endothelium cells, which 
was partially inhibited by AM251 (Chen et al., 2005). 
The detection of the COX-2 metabolites of AEA and 2-AG in vivo is 
central to the hypothesis that that route of metabolism has biological 
significance. There are, however, limited conflicting reports of the 
detection of COX-2 metabolites in na'ive tissue. The first report of COX-
2 metabolites of AEA was their identification in liver, kidney lung and 
small intestine following the exogenous administration of AEA in FAAH 
knock-out mice (Weber et aI., 2004). PGE2-GE has been detected in 
the rat hindpaw under control conditions, levels were decreased by 
inhibition of COX-2 and MAG lipase, but were unaffected by the 
inflammatory stimulus carrageenan (Hu et aI., 2008). Exogenous 
intraplantar administration of PGE2-GE produced mechanical allodynia 
and thermal hyperalgesia (Hu et aI., 2008), indicating that the 
generation of COX-2 metabolites of AEA may contribute to pain 
responses. 
Although evidence to date indicates that FAAH is the predominant 
metabolic enzyme for the ECls, there may be an enhanced role of 
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alternative metabolic pathways when the EC system is activated, or 
when FAAH activity is compromised. To date, few studies have 
investigated whether inhibition of FAAH, when the EC system is 
activated, results in the metabolism of ECls by alternative pathways in 
the CNS. 
-{OH ~ ~ C O O _ O _ H H _ _ ~ ~ C C O I I I
~ ~ M,.QL ' ~ , - " , , / / · FAAHa 
(FMU) 
2 ..... 0 /ORACHIDONIC /oC'D 
1 COX·2 
Figure 4.1. Metabolism pathways of anandamide and 2-AG (adapted 
from Woodward at aI., 2007). Anandamide, via FAAH, and 2-AG 
predominately via MAGl, but also by F AAH are metabolised to 
arachidonic acid. Metabolism via Cyclooxygenase-2 produces the 
intermediate product prostaglandin H2 (AEA), and prostaglandin H2-
glycerol (2-AG). This is then converted to corresponding prostamides 
(for AEA), and prostaglandin glycerol esters (for 2-AG) via specific 
prostaglandin synthases. 
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4.2 Aims 
The aims of study; 
• To investigate the effects of single and repeated systemic 
treatment with the FAAH inhibitor URB597 on carrageenan-
evoked changes weight bearing and paw circumference. 
• To measure levels of ECs and prostamides in the hindpaw and 
spinal cord and to compare behavioural changes due to 
carrageenan and URB597 treatment, with changes in levels of 
ECs in the tissues. 
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4.3 Methods 
4.3.1 Overview of Studies 
The effects of repeated systemic injection of URB597, in comparison 
with a single systemic injection of URB597, on levels of ECs and 
prostamides in the paw and spinal cord of carrageen or vehicle-treated 
rats were investigated. Rats were either treated once daily for 4 days 
with URB597 O.3mgkg-1(i.p) or vehicle, or received a single identical 
injection of URB597 or vehicle on the day of behavioural testing. A 
timeline of this study is shown in Figure 4.2. To summarise, treatment 
groups were: 
• URB597 (O.3mgkg-1) injection for 4 days in intraplantar saline-
treated rats (n = 6). 
• URB597 (O.3mgkg-1) injection for 4 days in intraplantar 
carrageenan-treated rats for 4 days (n = 12). 
• Single URB597 (O.3mgkg-1) injection in intraplantar saline-treated 
rats (n = 6). 
• Single URB597 (O.3mgkg-1) injection in intraplantar carrageenan-
treated rats (n = 12). 
• Vehicle injection for 4 days in intraplantar saline-treated rats (n = 
6). 
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• Vehicle injection for 4 days in intraplantar carrageenan-treated 
rats (n = 12). 
• Single vehicle injection in intraplantar saline-treated rats (n = 6). 
• Single vehicle in intraplantar carrageenan-treated rats (n = 12). 
The development of hyperalgesia following intraplantar injection of 
carrageenan was assessed by monitoring changes in weight bearing on 
injected versus non-injected hindpaw. Paw circumference and oedema 
were measured immediately following each injection and 3 hours after 
intraplantar injection of carrageenan or vehicle. 
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30 min: 
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i njecti on of 
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120 min. 
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Figure 4.2 A timeline of interventions and measurements used in the study of the effects of URB597 on carrageenan-
induced changes in weight bearing and levels of endocannabinoids and prostamides. Rats were pre-treated with 
URB597 or vehicle followed by injection of carrageenan or vehicle 30 minutes later. Weight bearing measurements 
were taken, as shown, to investigate effects of the different treatment combinations on pain sensitivity. The time from 
tissue collection until extraction and analysis of samples by LC-MSIMS was less than two months. Animals repeatedly 
treated received a single i.p injection on 3 consecutive days prior to behavioural testing at the same time of day. 
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4.3.2 Animals 
Male Sprague Dawley rats (200 - 260 g, Charles River, UK) were 
group housed and maintained on a 12 hour light I dark cycle, with 
access to food and water ad libitum. All experiments were carried 
out in accordance with UK Home Office regulations (Scientific 
Procedures Act, 1986). 
4.3.3 Measurement of carrageenan-induced 
inflammation and drug treatment 
4.3.3.1 Weight bearing Behaviour 
Rats normally distribute their weight evenly between their two hind 
paws; however when one paw is inflamed, the animals redistribute 
their weight, to reduce the pressure on the inflamed paw. Changes 
in weight bearing between the carrageenan-injected and contralateral 
paws were measured using an incapacitance tester (Linton 
Instrumentation, UK). The incapacitance tester measures the weight 
placed on each hindpaw at a given time point (Figure 4.3), providing 
a quantitative value which is independent of the experimenter. Care 
was taken to ensure weight bearing measurements were performed 
under comparable conditions and the experimenter was blind to the 
treatment groups. Measurements were taken when rats had settled 
with each hindpaw on the appropriate transducer, with their front 
paws on the sloping portion of the holder and their head up. Weight 
bearing scores were calculated over a 3 second period, repeated 3 
times in succession and averaged for each time point. Weight 
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bearing values are expressed as a percentage of the weight on the 
injected paw, compared to the contralateral paw. 
Figure 4.3 The incapacitance tester used in these experiments 
(taken from (Sove et aI., 2003). 
Baseline weight bearing measurements were made 30 minutes prior 
to the first systemic injection of drug. Rats then received an intra-
peritoneal injection of either URB597 (0.3mgkg-1) in 3% Tween 80 in 
saline or vehicle (3% Tween 80 in saline). Thirty minutes following 
the first injection, rats were briefly anaesthetised under 
isoflurane/N20 102 and received an intra-plantar injection of A-
carrageenan (1 00 ~ ~ , , 2 mg in saline, Sigma, UK) or vehicle (saline) 
into the left hindpaw. The dose of carrageenan used has previously 
been shown to produce a robust inflammation and associated 
behavioural changes (Hargreaves et aL , 1988b, Nackley et aL , 2003, 
Jhaveri et aL , 2005). Weight bearing measurements were taken at 1, 
2, and 3 hours post carrageenan-injection. 
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4.3.3.2 Measurement of Paw Circumference and Volume 
4.3.3.2.1 Paw Circumference 
In order to measure the degree of carrageenan-induced hindpaw 
inflammation, the paw circumference was recorded. Nylon thread 
was tied tightly around the paw. The knot was cut in the middle, and 
the length of thread was measured to the nearest millimetre 
(figure4.4). Measurements were taken prior to the carrageenan / 
vehicle injection and after the 3 hour time point, at the end of the 
experiment. Changes in paw circumference were expressed as the 
difference from control values (before carrageenan/vehicle) . 
Figure4.4 A diagrammatic representation of rat hind paw, showing 
the area measured for hind paw circumference. Black nylon was tied 
around the paw, and cut at position x, and the piece of thread is then 
measured. 
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4.3.3.2.2 Paw Volume 
To measure the degree of oedema, the volume of the paw was 
measured using Plethysmometer, which was calibrated using 0.5. 2 
and 4g probes. The rat paw was inserted into a solution of KCI in 
clear acrylic cell, up to a planned point. such as the knee. The 
volume of liquid displaced was measured by a transducer. 
Measurements are taken before carrageenan I vehicle injection, and 
at 3 hour time point. at the end of the experiment. Oedema was 
expressed as the difference in these values. 
4.3.4 Measurement of Eels and prostamides in rat 
hind paw and spinal cord 
After the last weight bearing measurement, rats were killed by 
stunning and decapitation. The spinal cord and hindpaw tissue were 
rapidly removed and placed onto dry ice. A laminectomy was 
performed and approximately 2 cm of the lumbar region (L4 and L5) 
of the spinal cord was removed. and bisected into sections ipsilateral 
and contralateral sections. Paw tissue was also removed from both 
the ipsilateral and contralateral hindpaws. 
Following collection, samples were stored at -80°C until analysis. 
The processing of samples with extraction and analysis of analytes 
was described in detail in chapter 2. Tissue was finely minced using 
scalpel blades and homogenised in ice-cold acetonitrile. Samples 
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were shaken twice at 4°C for 1hour and the supernatant collected. 
The LC-MS/MS method was optimised for the quantification of AEA, 
2-AG, virodhamine, OEA, PEA, and COX-2 metabolites of AEA, and 
2-AG (PG-EA andvPG-GE, respectively). AEA-d8, 2-AG-d8 and 
PGF2a-EA-d4 were used as internal standards. 
4.3.5 FAAH enzyme activity 
The ex vivo activity of FAAH was studied using a fluorimetric assay, 
as recently described (Patel et aI., 2007) and was carried out by 
Annie Patel. 
Dilute tissue preparations were assessed for hydrolysis of oleamide 
(100 ~ M ) ) as substrate, in a final volume of 100 ~ L L in 96-well plates. 
The evolved ammonia was quantified by the production of isoindole-
1-sulfonate, following incubation at room temperature with 0-
phthaldehyde for 30 min, measuring fluorescence at 360 nm 
(eXCitation) and 460 nm (emission). Protein content was determined 
by a modification of the method of Lowry et al. (1951). 
4.3.6 Data Analysis 
2 way analysis of variance (AN OVA) was used to compare weight-
bearing data between different treatment groups at different time 
points, with Bonferroni post-hoc analysis. 2-way ANOVA was used 
to compare paw circumference and volume measurements at 
different time points and a t-test to compare individual time points. 
Comparison of levels of ECs and prostamides was carried out using 
a Mann-Whitney non-parametric test. The level of statistical 
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significance levels was set at p<O.05. Data are expressed as mean ± 
SEM or median + range. A correlation analysis was applied to 
investigate the relationship between n-acyl ethanolamines (AEA, 
DEA, PEA) and acyl-glycerols (2-AG) in tissue, a random spearman 
rank coefficient was calculated for levels of AEA, DEA, PEA and 2-
AG within individual rats. 
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4.4 Results 
4.4.1 Carrageenan-induced hyperalgesia 
This study used two different dosing regimes, thus the effects of 
single versus repeated treatment with vehicle on behavioural 
responses and endocannabinoid levels were compared. There were 
no significant differences in the effects of intraplantar injection of 
carrageenan on paw volume, paw circumference, and weight bearing 
of animals receiving a single or repeated administration of vehicle. 
Similarly, levels of AEA, PEA, OEA and 2-AG in the hindpaw were 
not significantly different between rats that received single and 
repeated administration of vehicle prior to injection of carrageenan. 
These data were, therefore, combined for comparisons of the effects 
carrageenan-induced hyperalgesia to saline-treated animals. 
Comparisons of single versus repeated administration of URB597 
were compared to the appropriate vehicle control group for the 
individual study. 
Intraplantar injection of saline did not alter weight bearing on the 
ipsilateral and contralateral hindpaw, compared to pre-injection 
values. Intraplantar injection of carrageenan significantly reduced 
weight bearing on the ipsilateral hindpaw, compared to the 
contralateral hind-paw. At 2 and 3 hours post carrageenan injection, 
there was a significant difference between the change in weight 
bearing between the ipsilateral and contralateral hind paw of 
carrageenan-treated rats, compared to saline treated rats (Figure 
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4.5). Note, both saline and carrageenan treated rats received an i.p 
injection of vehicle 30 mins prior to saline / carrageenan. 
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Figure 4.5: Intraplantar injection of carrageenan increased the 
difference in weight bearing on the ipsilateral and contralateral 
hindpaws. Rats received a systemic injection of vehicle 
(3% Tween80 in saline) 30min prior to saline or carrageenan (2mg in 
1 0 0 ~ I ) . . Data were analysed using 2-way ANOVA followed by 
8onferroni post hoc test, ***P<0.005 vs. vehicle saline. Data are 
expressed as mean ±SEM of differences in weight bearing between 
contralateral and ipsilateral hindpaw (n=12-18). 
Hindpaw circumference was measured before injection of 
carrageenan / saline (baseline values) and immediately before tissue 
collection at 2 or 3 hours post carrageenan/saline injection. 
There was a significant increase in paw diameter and paw volume of 
vehicle treated rats at both 2 hours and 3 hours post carrageenan 
compared to saline treated rats (P<O.005). Intraplantar injection of 
carrageenan produced a robust increase in paw circumference at 
both 2 and 3 hours post injection, which was not seen in saline 
treated rats, (Figure 4.6 A+8). 
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Figure 4.6 A+B: Intraplantar injection of carrageenan produced a 
significant increase in paw circumference at 2 (A) and 3 (8) hours 
post carrageenan injection. Data were analysed using unpaired t-
test. ***P<O.005 vs. vehicle saline; +++P<O.01 vs. pre-carra. Data are 
expressed as mean ± SEM (n=6-9) 
Another device for measuring paw volume is the plethysmometer, 
measuring the whole paw volume, instead of specific cross-section. 
Hindpaw volume measurements were taken before intraplantar 
injection of carrageenan or saline (baseline value) and before tissue 
collection, 2 and 3 hours after injection of carrageenan I saline. 
Intraplantar injection of saline did not alter hindpaw volume, 
compared to baseline value. Intraplantar injection of carrageenan 
(2mg in 1 O O ~ I ) ) induced a significant increase in hindpaw volume at 
both 2 and 3 hours after carrageenan injection (Figure 4.7). 
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Figure 4.7: Intraplantar injection of carrageenan produced a 
significant increase in hind paw volume at 2 (A) and 3 (8) hours post 
carrageenan injection. Data are expressed as mean ± SEM (n=6-9) 
and analysed with an unpaired t-test. ***P<O.005 vs. vehicle saline, 
+++P<O.005 vs. pre-carra. 
There was a strong correlation between paw circumference and paw 
volume of rats pre-treated with vehicle, receiving an intraplantar 
injection of carrageenan (P<O.05, R2=O.81) (Data not shown) 
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4.4.2 Levels of Eels in the hindpaw and spinal cord of 
carrageenan treated rats 
To determine whether injection of saline into the hindpaw altered 
levels of ECs in the hindpaw, levels were compared to na'ive tissue 
from animals that underwent the same behavioural testing, and brief 
anaesthesia, but did not receive an injection. Intraplantar injection of 
saline significantly decreased levels of AEA and 2-AG in the 
hindpaw, compared to na'ive tissue. By contrast levels of PEA and 
OEA were unaltered in the hindpaw compared to na'ive tissue. 
These data shown that injection alone can alter levels of ECls and 
related compounds, but it does nor appear to be due to general 
changes in paw volume as some but not all Eels and related 
compounds were altered (Table 4.4). 
4.4.2.1 levels of ECs at 2 hours post-carrageenan injection 
Injection of carrageenan into the hindpaw significantly decreased 
levels of PEA, OEA and 2-AG in the ipsilateral hindpaw, compared to 
saline-treated rats, levels of AEA were unaltered (Figure 4.8). levels 
of AEA, PEA, OEA and 2-AG in the ipsilateral hindpaw of 
carrageenan-treated rats were significantly lower than levels in the 
contralateral hindpaw of carrageenan treated rats (Figure 4.8). 
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Figure 4.8: Effects of intraplantar injection of carrageenan (carra) or 
saline (sal) on the levels of endocannabinoids and related 
compounds in the ipsilateral and contralateral hindpaw of vehicle 
treated rats 2 hours post-carrageenan injection. Data are expressed 
as the median and range and were analysed using Mann-Whitney 
non-parametric test and, (n=6-8). +P<O.05, ++P<O.01 vs. ipsilateral 
vehicle saline hindpaw, "'P<O.05, ...... P<O.01, ......... P<O.001 vs. 
contralateral hind paw. 
Intraplantar injection of carrageenan decreased levels of PEA in the 
ipsilateral spinal cord of vehicle treated rats, compared to the 
ipSilateral spinal cord of saline treated rats (Figure 4.9). By contrast, 
there were no differences in the levels of AEA, OEA or 2-AG in the 
ipsilateral or contralateral spinal cord of rats at 2 hours following 
intraplantar injection of saline or carrageenan (Figure 4.9) . 
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Figure 4.9: Effects of intraplantar injection of carrageenan or saline 
on levels of endocannabinoids and related compounds in the 
ipsilateral and contralateral spinal cord of vehicle treated rats 2 hours 
post injection, Data are expressed as the median and range and 
were analysed using Mann-Whitney non-parametric test and, (n=6-
8) . ·P<O.05 vs, ipsilateral vehicle saline spinal cord, *P<O.05. 
4.4.2.2 levels of Eels at 3 hours post-carrageenan 
injection 
Injection of carrageenan into the hindpaw did not significantly alter 
levels of AEA, PEA, OEA or 2-AG in the ipsilateral hind paw, 
compared to saline-treated rats (Figure 4.10), Levels of PEA, and 
OEA in the ipsilateral hindpaw of carrageenan-treated rats were 
significantly lower than levels in the contralateral hind paw of 
carrageenan treated rats (Figure 4.10), This was not the case for the 
intraplantar injection of saline, with no differences observed between 
the ipsilateral and contralateral hindpaw of saline treated rats . Levels 
of AEA and PEA were higher in the contralateral hindpaw of 
carrageenan-treated rats compared to the contralateral hindpaw of 
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saline treated rats (Figure 4.10). These data emphasise the impact 
of changes in weight bearing on both the ipsilateral and contralateral 
hindpaw and emphasise the importance of having appropriate control 
groups included in this study. 
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Figure 4.10 Effects of intraplantar injection of carrageenan (carra) or 
saline on the levels of endocannabinoids and related compounds in 
the contralateral and ipsilateral hindpaw of vehicle treated rats 3 
hours post-injection. Data are expressed as the median and range 
and were analysed using Mann-Whitney non-parametric test (n=10-
21). $P<O.05, $$P<O.01 vs. contralateral vehicle saline hind paw, 
**P<O.01 vs. contralateral hindpaw. 
The impact of these treatments on levels of Eels in the spinal cord 
was also assessed at 3 hours post-injection. Intraplantar injection of 
saline did not alter levels of AEA, PEA, OEA or 2-AG in the ipsilateral 
spinal cord compared to the contralateral spinal cord (Figure 4.11). 
Intraplantar injection of carrageenan was associated with a 
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significant increase in levels of AEA in the ipSilateral spinal cord 
(P<O.05) compared to saline-treated rats (Figure 4.11). Note levels 
of AEA were also elevated in the contralateral spinal cord of 
carrageenan treated rats, however significance wasn't reached . 
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Figure 4,11: Effects of intraplantar injection of carrageenan or saline 
on levels of endocannabinoids and related compounds in the 
ipsilateral and contralateral spinal cord of vehicle treated rats 3 hours 
post-injection. Data are median and range and were analysed using 
Mann-Whitney non-parametric test (n=11 -19). ·P<O.05 vs , ipsilateral 
vehicle saline hind-paw. 
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4.4.3 Effects of a single systemic administration of 
URB597 on carrageenan induced hyperalgesia 
A single i.p injection of URB597 (0.3mgkg-1) significantly delayed the 
onset and changes in weight bearing on the ipsilateral paw of 
carrageenan-treated rats, compared to rats pre-treated with vehicle 
prior to intraplantar injection of carrageenan (Figure 4.12). Weight 
bearing was unaltered in URB597 pre-treated rats which received 
intraplantar injection of saline (data not shown) . 
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Figure 4.12: Effects of single systemic injection of URB597 on 
carrageenan induced changes in weight bearing. Rats received 
URB597 or vehicle 30m ins prior to intraplantar injection of 
carrageenan (2mg in 1001-11). Data are expressed as mean SEM of 
differences in weight bearing between contralateral and ipsilateral 
hindpaw (n=B-10) . Data were analysed using 2-way ANOVA 
followed by Bonferroni post hoc test, · P<0.05, · ··P<0.005 vs. vehicle 
Carra. 
A single injection of URB597 did not alter the carrageenan-induced 
increase in paw circumference, or paw volume, compared to vehicle 
pre-treated rats receiving intraplantar carrageenan (Figure 4.13 
A+B). 
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Figure 4.13: UR8597 did not alter the carrageenan-induced increase 
in paw circumference (A), or carrageenan-induced increase in paw 
volume (8). Paw circumference and paw volume was measured 3 
hours after carrageenan injection. Data expressed as the difference 
in pre-carrageenan injection paw circumference and paw volume, as 
mean ± SEM (9-10). 
URB597 treatment did not alter the normal progression in the 
increase in paw diameter and oedema formation between 2 and 3 
hours post-carrageenan injection (Figure 4.14). 
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Figure 4.14: Effects of URB597 on paw circumference and volume 2 
hours and 3 hours post-carrageenan injection. Data were analysed 
using 1-way ANOVA and expressed as the difference in pre-
carrageenan injection paw circumference, as mean ± SEM (n=8-9). 
4.4.4 Effects of a single systemic administration of 
URB597 on FAAH enzyme activity in the Midbrain and 
Liver 
To confirm that the single dose of URB597 used was appropriate, 
levels of F AAH activity in the liver and midbrain in these rats were 
determined. 
URB597 (O.3mgkg-1) produced a small, but non-significant decrease 
in FAAH activity in the liver and midbrain (Figure 4.15 A+B) Note, 
FAAH activity in the midbrain was lower than activity in the liver. 
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Figure4.15: Ex vivo assessment of FAAH activity in liver (A) and 
midbrain (B) of vehicle or URB597 treated rats. Data are expressed 
as mean ±SEM of fluorescence at 360nm (emission) and 460nm 
(excitation) from 6 animals using 1uM URB597 to define specific 
FAAH activity. Data were analysed by one-way ANOVA followed by 
Newman-Keulis post hoc test. 
4.4.5 Effects of a single systemic administration of 
URB597 on levels of Eels and related compounds 
The effects of URB597 on Eel levels in the hindpaw and spinal cord 
at 2 hours and 3 hours post-carrageenan injection were also 
determined. 
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4.4.5.1 levels of Eels 2 hours post-carrageenan injection 
Single injection of URB597 did not alter levels of AEA, PEA, OEA 
and 2-AG in the ipsilateral hindpaw at 2 hours post-carrageenan 
injection, compared to levels in the ipsilateral hindpaw of 
carrageenan treated rats which received vehicle (Table 4.5) 
In all cases, levels of AEA, PEA, OEA and 2-AG in the ipsilateral 
hindpaw of URB597 pre-treated rats receiving intraplantar injection of 
carrageenan were significantly lower than levels in the contralateral 
hindpaw of these rats (Fig 4.16), which reflects the observation that 
levels of ECs in the ipsilateral hindpaw are lower following 
carrageenan injection, compared to the contralateral hindpaw (Page 
4). A single injection of URB597 did not alter levels of Eels in the 
hindpaw of rats which subsequently received an intraplantar injection 
of saline, compared to vehicle (Table 4.5). 
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Group AEA pmolg- l ~ ~ OEA nmolg-1 PEA nmolg-1 J 2AG nmolg-1 
median (range) median ( r a n ~ e l l median(rangeJ median (range) 
!psi Contra Ipsi Contra Ispi Contra Ipsi Contra 
Naive 10.21(7.41- 10.57 (8.38- 0.14 (0.11- 0.15 (0.14- 0.18 (0.13- 0.17 (0.16- 15.01 (6.50- 13.46 (8.94-
11.74) 12.05) 0.211 0.38) 0.32) 0.36) 18.83) 16.40) 
Vehicle 9.40 (4.74- 7.36 (4.77- 0.19 (0.10- 0.19 (0.16- 0.28 (0.20- 0.34 (0.26- 3.78 (2.29- 5.65 (3.57-
saline 15.31) 9.66) 0.32) 0.24) 0.38) 0.44) 5.17) AI\ 7.26) -
Vehicle 5.62 (3.29- 15.00 (5.62- 0.07 (0.06- 0.14 (0.13- 0.11 (0.09- 0.27 (0.21- 2.08 (1.93- 5.35 (1.30-
carrageenan 7.50)**+ 35.08) 0.11) ***++ 0.19)$ 0.15) *-+++ 0.36) 2.25)*++ 10.49) 
URB597 10.56 (6.84- 9.56 (6.42- 0.18 (0.14- 0.19 (0.15- 0.27 (0.21- 0.31 (0.22- 3.75 (2.42- 4.21 (3.26-
saline 15.0) 18.33) 0.22) 0.24) 0.44) 0.52) 6.30) 7.22) 
URB597 5.06 (2.68- 20.44 (4.20- 0.07 (0.05- 0.18 (0.14- 0.10 (0.07- 0.36 (0.17- 2.11 (1.47- 5.12 (2.40-
carrageenan 7.58)" 42.93)A 0.10) **### 0.27) 0.16)*'- 0.55) 3.57)## 9.25) 
-- --- -- ------ - -
Table 4.5 levels of Eels in the hindpaw of rats treated with a single dose URB597 0.3mgkg-1or vehicle (i.p), 2 hours following 
intraplantar injection of carrageenan or saline. Data expressed as median and range and were analysed using non-parametric 
Mann-Whitney test. *P<0.05, **P<0.01, ***P<0.001 vs. contralateral hindpaw, +P<0.05, ++P<0.01 vs ipsilateral vehicle saline, 
·p<0.01 vs ipsilateral URB597 saline, $ P<0.05 vs contralateral vehicle saline, A1\P<0.01 vs ipsilateral na'ive, -P<0.05 vs 
contralateral naIve. 
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AEA OEA PEA 2-AG 
Vehicle ~ ~ ~ ~ ~ ~ ~ ~
URB597 t t ~ ~ ~ ~
Table 4.5a summarises the effects of intraplantar injection of 
carrageenan on levels of ECls in hindpaw of rats treated with a 
single injection of vehicle/ URB597 2 hrs post saline/carrageenan 
injection. 
AEA OEA PEA 2-AG 
Saline +-+ +-+ +-+ +-+ 
Carrageenan +-+ +-+ +-+ +-+ 
.. Table 4.5b summarises the effects of a single injection of URB597 
on levels of ECls in hindpaw 2 hrs post saline/carrageenan 
injection. 
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Figure 4.16: Effects of single systemic injection of URB597 or 
vehicle on carrageenan (carra) or saline (sal) induced changes in 
levels of endocannabinoids and related compounds in the ipsilateral 
and contralateral hindpaw at 2 hours post injection. Data were 
expressed as Median and range (n=8-9) and were analysed using 
Mann-Whitney non-parametric test. **P<O.01, ***P<O.005 vs. 
contralateral hind paw. 
Systemic injection of URB597 significantly (P<O.01) increased levels 
of AEA, OEA, and PEA in the contralateral spinal cord of 
carrageenan-treated rats compared to the contralateral spinal cord 
of carrageenan-treated rats receiving systemic injection of vehicle. 
Levels of 2AG were unaltered (Figure 4.17). There was a trend 
towards an increase in levels of AEA, PEA and OEA in the 
ipsilateral spinal cord of carrageenan-treated rats receiving 
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URB597, compared to the ipsilateral spinal cord of carrageenan 
treated rats receiving URB597; however significance was not 
reached (Figure 5.19). Levels of AEA were significantly increased 
in the both the ipsilateral and contralateral spinal cord of URB597-
treated rats receiving an intraplantar injection of saline, compared to 
saline-treated rats receiving vehicle (Table 4.6) . Levels of PEA 
were significantly increased in the contralateral spinal cord of 
URB597 -treated rats receiving an intraplantar injection of saline, 
compared to saline-treated rats receiving vehicle (Table 4.6). 
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Figure 4.17: Effects of intraplantar injection of carrageenan or 
saline on levels of endocannabinoids and related compounds in the 
ipsilateral and contralateral spinal cord of vehicle treated rats 2 
hours post injection. Data are expressed as the median and range 
and were analysed using Mann-Whitney non-parametric test, (n=8-
9). *P<O.05 vs. contralateral vehicle carrageenan spinal cord. 
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Group AEA pmolg-1 OEA nmolg-1 PEA nmolg-1 2AG nmolg-1 
median (range' median (range) median ( r a n ~ ~ e) median _ ( r a n g ~ ) )
Ipsi Contra Ispi Contra Ispi Contra Ipsi Contra 
Naive 27.89 (21.17- 34.07 (30.14- 0.58 0.71 (0.54- 0.46 (0.27- 0.62 (0.39- 30.55 45.46 
34.84) 40.04) (0.40- 0.92) 0.58) 0.81) (24.63- (32.88-
0.64) 35.42) 48.05) 
Vehicle 20.75 (16.16- 24.20 (18.03- 1.03 0.81 (0.57- 0.70 (0.44- 0.63 (0.41- 59.45 (4.09- 64.82 
saline 24.6) 32.21) (0.63- 1.15) 0.99) 1.0) 103.8) (38.53-
1.55) 93.13) 
Vehicle 25.04 (15.31- 28.46 (17.66- 0.74 0.80 (0.59- 0.53 ~ 0 . 3 5 5 0.54 (0.35- 54.63 65.85 
carrageenan 35.45) 39.89) (0.52- 1.04) 0.73) Q 0.79) (27.99- (30.54-
1.04) 79.48) 81.52) 
URB597 45.72 (24.64- 37.6 ~ 2 7 . 3 7 7 1.86 1.80 (1.00- 1.06 (0.39 1.01 (0.57- 53.72 71.87 
Saline 92.14) % 67.52) (0.70- 3.68) # 1.86) 1.55) (21.83- (38.65-
! 3.30) 80.32) 113.7) 
I URB597 46.99 (13.68- 50.32 121.63- 1.53 1.88 (0.67- 0.88 (0.24- 1.10 (0.38- 63.07 63.22 (31.2-
Carrageenan 101.4) 99.61) (0.18- 3.85) b. 2.36) 2.19) b. (44.11- 93.96) 
3.95) 93.78) 
Table 4.6 levels of ECls and related compounds in the spinal cord of rats treated with a single dose URB597 0.3mgkg-1or vehicle 
(i.p). 2 hours following intraplantar injection of carrageenan or saline. Data are expressed as median and range and were analysed 
using non-parametric Mann-Whitney test. % P<0.05 vs ipsilateral vehicle saline. b. P<0.05 vs contralateral vehicle carrageenan. 
#P<0.05 vs contralateral vehicle saline. 
227 
I 
i 
i 
Effects of inhibition of fatty acid amide hydrolase in the carrageenan model of 
inflammation 
AEA OEA PEA 2-AG 
Vehicle +-+ +-+ ~ ~ +-+ 
URB597 +-+ +-+ +-+ +-+ 
.. Table 4.6a summarises the effects of Intraplantar injection of 
carrageenan on levels of ECLs in the spinal cord of rats treated with 
a single injection of Vehicle/ URB597 2 hrs post saline/carrageenan 
injection. 
AEA OEA PEA 2-AG 
Saline i +-+ +-+ +-+ 
Carrageenan +-+ +-+ +-+ +-+ 
.. Table 4.6b. summarises the effects of a single Injection of URB597 
on levels of ECLs in spinal cord 2 hrs post intraplantar injection of 
saline/carrageenan injection compared to i.p administration of 
vehicle/URB597 saline. 
A correlation analysis of the levels of Eels in the ipsilateral spinal 
cord 2 hours post carrageenan / saline injection was undertaken in 
vehicle and URB597 treated rats to investigate the relationship 
between each of the N-acylethanolamines (AEA, OEA, and PEA) 
and acyl-glycerols (2-AG) in each individual rat. Spearman rank 
correlation coefficient (R2) were calculated and are presented in 
Table 5.7. Representative correlation graphs are shown in Figure 
4.18. This analysis demonstrates that irrespective of group, levels 
of 2-AG are not correlated with AEA, PEA or OEA. There was a 
significant correlation between levels of OEA and PEA for each 
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treatment group. AEA and OEA were correlated in both the vehicle 
carrageenan group and URB597 carrageenan group. Interestingly 
treatment with URB597 was associated with a significant correlation 
in AEA and PEA, which was not present in the absence of URB597 
treatment or the absence of carrageenan treatment. 
RL 
URB Carra Veh Carra URB saline Veh Saline 
AEA vs 0.87** 0.40 0.77 0.94* 
PEA 
AEA vs 0.83** 0.74** 0.77 0.94* 
OEA 
AEA vs 2- -0.05 0.29 0.43 0.14 
AG 
OEA vs 0.97*** 0.85* 0.83* 1.00* 
PEA 
2-AG vs -0.18 -0.02 0.09 0.25 
PEA 
2-AG vs -0.18 0.10 0.30 0.26 
OEA 
Table 4.7 Spearman Rank coefficient correlating levels of ECls 
following single systemic injection of URB597 or vehicle, in the 
spinal cord 2 hours post-injection of carrageenan/saline into the 
hindpaw. *P<0.05, **P<0.01, ***P<0.005 = significant correlation. 
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Figure 4.18 Representative graphs showing the correlation 
coefficient between AEA, OEA, PEA and 2-AG in ipsilateral spinal 
cord of URB597 treated rats receiving an intraplantar injection of 
carrageenan. 
4.4.5.2 levels of Eels 3 hours post-carrageenan injection 
Single injection of URB597 did not alter levels of AEA, PEA, OEA 
and 2-AG in the ipsilateral hind paw of carrageenan-treated rats, 
compared to levels in the ipsilateral hindpaw of carrageenan treated 
rats, which received vehicle (table 4.8). Levels of AEA in the 
contralateral hindpaw of carrageenan-treated rats were increased in 
URB597 treated rats compared to rats pre-treated with vehicle 
(Figure 4.19). 
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In all cases levels of AEA, PEA, OEA and 2-AG in the ipsilateral 
hindpaw of URB597 pre-treated rats receiving intraplantar injection 
of carrageenan were significantly lower than levels in the 
contralateral hind paw of these rats (Fig 4.19), which reflects the 
observation that levels of ECs in the ipsilateral hind paw are lower 
following carrageenan treatment, compared to the contralateral 
hind paw. A single injection of URB597 did not alter levels of Eels 
in the hindpaw of rats receiving intraplantar injection of saline, 
compared to vehicle (Table 4.8). 
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Group AEA pmolg-1 I OEA nmolg-1 PEA nmolg-1 12AG nmolg-1 
I median (range) median ( r a n ~ ~el median (range) median {rangel 
!psi Contra Ipsi Contra Ispi Contra Ipsi Contra 
Naive 10.21(7.41- 10.57 (8.38- 0.14 (0.11- 0.15 (0.14- 0.18 (0.13- 0.17 (0.16- 15.01 (6.50- 13.46 (8.94-
11.74) 12.05) 0.21) 0.38) 0.32) 0.36) 18.83) 16.40) 
Vehicle 5.4 (4.1-9.6) 6.5 (5.4-7.8) 0.09 (0.08- 0.13 (0.10- 0.11 (0.08- 0.14 (0.1- 7.16 (3.37- 9.90 (8.48-
saline A - 0.15) 0.22) 0.15) 0.23) 11.49) AA 11.02)-
I 
Vehicle 8.55 (5.28- 0.12 (0.04- 0.12 (0.05- 0.39 (0.14- 5.71 (2.58-5.22 (4.34- 0.36 (0.12- 12.15 (7.54-
carrageenan 6.89) 11.76) 0.19) ** 0.48) 0.34) ** 0.78)$ 10.31) 18.73) I 
I 
URB597 9.23(6.13- 8.25 (5.15- 0.13 (0.12- 0.14 (0.11- 0.13 (0.12- 0.13 (0.11- 3.55 (2.41- 10.48 (7.95- i 
saline 12.6) 13.93) 0.25) 0.16) 0.22) 0.17) 5.97)* 14.16) 
URB597 6.47 (4.26- 12.68 (8.72- 0.09 (0.07- 0.29 (0.14- 0.14 (0.06- 0.24 (0.15- 4.19 (2.52- 11.24(7.57-
carrageenan 11.15)* 23.49)/1 0.17) ** 0.51) 0.30) ** 0.93) 6.55) 17.51) 
Table4.8 Levels of ECLs in the hindpaw of rats treated with a single dose URB597 0.3mgkg- 'or vehicle (i.p), 3 hours follOWing 
intraplantar injection of carrageenan or saline. Data were analysed using non-parametric Mann-Whitney test. Data eXfrressed as 
median and range. *P<0.05, **P<0.01 vs. contralateral hindpaw, /1 P<0.05 vs contralateral vehicle-carrageenan, P<0.05 vs 
contralateral vehicle saline, AP<0.05, AAP<0.01 vs ipsilateral naive, - P<0.05 vs contralateral na·ive. 
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AEA OEA PEA 2-AG 
Vehicle +-+ +-+ +-+ +-+ 
URB597 +-+ +-+ +-+ +-+ 
Tables4.8a summarises the effects of Intraplantar Injection of 
carrageenan on levels of ECls in the hindpaw of rats treated with a 
single injection of Vehicle/ URB597 3 hrs post saline/carrageenan 
injection. 
AEA OEA PEA 2-AG 
Saline +-+ +-+ +-+ +-+ 
Carrageenan +-+ +-+ +-+ +-+ 
Table4.8b summarises the effects of a single injection of URB597 
on levels of Eels in hind paw 3 hrs post intraplantar injection of 
saline/carrageenan injection. 
233 
Effects of inhibition of fatty acid amide hydrolase in the carrageenan model of 
inflammation 
S 1 ~ ~ S 1 ~ ~ S 1 ~ ~ S 1 ~ ~4 . ~ ~ ~ ~ ~ 4 . ~ ~ ~ , ,
0. 
o. 
f: 
~ ~ o. 
0.1 
contra ipsi 
': " 
contra 
-
n 
" 
.. 
.... 
ipsi 
-,f.-
I. 
III 0.7 
=a 
I 0. 
~ ~
II. 0.2 
.. 
" 
- , 
, 
-+- -.... . ... O.IICI*-..,...-..,...-r......r--..,...-
~ ~ ~ . . ~ ~ ~ . .JJ _oJ? ~ ~ _Ibr? 
..14- ~ ' t ' ' ~ ~ ~ ' t ' '
contra ips I 
... 
" ~ I I
.' . 
'. 
contra ipsi 
.. ' 
-.-: . 
Figure 4.19: Effects of single systemic injection of URB597 or 
vehicle on carrageenan (carra) induced changes in levels of 
endocannabinoids and related compounds in the ipsilateral and 
contralateral hindpaw 3 hours post injection. Data are expressed as 
Median and range (n=7 -9). Comparisons were made using Mann-
Whitney non-parametric test. **P<0.01, ***P<0.005 vs. contralateral 
hindpaw, Ap<0.05 vs. contralateral vehicle carrageenan hindpaw. 
The effect of single systemic dose of URB597 on levels of ECls in 
the spinal cord was also determined. Systemic injection of URB597 
significantly (P<0.01) increased levels of AEA, OEA, and PEA in the 
ipsilateral spinal cord of carrageenan-treated rats, compared to the 
ipsilateral spinal cord of carrageenan-treated rats receiving systemic 
injection of vehicle. Levels of 2AG were unaltered (Figure 4.20). 
levels of AEA were also significantly increased in the ipsilateral 
spinal cord of saline-treated rats receiving URB597, compared to 
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the ipsilateral spinal cord of saline treated rats receiving vehicle 
(Figure 4.20). Levels of PEA and OEA were significantly increased 
in the contralateral spinal cord of URB597-treated rats receiving an 
intraplantar injection of saline, compared to saline-treated rats 
receiving vehicle (Table 4.9). 
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Group AEA pmolg-1 OEA nmolg-1 PEA nmolg-1 2AG nmolg-1 
median(ranRe median (ran ~ e ) ) median (ran ~ e ) ) median (range) 
Ipsi Contra Ispi Contra Ispi Contra ~ s i i Contra 
Naive 27.89 (21.17- 34.07 (30.14- 0.58 (0.40- 0.71 (0.54- 0.46 (0.27- 0.62 (0.39- 30.55 45.46 
34.84) 40.04) 0.64) 0.92) 0.58) 0.81) {24.63- (32.88-
35.42) 48.05) 
Vehicle 22.98 (10.43- 27.87 (17.22- 1.19 (0.55- 1.20 (0.78- 1.00 (0.24- 0.96 (0.54- 29.36 28.77 (3.77-
saline 27.25) 35.94) 1.38) 1.52) 1.51) 1.60) (18.55- 40.67) 
33.57) 
Vehicle 20.16 (12.24- 35.82 (25.9- 1.04 (0.74- 2.04 (1.02- 0.83 (0.48- 1.85 (0.81- 12.49 (8.34- 6.90 (3.83-
carrageenan 32.72) - 49.98) 1.60) 2.56) 1.52) 2.42) 68.73) 29.74) 
URB597 31.99 ~ ? 7 . 7 7 7 72.02 ~ 3 5 . 3 6 6 1.68 (0.99- 4.72 \1.93- 1.32 (0.27 3.53 ~ 1 . 5 5 5 22.36 (8.92- 17.03 (2.60-
Saline 52.64) 99.85) 0 % 3.83) 5.68) %*' 2.71) 5.74) 0. 31.74) 28.29) 
URB597 51.29 (20.18- 39.68 (10.56- 3.62 (0.96- 3.25 (0.97- 2.19 (0.80- 2.36 (0.83- 11.81 (5.98- 9.47 (6.71-
Carrageenan 77.8t+ 95.46) 8.54) ++ 5.26) 5.70)++ 3.47) 37.69) 46.88) 
Table4.9 levels of ECls in the spinal cord of rats treated with a single dose URB597 0.3mgkg- 'or vehicle, 3 hours follOWing 
injection of carrageenan or saline. Data were analysed using n o n ~ a r a m e t r i c c Mann-Whitney test. Data expressed as median and 
range. *P<0.05, **P<0.01 vs contralateral spinal cord, %P<0.05, 0 %P<0.01 vs. contralateral vehicle saline, 'P<0.05 vs. ipsilateral 
vehicle saline, ++P<0.01 vs ipsilateral vehicle carrageenan. 
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AEA OEA PEA 2-AG 
Vehicle +-+ +-+ +-+ +-+ 
URB597 +-+ +-+ +-+ +-+ 
Tables4.9a summarises the effects of Intraplantar injection of 
carrageenan on levels of ECLs in the spinal cord of rats treated with 
a single injection of Vehicle/ URB597 3 hrs post saline/carrageenan 
injection. 
AEA OEA PEA 2-AG 
Saline t +-+ +-+ +-+ 
Carrageenan t t t +-+ 
.. Table 4.9b summanses the effects of a single injection of URB597 
on levels of Eels in spinal cord 3 hrs post intraplantar injection of 
saline/carrageenan injection. 
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Figure 4.20: Effects of single systemic injection of URB597 or 
vehicle on carrageenan (carra) or saline (sal) induced changes in 
levels of endocannabinoids and related compounds in the 
contralateral and ipsilateral spinal cord 3 hours post injection. Data 
are expressed as Median and range (n=8-9) and analysed using a 
Mann Whitney non-parametric test. ++P<O.01, ipsilateral vehicle 
carrageenan spinal cord. 
To ease comparisons of the effects URB597 on levels of ECls and 
related compounds, at the two different time points, in the hindpaw 
and spinal cord of URB597 -carrageenan treated rats, data were 
expressed as a percentage of the mean level of ECl in the 
ipsilateral hindpaw or spinal cord of vehicle pre-treated rats 
receiving intraplantar injection of carrageenan. Single treatment 
with URB597 did not alter levels of ECs or related compounds in the 
hindpaw at 2 hours post-carrageenan, but increased levels of AEA 
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in the hindpaw at 3 hours post-carrageenan treatment. Levels of 
PEA, OEA and 2-AG in the hindpaw were unaltered by single 
treatment with URB597 at 2 or 3 hours post-carrageenan injection 
(Table 4.10). At the level of the spinal cord, there was a trend for 
single treatment with URB597 to increase levels of AEA, PEA and 
OEA in the spinal cord at 2 hours post-carrageenan-injection (Table 
4.10). At 3 hours post-carrageenan injection, effects of URB597 on 
AEA were significant (Table 4.10). 
% of mean levels in vehicle carrageenan-treated rats 
AEA PEA OEA 2-AG 
Paw Single 90.06±9.5 93.16±8.3 103.1±8.2 104.5±10.4 
2hr 
Single 139.6±1S.8* 86.6±16.8 93.3±10.6 73.3±7.1 
3hr 
Spinal Single 187.6±38.1 168.4±42.2 208.0±S6.1 11S.S±10.1* 
Cord 2hr 
Single 213.0±31.5* 278.1±62.0 337.2±71.9 83.9±32.5 
3hr 
Table 4.10: Effects of a single injection of URB597 (0.3mgkg-1) 2 
and 3 hours post-carrageenan injection on levels of AEA. PEA, 
OEA, and 2-AG in the hindpaw and spinal cord of rats. Data were 
analysed using Mann-Whitney non-parametric test and are 
expressed as a percentage of the ipsilateral mean level of EC of 
vehicle treated rats, receiving an intraplantar injection of 
carrageenan. (n=7-9) ·P<0.05, versus 2 hour URB597 
administration. 
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4.4.6 Effects of a repeated systemic administration of 
URB597 on carrageenan induced hyperalgesia 
Repeated Lp injection of URB597 (O.3mgkg-1) once a day, for 4 days 
did not alter carrageenan-induced changes in weight bearing on the 
ipsilateral hindpaw, compared to rats receiving 4 day treatment with 
vehicle prior to intraplantar injection of carrageenan (Figure 4.21). 
-a- URB 597-Carra (n=9) 
.... Vehicle-Carra (n=8) 
-30 0 30 60 90 120 160 180 210 240 
.. Time (min) 
Vehic1ellRl597 
Figure 4.21: Effects of repeated systemic injection of O.3mgkg-
1URB597 on carrageenan-induced changes in weight bearing. Rats 
received Lp injection of URB597 once daily for 4 days, receiving the 
final injection 30 mins prior to injection of carrageenan. Data are 
expressed as mean SEM of differences in weight bearing between 
contralateral and ipsilateral hind-paw (n=8-9). Data were analysed 
using 2-way ANOVA. 
Repeated systemic injection of URB597 did not alter carrageenan-
induced increases in paw circumference, or paw oedema, compared 
to rats receiving repeated injection of vehicle prior to intraplantar 
injection of carrageenan. (Figure 4.22 A+B). 
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Figure 4.22: Repeated URB597 pre-treatment did not alter the 
carrageenan-induced increase in paw circumference (A), or 
carrageenan-induced increase in paw volume (8). Paw 
circumference and paw volume was measured 3 hours after 
carrageenan injection. Data are expressed as the difference in pre-
carrageenan injection paw circumference and paw volume and 
presented as mean ± SEM (6-9) 
There was a strong correlation between paw circumference and paw 
volume of rats pre-treated with either vehicle or UR8597, receiving 
an intraplantar injection of carrageenan (P<O.05, R=O.72) (Data not 
shown). 
4.4.7 Effects of repeated systemic injection of URB597 
on FAAH enzyme activity in the Midbrain and Liver 
Repeated systemic injection of URB597 (O.3mgkg-1) significantly 
decreased FAAH activity in the liver (Figure 4.23A) and midbrain 
(Figure 4.238). 
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Figure 4.23: Ex vivo assessment of FAAH activity in liver (A) and 
midbrain (8) of repeated vehicle or UR8597 treated animals. Data 
were analysed by one-way ANOVA followed by Newman-Keulis 
post hoc test, *P<O.05, ***P<O.005. Data are expressed as mean 
±SEM of fluorescence at 360nm (emission) and 460nm (excitation) 
from 6 animals using 1uM URB597 to define specific FAAH activity 
4.4.8 Effects of repeated systemic injection of URB597 
on levels of Eels in the hindpaw and spinal cord of 
carrageenan treated rats 
Repeated injection of UR8597 (O.3mgkg-1) did not alter levels of 
AEA, OEA or 2-AG in the ipsilateral hindpaw of carrageenan-treated 
rats, compared to levels in rats receiving repeated injection of 
vehicle prior to injection of carrageenan (Table 4.11). Levels of PEA 
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in the ipsilateral hindpaw of URB597 treated rats were decreased 
compared to levels in vehicle treated rats receiving an intraplantar 
injection of carrageenan (Figure 4.24). 
As reported in section 4.3.5, levels of AEA, PEA, and OEA in the 
ipsilateral hindpaw of vehicle pre-treated carrageenan rats were 
lower than levels in the contralateral hindpaw of these animals. This 
was also the case for the ipsilateral hindpaw of URB597 pre-treated 
carrageenan rats, compared to the contralateral hind paw of these 
rats (Figure 4.24, Table 4.11). In the case of AEA and PEA this 
difference between the ipsilateral and contralateral hind paw was 
significant (Figure 4.24). Repeated systemic administration of 
URB597 in rats receiving intraplantar injection of saline did not alter 
levels of AEA, PEA, OEA or 2-AG in either the ipsilateral or 
contralateral hindpaw, compared to systemic vehicle treatment in 
rats receiving intraplantar injection of saline (Table 4.11). 
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Group AEA pmolg-1 OEA nmolg-1 PEA nmolg-1 2AG nmolg-1 
I 
median {rangel median ( r a n ~ ~ e) median ( r a n ~ e ) ) median (range) 
Ipsi Contra Ispi Contra Ispi Contra Ipsi Contra 
, 
Naive 10.21(7.41- 10.57 (8.38- 0.14 (0.11- 0.15 (0.14- 0.18 (0.13- 0.17 (0.16- 15.01 13.46 (8.94-
11.74) 12.05) 0.21) 0.38) 0.32) 0.36) (6.50- 16.40) 
18.83) 
Vehicle 5.35 (4.33- 4.25 (2.14- 0.16 (0.12- 0.21 (0.17- 0.19 (0.10- 0.22 (0.16- 5.87 (2.67- 6.31 (2.67-
saline 6.85)" 7.12) - 0.23) 0.29) 0.28) 0.31) 8.63)" 8.68)- I 
Vehicle 7.24 (1.45- 9.05 (5.55- 0.15 (0.06- 0.31 (0.14- 0.19 (0.14- 0.31 (0.17- 7.99 (4.11- 8.13 (4.11-
1 
carrageenan 12.28) 15.31) 0.28)** 0.61) 0.24)** 0.47) 13.89) 13.89) 
URB597 5.35 (4.78- 5.02 (4.33- 0.23 (0.18- 0.20 (0.18- 0.12 (0.10- 0.20 (0.11- 7.20 (2.65- 6.73 (2.65-
Saline 7.20) 6.85) 0.30) 0.25) 0.18) 0.30) 10.86) 10.86) 
URB597 5.07 (1.38- 9.04 (2.36- 0.16 (0.07- 0.20 (0.10- 0.13 (0.08- 0.27 (0.15- 6.05 (1.81- 5.83 (1.81-
Carrageenan 14.14)** . 15.32) 0.19) 0.31) A 0.19)***++ 0.45) 9.41) 9.41) 
.-
--------
Table 4.11: levels of ECls and related compounds in the hindpaw of rats receiving repeated dosing with URB597 0.3mgkg-1 ) or 
vehicle, and the intraplantar injection of carrageenan or saline. Tissue were collected 3 hours following injection of carrageenan or 
saline. Data expressed as median and range and were analysed using non-parametric Mann-Whitney test. -P<0.01, ***P<0.005 
vs. contralateral hindpaw, ++P<0.01 vs ipsilateral vehicle carrageenan, A P<0.05 vs contralateral vehicle-carrageenan, "P<0.05 vs 
ipsilateral na"ive, -P<0.05,-P<0.01vscontralateral naIve. 
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AEA OEA PEA 2-AG 
Vehicle +-+ +-+ +-+ +-+ 
URB597 +-+ +-+ +-+ +-+ 
Tables4.11 a summarises the effects of intraplantar injection of 
carrageenan on levels of ECLs in the hindpaw of rats treated with a 
single injection of Vehicle/ URB597 3 hrs post saline/carrageenan 
injection. 
AEA OEA PEA 2-AG 
Saline +-+ +-+ +-+ +-+ 
Carrageenan +-+ +-+ ~ ~ +-+ 
.. Table 4.11 b summarises the effects of a repeated Injection of 
URB597 on levels of ECLs in the hindpaw 3 hrs post intraplantar 
injection of saline/carrageenan injection. 
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Figure 4.24: Effects of repeated systemic injection of URB597 or 
vehicle on carrageenan (carra) or saline (sal) induced changes in 
endocannabinoid levels in the contralateral and ipsilateral hindpaw 3 
hours post carrageenan injection, Data were expressed as Median 
and range (n=9-14), and analysed using Mann-Whitney non-
parametric test, **P<O.01, ***P<O.005 vs. contralateral hind-paw, 
++P<O.01 vs. ipsilateral vehicle-carrageenan hind-paw, ~ P < O , 0 5 5 vs. 
contralateral vehicle carrageenan hind-paw. 
Repeated URB597 treatment in rats receiving intraplantar injection 
of saline did not alter levels of AEA, PEA, OEA or 2-AG in the 
ipsilateral spinal cord, compared to vehicle saline treated rats (Table 
4.12). This was also the case for the contralateral spinal cord, with 
the exception of PEA. Repeated URB597 treatment in rats 
receiving intraplantar injection of carrageenan did not alter levels of 
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AEA in the ipsilateral spinal cord compared to vehicle treated 
carrageenan rats. By contrast levels of OEA and PEA were 
increased (Figure 4.25, Table 4.12) in the ipSilateral spinal cord of 
rats repeatedly dosed with URB597 and receiving intraplantar 
injection of carrageenan, compared to vehicle treated carrageenan 
rats. 
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Figure 4.25: Effects of repeated systemic injection of URB597 or 
vehicle on carrageenan (carra) or saline (sal) induced changes in 
levels of endocannabinoids in the contralateral and ipSilateral spinal 
cord of vehicle treated rats 3 hours post-injection. Data are 
expressed as median and range (n=10-13) and analysed using 
Mann-Whitney non-parametric test, + P < 0.05, vs. ipSilateral 
vehicle-carrageenan spinal cord, A P < 0.05, M P < 0.01 vs. vehicle 
carra contralateral spinal cord. 
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Group AEA pmolg-1 OEAnmolg-1 PEA nmolg-1 2AG nmolg-1 
median _(range) median (range) median (range) median (range) 
lpsi Contra Ispi Contra Ispi Contra Ipsi Contra 
NaIve 27.89(21.17- 34.07 (30.14- 0.58 (0.4- 0.71 (0.54- 0.46 0.62 30.55 (24.63- 45.46 (32.88-
34.84) 40.04) 0.64) 0.92) (0.27- (0.39- 35.42) 48.05) i 
0.58) 0.81) I 
Vehicle 12.55 (3.01- 25.09 (9.65- 1.20 1.09 (0.83- 1.22(0.38- 0.87 19.55 (2.38- 14.73(9.27-
saline 35.9( 32.36f (0.63- 1.41) 2.30)1\J\ (0.31- 37.98)" 20.96r-
2.18)"" 1.33f I 
Vehicle 30.77 (6.98- 23.59 (11.00- 1.05 0.99 (0.30- 0.86 0.80 38.84 (5.76- 24.88 (6.58- I 
carrageenan 56.08) 54.6) (0.34- 1.78) (0.27- (0.31- 82.38) 49.02) 
2.56) 1.57) 1.29) 
URB597 18.93 (8.62- 35.08 (7.20- 1.39 1.79 (J.35- 1.34 1.68 23.68 (7.63- 24.73 (13.94-
Saline 37.37) 56.22) (0.84- 2.64) (0.44- (0.73- 56.78) 44.15) 
2.16) 2.14) 2.31f 
URB597 37.77 (10.68- 51.50 (25.14- 1.65 2.00(1.07- 1.31(0.91- 0.90 43.69(10.08- 45.73 (26.37-
carrageenan 89.29) 101.1)i100 (0.52- 4.10) 2.74)+ (0.38- 79.21) 77.84)i100 
l__ ~ ~____ 
- ----- - . - - - ~ - -
3.08t 1.47)00 
- -
Table 4.12: levels of Eels and related compounds in the spinal cord of rats receiving repeated dosing with URB597 (0.3mgkg-1)or 
vehicle, 3 hours following injection of carrageenan or saline. Data are expressed as median and range and were analysed using 
non-parametric Mann-Whitney test. ·P<0.05, -P<0.01 vs contralateral vehicle saline, ooP<0.05 vs contralateral URB597 saline, 
i1P<0.05 vs contralateral vehicle carrageenan, +P<0.05 vs ipSilateral vehicle carrageenan, -P<0.05, -P<0.01 vs contralateral naIve, 
1\<0.05, ""0.01 vs ipsilateral naIve. 
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AEA OEA PEA 2-AG 
Vehicle +-+ +-+ +-+ +-+ 
URB597 +-+ +-+ +-+ +-+ 
.. Table 4.12a summarises the effects of Intraplantar Injection of 
carrageen on levels of ECls in the spinal cord of rats treated with a 
single injection of Vehicle/ URB597 3 hrs post saline/carrageenan 
injection. 
AEA OEA PEA 2-AG 
Saline +-+ +-+ +-+ +-+ 
Carrageenan +-+ i t +-+ 
.. Table 4.12b summarises the effects of a repeated injection of 
URB597 on levels of Eels in the spinal cord 3 hrs post intraplantar 
injection of saline/carrageenan injection. 
To ease comparisons of the effects of acute versus repeated 
URB597 treatment on levels of Eels in the ipsilateral hindpaw and 
spinal cord of URB597-carrageenan treated rats, data were 
expressed as a percentage of the mean level of Eel in the ipsilateral 
hindpaw or spinal cord of vehicle pre-treated rats receiving 
intraplantar injection of carrageenan. For the hindpaw, there was a 
higher percentage increase in levels of AEA in rats receiving a single 
dose of URB597, compared to repeated dose of URB597. at 3 hours 
post-carrageenan injection (Table4.13). There were no significant 
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differences in the increase in levels of PEA, OEA, and 2-AG in the 
hindpaw following repeated or single treatment with URB597. 
In the spinal cord, there was a significantly larger increase in levels of 
AEA and OEA in rats receiving a single dose of URB597, compared 
to repeated treatment with URB597 at 3 hours post-carrageenan 
injection (Table 4.13). There was also a trend towards an increase in 
levels of PEA following the single dose of URB597 compared to 
repeated treatment; however this did not reach significance (Table 
4.13). 
% of mean level in vehicle carrageenan-treated rats 
AEA PEA OEA 2-AG 
PAW Single 139.6± 86.6±1 93.3±10.6 73.3±7.1 
15.8** 6.8 
Repeated 69.4±1 69.7±5. 89.9±5.8 71.7±8.9 
5.2 3 
SPINAL Single 213.0± 278.1± 337.2±71.9 83.9±32.5 
CORD 31.5* 62.0 3* 
Repeated 122.8± 168.5± 157.9±25.8 112.5±16.9 
22.2 25.8 
Table 4.13: Effects of intraplantar injection of carrageenan on levels 
of AEA, PEA, OEA, and 2-AG in the hindpaw and spinal cord of rats 
which received either a single or repeated treatment with URB597 
(O.3mgkg-1). Data were analysed using Mann-Whitney non-
parametric test and are expressed as a percentage of the ipsilateral 
mean level of EC of vehicle treated rats, receiving an intraplantar 
injection of carrageenan. (n=7-9) *P<0.05, **P<O.01 versus repeated 
URB597 administration. 
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Overall, the greater increase in the levels of AEA, PEA and OEA in 
rats receiving a single dose of URB597 may explain the significant 
inhibitory effect of a single dose URB597 on pain behaviour, 
compared to the lack of effect of repeated URB597 treatment. The 
basis for the differential effect of repeated URB597 treatment 
compared to a single dose of URB597 is unknown. 
A correlation analysis of the levels of ECs in the ipsilateral spinal 
cord 3 hours post carrageenan I saline injection was also undertaken 
in rats treated with a single systemic injection of vehicle or URB597 
to investigate the relationship between each of the N-
acylethanolamines (AEA, OEA, and PEA) and acyl-glycerols (2-AG) 
in each individual rat. Spearman rank correlation coefficient (R2) are 
presented in Table 4.14 and representative correlation graphs are 
shown in Figure 4.26. This analysis demonstrates that irrespective of 
group levels of 2-AG are not correlated with AEA, PEA or OEA. 
There was a significant correlation between levels of OEA and PEA 
for each treatment group. AEA and OEA were correlated in both the 
vehicle carrageenan group and URB597 carrageenan group. 
Interestingly treatment with URB597 was associated with a 
Significant correlation in AEA and PEA, which was not present in the 
absence of URB597 treatment. 
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R4:: 
URB Carra Veh Carra URB saline Veh Saline 
AEA vs 0.85** 0.68 0.80 0.60 
PEA 
AEA vs 0.85** 0.82* 0.40 0.51 
OEA 
AEA vs 2- 0.13 0.20 0.61 0.80 
AG 
OEA vs 0.97*** 0.77* 0.80* 0.72* 
PEA 
2-AG vs -0.03 0.02 0.41 0.24 
PEA 
2-AG vs 0.1 0.38 0.20 0.61 
OEA 
Table 4.14 Spearman Rank coefficient correlating levels of Eels in 
spinal cord 3 hours following intraplantar injection of carrageenan I 
saline,*P<0.05, **P<0.01, ***P<0.005. 
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Figure 4.26 Representative graphs showing the correlation 
coefficient between AEA, OEA, PEA and 2-AG in ipsilateral spinal 
cord of URB597 treated rats 3 hours post following intraplantar 
injection of carrageenan. 
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In Chapter 2. I describe the development and validation of a 
sensitive LC-MS/MS method for the detection of COX-2 metabolites 
(PG E2, PGD2, PGF2a EA, PGE2 GE and PGF2a GE) in biological 
tissue. This method was employed to determine whether COX-2 
metabolites of AEA or 2-AG are present in the hind paw or spinal cord 
following the induction of inflammation an lor the inhibition of FAAH. 
In particular, this analytical approach was used to identify if 
alternative catabolism pathways for AEA may account for the 
reduced effect of repeated URB597 treatment on pain behaviour. 
Neither COX-2 metabolites of AEA or 2-AG was detected in either 
the hindpaw or spinal cord of rats treated with single or repeated 
URB597 and intraplantar injection of carrageenan or saline. 
Prostaglandin ethanolamides and prostaglandin glycerol esters were 
detected if they were spiked into rat brain tissue (Figure 4.27), 
showing the functionality of the method. The limit of detection of PG-
EAs and PG-GEs was 10pmol/g and 100pmollg respectively. On this 
basis, we assume that if the COX-2 metabolites of AEA and 2-AG 
are present, they are below our limit of detection. 
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Figure 4.27: Representative chromatograms of the 
endocannabinoids detected in rat brain and COX-2 metabolites of 
AEA with the addition of synthetic standards. 
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4.5 Discussion 
In this chapter I have shown that intraplantar injection of carrageenan 
results in hind paw oedema and hyperalgesia 3 hours post 
carrageenan administration. A single systemic injection of URB597 
did not alter carrageenan-induced hindpaw oedema, but did delay 
the onset of carrageenan-induced hyperalgesia at 2 hours post-
carrageenan injection, and also attenuated carrageenan-induced 
hyperalgesia at 3 hours. By contrast repeated systemic 
administration of URB597 did not alter carrageenan-induced 
hyperalgesia or hindpaw oedema at either 2 or 3 hours post-
carrageenan injection. 
The analgesic effects of a single injection of URB597 on 
carrageenan-induced hyperalgesia were not associated with changes 
in levels of Eels in the ipsilateral hindpaw of carrageenan- inflamed 
animals. It was, however, associated with an increase in levels of 
AEA, OEA and PEA in the ipsilateral spinal cord, compared to the 
ipsilateral spinal cord of vehicle treated animals. These data suggest 
that a spinal site of action contributes to the inhibitory effects of 
URB597 in this model of inflammatory pain. In line with the lack of 
effect of repeated URB597 on hyperalgesia, there was a modest 
effect of this treatment on levels of OEA and PEA in the ipsilateral 
spinal cord of carrageenan-treated rats, compared to vehicle. 
Comparison of the effects of a single versus repeated URB597 
treated rats on levels of ECls in the spinal cord revealed that there 
was a larger percentage increase in levels of AEA in both the 
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hindpaw and spinal cord of animals receiving a single injection of 
URB597, compared to repeated injection of URB597. Repeated 
injection of URB597 only elevated PEA and OEA in the spinal cord, 
suggesting that elevation of AEA, OEA and PEA is required to 
attenuate carrageenan induced hyperalgesia, which is in keeping 
with previous studies demonstrating a role of the CB1 receptor in 
mediating the effects of URB597 (Jayamanne et aI., 2006a, Maione 
et al., 2006, Ahn et al., 2009b). 
4.5.1 The effects of carrageenan at 2 hours and 3 hours 
on carrageenan-induced hyperalgesia and levels of 
Eels. 
It is well established that intraplantar injection of carrageenan 
produces a behavioral pain response which is associated with 
hindpaw expansion of receptive field of spinal neurones innervating 
the inflamed site (Elmes et al., 2004). The behavioral pain response 
can be assessed through changes in behavioural responses such as 
withdrawal latency to mechanical or thermal stimuli and changes in 
weight bearing. 
The increase in hindpaw oedema is associated with an increase in 
paw volume and circumference 3 hours following injection of 
carrageenan (Hargreaves et aI., 1988a), which is consistent with our 
observations. Carrageenan-induced hyperalgesia was assessed by 
rats placing significantly less weight on the injected hindpaw and 
more weight on the non-injected hindpaw. In keeping with previous 
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studies, we show that the increase in hindpaw oedema and 
hyperalgesia is maximal after 3 hours, and significantly different from 
saline-treated rats (Hargreaves et aI., 1988a, Clayton et aI., 2002, 
Elmes et aI., 2005). 
The effect of inflammation on levels of ECls is unclear and varies 
depending on the nature of inflammation and the tissue under 
investigation. For example in lPS induced pulmonary inflammation, 
levels of AEA and PEA were unaltered (Holt et aI., 2004) and in a 
formalin model of hindpaw inflammation levels of AEA, PEA and 2-
AG were also unaltered (De Petrocellis et ai, 2000). While in the 
carrageenan model of inflammation, a decrease in AEA, PEA and 
OEA was observed in the hindpaw (Jhaveri et aI., 2008b). 
Carrageenan-induced inflammation peaks at 3 hours post injection 
and, although it could be argued that the increased activity, both at 
nociceptors and local immune cells, would be expected to increase 
levels of ECls, this time point was associated with increased 
hindpaw levels of cytokines such as tumour necrosis factor-a (TNF-
a), interleukin 1b (IL-1b), Il-6 ((Cunha et aI., 2000, Loram et aI., 
2007» and prostaglandins such as PGE2 (Guay et aI., 2004) which 
contribute to neuronal sensitisation and an increase in nociceptive 
activity (for review see (Gold and Flake, 2005, Cheng and Ji, 2008) , 
which, in turn may contribute to the on-demand synthesis of 
endocannabinoids (see reviews (Howlett et aI., 2002, Piomelli, 2003). 
The carrageenan-induced hyperalgesia and hind paw oedema 
observed in this study were, however, associated with a decrease in 
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levels of ECls in the ipsilateral hindpaw, compared to levels in the 
contralateral hindpaw of carrageenan-inflamed hindpaw at both 2 
and 3 hours post carrageenan. We also observed a decrease in 
levels of ECls in the ipSilateral hindpaw at 2 hours post carrageenan 
injection, compared to saline treated rats, however, this was not 
apparent at 3 hours post-carrageenan. 
Cannabinoid receptors have been shown to be up-regulated during 
inflammation (Izzo et aI., 2001), which could be consistent with 
decreased local levels of endogenous ligands. levels of AEA and 2-
AG were significantly lower in the hindpaw of saline-treated rats 
compared to na'ive tissue, indicating that injection alone can alter 
levels of ECs, possibly due to volume changes. 
In the spinal cord of vehicle treated rats, there were no changes in 
levels of ECs 2 hours post-carrageenan injection, compared to saline 
treated rats. However, at 3 hours post carrageenan injection levels 
of AEA, were increased in the ipsilateral spinal cord of carrageenan-
treated rats, compared to the ipsilateral spinal cord of saline treated 
controls, whilst levels of AEA, OEA, PEA and 2-AG were unaltered 
compared to na'ive tissue. This suggests that the physiological 
noxious response to inflammation in the hind paw increases levels of 
AEA at the spinal level where there is considerable processing of 
noxious inputs. 
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4.5.2 Effects of URB597 on carrageenan-induced 
changes in weight bearing and paw oedema. 
Neither single nor repeated systemic injection of URB597 (0.3mg/kg) 
altered carrageenan-induced hind paw oedema. These data are 
consistent with the earlier report that 3mg/kg, but not 0.3mg/kg 
URB597 attenuates carrageenan-induced changes in hindpaw (Holt 
et aI., 2005b). It is clear that oedema formation is modulated by 
endocannabinoids as deletion of the FAAH gene reduced the 
development of carrageenan-induced oedema by less than half. This 
presumably reflects the capacity of the cannabinoid receptor system 
to modulate oedema as exogenous administration of AEA or PEA did 
not further decrease oedema in FAAH knockout mice (Wise et aI., 
2007). On this basis, only a proportion of carrageenan-induced 
oedema can be modulated by ECLs and related substances. 
Despite the lack of effect of single injection of URB597 on oedema, 
this treatment delayed the onset, and attenuated carrageenan-
induced hyperalgesia at 3 hours post carrageenan injection. These 
data are consistent with the reported anti-nociceptive effects of 
URB597(0.3mg/kg) in CFA model of inflammatory pain (Jayamanne 
et aI., 2006a). It is of interest to note that URB597 did not reduce 
allodynia in the partial nerve ligation model of neuropathic pain, 
whereas the CB receptor agonist HU210 (0.03mg/kg) attenuated 
CFA-induced inflammation and allodynia in neuropathic pain model 
(Jayamanne et aI., 2006). Thus, following peripheral inflammation 
URB597 mediated analgesia may be arise as a result of an 
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enhancement of peripheral endogenous cannabinoids acting at 
CB1I2 receptors, which may not be elevated following nerve injury. 
4.5.3 Central versus peripheral effects of FAAH 
inhibition in inflammatory pain. 
Inhibition of FAAH through the use of knock out mice and 
pharmacological inhibition of FAAH elevates levels of AEA in nervous 
tissue (Cravatt et aI., 2004, Maione et aI., 2007, Ahn et al., 2009b) 
and these increases have been associated with the analgesic effects 
of FAAH inhibition. Our finding that single dose of URB597 did not 
alter levels of ECls in the hindpaw, but did increase levels in the 
spinal cord of carrageenan treated rats is consistent with the notion 
of a predominant central site of action mediating the analgesic effects 
of FAAH inhibitors. These increases were most apparent at 3 hours 
post-carrageenan injection, with levels of levels of AEA, OEA and 
PEA in the ipsilateral spinal cord of carrageenan treated rats 
significantly increased by URB597. These data are consistent with 
previous studies showing single systemic administration of URB597 
time-dependently increased levels of AEA in brain from 30 minutes to 
2 hours post URB597 (0.3mg/kg) administration while levels were 
unaltered in peripheral tissue (Fegley et aI., 2005). An increase in 
levels of AEA in the hippocampus, cortex and midbrain was also 
reported 2 hours following UR8597 (0.1 mg/kg) treatment (Gobbi et 
al.,2005). 
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Comparison of the effects of pharmacological manipulation of FAAH 
versus genetic deletion identifies some interesting differences. As 
discussed above the dose of URB597 used in this study did not alter 
oedema formation. However, studies using tissue specific FAAH 
knock out mice demonstrated a contribution of peripheral FAAH to 
the reduction in oedema observed in the carrageenan model (Cravatt 
et aI., 2004). levels of ECls in peripheral tissue were significantly 
elevated in FAAH-NS tissue, compared to wild-type, while levels in 
brain and spinal cord were unaltered, however analgesic effects was 
not mediated through CB1 or CB2 receptors (Cravatt et aI., 2004). 
Collectively, these data suggest that the analgesic phenotype 
exhibited by FAAH-1- mice is through the elevation of central ECls, 
and the anti-inflammatory properties of are through the elevation of 
peripheral ECs. Consistent with these findings, we suggest that 
analgesic properties of URB597 are mediated through an elevation of 
ECs in the spinal cord, while we observed no effect on odema or 
levels of ECs in the hindpaw. 
As would be expected, there was an increase in the levels of AEA in 
the ipsilateral spinal cord of URB597 treated rats receiving an 
intraplantar injection of saline compared to vehicle treated. This 
observation is in keeping with previous reports of increases in levels 
of AEA in the brain at 2 hours post URB597 treatment (Kathuria et 
aI., 2003a, Gobbi et aI., 2005, Ahn et aI., 2009b) 
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4.5.4 Effects of repeated administration of URB597 on 
carrageenan-induced hindpaw inflammation and 
endocannabinoid levels. 
Repeated administration of URB597 did not alter carrageenan-
induced hyperalgesia or oedema, despite significantly decreasing 
FAAH activity in both midbrain and liver. The lack of analgesia was 
paralleled by a lack of effect of repeated administration of URB597 
on levels of AEA in the ipsilateral hindpaw of carrageenan treated 
rats, compared to ipsilateral hindpaw of vehicle treated rats. 
Repeated URB597 treatment was associated with a small, but 
significant, decrease in PEA levels compared to vehicle. Levels of 
PEA and OEA, but not AEA, were elevated in the ipsilateral spinal 
cord following repeated URB597 treatment in carrageenan treated 
rats. Overall, levels of AEA were significantly higher in the hindpaw 
and spinal cord of rats treated with a single injection of URB597, 
compared to repeated administration URB597. The larger 
percentage increase, along with the elevation of AEA, OEA and PEA 
in the spinal cord of rats receiving a single injection of URB597 may 
explain the analgesic properties of this treatment. 
Previous work has reported that repeated URB597 treatment 
(O.3mgikg for 5 weeks) in a model of chronic mild stress, elevated 
levels of AEA in midbrain, thalamus and striatum, however levels 
were unaltered in the hippocampus and pre-frontal cortex, while 
levels of PEA and OEA were elevated in all brain regions. Thus, 
both our data, and this early work, suggests that the effects of 
URB597 on AEA versus OEA and PEA are not identical and that 
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elevations may be specific to one of these compounds and also 
tissue dependent. Our data demonstrating that the effects of 
URB597 on pain behavior are absent following repeated dosing is in 
keeping with the report that the ability of repeated URB597 treatment 
(0.1 mg.kg once daily for 4 days) to elevate levels of AEA in rat brain 
is diminished compared to the effects of a single dose of URB597 
(Gobbi et aI., 2005). 
4.5.5 Is the lack of effect of repeated administration of 
URB597 due to changes in endocannabinoid 
biosynthesis and catabolism? 
The mechanisms behind the lack of effect of repeated injection of 
URB597 on pain behavior and levels of ECs are unclear and warrant 
further investigation. Previous work has suggested that prolonged 
exposure to the FAAH inhibitor may result in a down regulation of 
AEA mobilization in certain tissue (e.g. spinal tissue) and not in 
others such as thalamus. The mechanism underlying this 
hypothetical down-regulation of AEA signalling remains 
undetermined (Bortolato et aI., 2007). Repeated administration with 
a FAAH inhibitor may also affect the synthesis and catabolism of 
ECs. It is generally accepted that AEA and other NAEs are 
principally biosynthesized from membrane phospholipids through a 
common two-step pathway, termed 'the transacylation-
phosphodiesterase pathway. The first reaction in this pathway 
involves the formation of (N-acylated phosphatidylethanolamines 
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(NAPE) by a Ca2+-dependent N-acyltransferase (NAT), followed by 
phospholipase type-D (PLD) hydrolysis of the resultant NAPE by 
NAPE-PlD, leading to the formation of AEA, (see Chapter 1 for 
further explanation). Since specific inhibitors of NAPE-PLD are not 
available, generation of gene-disrupted mice is of great importance to 
elucidate its physiological function. NAPE-PLD-deficient mice have 
decreased levels of long chain, saturated NAEs, however 
polyunsaturated NAEs, including AEA, were unaltered in these 
animals suggesting additional routes for AEA synthesis (leung et aI., 
2006). Consistent with this finding, siRNA knockdown of NAPE-PLD 
in macrophages did not significantly reduce levels of AEA (Liu et aI., 
2006), again suggestive of additional routes of synthesis of AEA. 
Further understanding of different routes of synthesis and how this 
may influence our data requires methods to study synthesis 
pathways. Screening through lC/MS/MS for AEA precursors such 
GP-NAEs (Simon and Cravatt, 2006, 2008), and pAEA (Liu et aI., 
2008) may provide some insight into the synthesis of these 
compounds. 
In addition to their hydrolysis by FAAH, ECls can also under go 
degradation and catabolism via alternative routes including COX-2 to 
generate prostaglandin ethanolamides (PG-EA) and prostaglandin 
glycerol esters (PG-GE) (Yu et aI., 1997, Kozak et aI., 2000, Kozak et 
a!., 2001a, Kozak and Marnett, 2002, Kozak et aI., 2004, Fowler, 
2007), 12- and 15-lipoxygenase (lOX) to generate hydroperoxides 
((Hampson et aI., 1995, Ueda et aI., 1995b, Kozak et aI" 2002b), 
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cytochrome P450 (CYP450) to produce hydroxy and epoxide 
metabolites (Snider et aI., 2007, Snider et aI., 2008), and N-
acylethanolamine-hydrolyzing acid amidase (NAAA), to produce 
ethanolamine and arachidonic acid. The lack of elevation of AEA 
with repeated treatment with URB597 may be due to the increased 
catabolism via other metabolic routes. The majority of evidence for 
COX-2 metabolism of AEA and 2-AG to PG-EA and the 
corresponding PG-GE is derived from in vitro studies (Yu et aI., 1997, 
Kozak et aI., 2002a) there is evidence for a role of this route of 
metabolism under certain conditions in vivo. Oxidative metabolites of 
AEA were detected following exogenous administration of AEA in 
FAAH knockout mice (Weber et aI., 2004) and PGE2-GE, the COX-2 
metabolite of 2-AG was detected in the rat hindpaw (Hu et aI., 2008). 
Although increased catabolism via COX-2 is an attractive theory for 
the lack of effect of repeated dosing with URB597 on pain behaviour, 
we found no evidence that metabolism of ECs via COX-2 contributes 
to the lack of effect of repeated treatment with URB597. Of the two 
endocannabinoids AEA and 2-AG, endogenous levels of 2AG are 
more compatible with substrate affinities at COX-2 suggesting that 
2AG may be a better substrate for COX-2 (Kozak and Marnett, 
2002). The amount of PGE2-GE found in the rat hindpaw (fmol/g) 
was low relative to the nmol/g levels of 2-AG, which may indicate that 
very little 2-AG is metabolized by COX-2 in vivo, or it may be the 
result of the rapid hydrolysis of PGE2-GE into PGE2 (Kozak et aI., 
2001 a, Hu et aI., 2008). It appears that high levels of AEA are 
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required in vivo for prostamide formation (Weber et aI., 2004), which 
may not occur due to other routes of inactivation. 
An important consideration is the validity of the analytical method 
employed to quantify the COX-2 metabolites of AEA and 2-AG. As 
described in chapter 2, the methods used in this thesis for the 
identification and quantification of COX-2 metabolites has been 
validated in biological tissue to FDA guidelines, unlike previous 
methods (Weber et aI., 2004, Hu et aI., 2008). On this basis we are 
confident that if COX-2 metabolites of AEA and 2-AG are formed 
endogenously our method allows their quantification at levels down 
to 10 pmol/g. Nevertheless, it is possible that these metabolites fall 
below the limit of detection of our analytical method. 
In conclusion, we have shown that single administration of URB597 
delays the onset and attenuated carrageenan-induced hyperalgesia, 
which was associated with an increase in levels of AEA, OEA and 
PEA in the spinal cord. However repeated administration of URB597 
did not alter carrageenan-induced hyperalgesia, possibly due to the 
lack of elevation in levels of AEA in the spinal cord. We found no 
evidence for the role of COX-2 metabolism in this model of 
inflammation, and further work will determine if these compounds are 
formed in vivo under other inflammatory conditions. 
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Chapter 5. 
The role of the endocananbind 
system in MIA model of 
Osteoarthritis. 
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5 The role of the endocananbind system in MIA 
model of Osteoarthritis. 
5.1 Introduction 
Osteoarthritis (OA) is a degenerative joint disease commonly 
described as a non-inflammatory degenerative disease of articular 
cartilage resulting in changes in the underlying subchondral bone, 
synovium and capsule (Guilak, 2000). OA is the most common form 
of arthritis, and is particularly prevalent in the elderly, with 10 - 20% 
of over 65 year olds suffering from OA (ARC, 2005). OA is 
associated with chronic pain (Oieppe and Lohmander, 2005), 
however the aetiology of OA is poorly understood, with mechanical, 
metabolic and inflammatory causing other symptoms which may 
include tenderness, stiffness, inflammation, locking of joints, and 
pain. 
The relationship between degeneration of the joint and the pain 
experienced is poorly understood. Currently there is a lack of drugs 
that delay the onset or repair joint damage caused by OA. and 
current NSAIO treatments do not always provide adequate pain relief 
long-term, and have detrimental side-effects (Patrignani et aI., 2005). 
Thus, there is a strong need for the identification of novel targets for 
safer drugs which alleviate OA pain (Berenbaum, 2008), with a 
reduced side-effect which can only be achieved by an improved 
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mechanistic understanding of the changes associated with this 
disease. Studies of animal models of degenerative joint disease, that 
replicate the major symptoms of the clinical condition, will improve 
our understanding of the mechanisms underlying OA pain (Am eye 
and Young, 2006). 
5.2 Synovial Joint Histology 
Synovial joints, such as the knee, consist of two bone ends covered 
by articular cartilage. The articular cartilage is smooth and flexible 
and enables frictionless movement of the jOint; a normal joint is 
shown in Figure 5.1. The joint capsule is made up of the fibrous 
capsule which aids structural integrity and an inner lining layer, the 
synovial membrane. The synovial membrane secretes synovial fluid 
which provides lubrication within the jOint. The joint is further 
stabilised by attached tendons and ligaments. 
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Figure 5.1 Normal physiology of a synovial joint. The two bones are 
held in place a short distance from each other with tendons and 
ligaments. Cartilage lines the areas of the bones which are in close 
proximity to each other, and is surrounded by a synovial fluid filled 
sac. Taken from (ARC, 2005) 
Frictionless motion is provided by the combination of a smooth 
articular cartilage as well as lubrication of both the articular cartilage 
and the synovial membrane. Shock absorption to the joint is 
provided by a combination of structures, including articular cartilage, 
subchondral bone and the soft tissue structures namely the jOint 
capsule and ligaments. Cartilage is mainly composed of a mixture of 
water, collagen, proteoglycans and various cellular constituents 
(Guilak, 2000), and is essential for structure and mechanical strength 
of the joint, providing cushioning and evenly distributing weight 
applied on the bones to ease movement. Both the collagen and 
proteoglycans are very important for normal function of articular 
cartilage. The synovial tissue and fluid add nourishment, rigidity for 
cartilage, and prevent excess movement (Guilak, 2000). Loss of 
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proteoglycans or breakdown of collagen means that the articular 
cartilage cannot function normally. Chondrocytes, which are in the 
extracellular matrix of cartilage, produce and maintain the 
cartilaginous matrix, which consists mainly of collagen and 
proteoglycans (Goldring, 2006). 
5.3 Pathophysiological changes in the joint in OA 
OA is characterised by a loss of cartilage due to faster degradation of 
the extracellular matrix (ECM) compared to synthesis, and 
subsequent changes in the underlying bone (for a review see (Sarzi-
Puttini et al., 2005). During the development of OA, the cartilage 
gradually roughens and thins, while the bone underneath thickens. 
The bone at the edge of the joint grows outwards and forms 
osteophytes (bony spurs). The synovium produces extra fluid, 
causing a swelling of the joint, along with the thickening and 
contraction of ligaments trying to stabilise the jOint as it changes 
shape (See Figure 5.2). The release of cytokines, such as IL-B, 
inhibits the synthesis of matrix constituents such as collagen and 
proteoglycans, and stimulates the synthesis and release of some 
eicosanoids, including prostaglandins and leukotrienes from the 
synovium and chondrocytes. Collectively, this contributes to 
cartilage degradation and the roughening of the cartilage surface, 
slight inflammation of the joint and apoptotic events in the 
chondrocytes (Pelletier et a\., 1999, Mathy-Hartert et aI., 2002, 
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Barksby et aI., 2006). Instability and inflammation in the joint also 
induce alterations in other cells: osteoblasts proliferate along the joint 
margin, resulting in osteophyte formation (Mankin and Lippiello, 
1970), synovial cells proliferate resulting in synovial cell hyperplasia 
(Goldenberg et aI., 1982, Lindblad and Hedfors, 1987) and new 
subchondral bone formation results in sclerosis underlying damaged 
cartilage (Bendele and Hulman, 1988). 
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Figure 5.2 A comparison of the physiological changes in the joint observed in patients suffering with (A) mild osteoarthritis, with thinning and 
roughening of cartilage and production of 'spurs'. The joint becomes swollen due to excess synovium fluid or (8) severe osteoarthritis, with a 
destruction of cartilage, severely inflamed synovium and bone deformity due to lack of stabilastion of knee joint by tendons. A key difference 
between the severities of the two diseases is the lack of cartilage, bone derfomity and inflamed synovium. Taken from (ARC, 2005). 
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5.3.1 Animal models of OA 
Animal models of OA frequently study the pathogenesis of cartilage 
degeneration and potential therapeutic modulation of disease. These 
models are either naturally occurring or surgically-induced. 
Spontaneous OA occurs in the knee joints of various strains of mice 
(Sokoloff et aI., 1962, Walton, 1977) where arthritis occurs in 
approximately 80% of aging male DBAl1 mice, characterized by 
synovial lining proliferation and infiltration of mononuclear 
inflammatory cells(Nordling et al., 1992) and in guinea pigs (Bendele 
and Hulman, 1988, Bendele et aI., 1989), which note the histological 
changes, including lesions on the medial tibial plateau, chondrocyte 
death, proteoglycan loss and fibrillation progressing as the animal 
gets older. Furthermore guinea pigs have been shown to express 
matrix metalloproteinase (MMX) proteins (Huebner et aI., 1998), 
which include collagenases and gelatinases., and collagenase 1 
(MMP-1) and collagenase 3 (MMP-3) have been implicated in the 
pathogenesis of arthritis in humans (Mitchell et aI., 1996, Reboul et 
aI., 1996). The pathology and pathogenesis of naturally occurring 
OA are similar to those occurring in humans, however the 
progression of OA in these models are slow, and inevitably costly, 
making the period of drug testing long, hence other models are 
required. Surgically-induced models of OA have also been used, 
with the most common being medial meniscal tear (MMT). In the 
MMT model, the jOint space is exposed through the transaction of the 
274 
The role of the endocannabinoid system in MIA model of Osteoarthritis 
medial collateral ligament of the femorotibial joint. The medial 
meniscus is then cut to mimic a meniscal tear. Histologically, the 
MMT model is similar to that of human OA, with cartilage damage 
starting with fibrillation and loss of proteoglycan, progressing to 
complete loss of the cartilage layer and exposure of the subchondral 
bone (Bendele, 2001). The advantage of a rat model is it quick, and 
allows evalution of potential pharmacological agents. Rats, also 
have very little spontaneous degradation in their knees (Smale et aI., 
1995), thus the lesions are generally as a result of surgical/chemical 
manipulation. 
5.3.2 MIA model of OA pain 
However, to date, the vast majority of studies of animal models of 
osteoarthritis have investigated the pathophysiology and progression 
of joint damage with little characterisation of the associated pain. 
More recently a number of studies have investigated pain behaviour 
in some of these models of OA (Guingamp et aI., 1997, Sove et aI., 
2003, Kobayashi et aI., 2003, Pomonis et al., 2005, Vermeirsch et aI., 
2007). 
The monosodium iodoacetate (MIA) induced arthritis model was first 
described around 20 years ago (Kalbhen, 1987). MIA is an inhibitor 
of glycolysis, which induces chondrocyte death and produces 
cartilage degeneration (Dunham et aI., 1993). The histopathology of 
the MIA-injected joint has some similarities to that seen in human 
osteoarthritic joints, with exposed subchondral bone, loss of cartilage 
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and damaged synovium (Sove et al., 2003, Guzman et al., 2003, 
Kobayashi et aI., 2003, Combe et aI., 2004, Ivanavicius et aI., 2007). 
The degradation of the joint is therefore associated with chronic pain 
behaviour, first described by Fernihough (Fernihough et aI., 2004). 
This joint pathology is associated with a pronounced decrease in 
weight-bearing on the injected hind-paw (Sove et al. 2003; 
Kobayashi et al. 2003; Combe et al. 2004), a correlate of behavioural 
hyperalgesia. The MMT and MIA models produce comparable joint 
pathology, but more robust, and clinically relevant, pain behaviour is 
produced in the MIA model (Combe et aI., 2004, Fernihough et al., 
2004). In addition, the hindpaw ipsilateral to MIA knee joint injection 
has decreased thresholds for mechanical withdrawal (tactile 
allodynia), indicative of central sensitisation (Combe et aI., 2004, 
Fernihough et aI., 2004). 
The advantage of the MIA model is the relatively rapid onset of the 
disease, which produces robust pain behaviour, whilst being non-
invasive, allows for evaluation of analgesic compounds. The main 
problem associated with MIA is the dose given (Pomonis et al., 
2005), too Iowa dose produces histological changes associated with 
OA, whilst not producing robust pain behaviour, too high dose results 
in severe cartildge and bone destruction, differing form the human 
condition. 
The treatment of patients with OA is often directed at relieving pain 
and restoring function through the use of pharmacologic therapies. 
Intra-articular injections of corticosteroids have been demonstrated to 
276 
The role of the endocannabinoid system In MIA model of Osteoarthritis 
relieve inflammation and associated pain, but due to their shortness 
of effect are rarely used. The effects of analgesic drugs, including 
the opioid morphine and the non-steroidal anti-inflammatory drugs 
(NSAIDs), on MIA-induced pain behaviour have been reported. 
Administration of non-selective NSAIDs and morphine attenuates 
MIA-induced changes in weight bearing (Bove et aI., 2003, 
Fernihough et aI., 2004, Pomonis et aI., 2005, Beyreuther et aI., 
2007, Ivanavicius et aI., 2007), but not mechanical allodynia 
(Fernihough et al., 2004, Beyreuther et aI., 2007). 
5.3.3 The cannabinoid receptor system: implications 
forOA 
Cannabinoids have also been shown to play and important role in the 
treatement of chronic pain (see reviews (Hohmann, 2002, Iversen 
and Chapman, 2002, Goya et aI., 2003). The endocannabinoids, 
AEA and 2-AG inhibit neuronal responses and attenuate nociceptive 
processing (for review see Jhaveri et aI., 2007a). Constitutive 
expression of both CB 1 and CB2 receptors have been isolated on 
chondrocytes and implicated in a potential disease modifying role in 
OA (Mbvundula et aI., 2006), hence, the phytocannabinoid 
preparation Sativex has been reported to Significantly attenuate pain 
associated with rheumatoid arthritis (Blake et aI., 2006, Wright et aI., 
2006), while ajulemic acid, a synthetic cannabinoid acid, has anti-
inflammatory properties in human synovial cells through an increase 
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in COX-2 mRNA expression and prostaglandin 15d-PGJ2 synthesis 
(Stebulis et aI., 2008), which has anti-inflammatory properties, 
possibly through the activation of PPARy. (1995 ,.Forman et al) 
Furthermore local administration of the CB1 agonist arachidonyl-2-
chloroethylamide (ACEA) reduced the mechanosensitivity of afferent 
knee fibres in control and MIA-treated rats (Schuelert and McDougall, 
2008), while SR141716A reduced thermal hyperalgesia and 
mechanical allodynia is CFA model of arthritis (Croci and Zarini, 
2007), which may be mediated through the endocannabinoid system. 
Previous work from Nottingham has shown that levels of 
endocannabinoids and related compounds are altered in the synovial 
fluid taken from patients with end stage osteoarthritis and rheumatoid 
arthritis (Richardson et al., 2008), however it is unknown if these 
changes are associate with an increase in pain behaviour and 
cartilage damage. 
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5.3.4 Aims 
The aim of this study was to investigate whether the behavioural and 
histological changes associated with intra-articular injection of MIA is 
associated with changes in the levels of ECs in the hindpaw and 
spinal cord in this model of OA. 
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5.4 Methods 
Rats were purchased from Charles River U.K. All studies were 
carried out in accordance with UK Home Office Animals (Scientific 
Procedures) Act (1986) and follow guidelines of the International 
Association for the Study of Pain. Male Sprague Dawley rats 
weighing 120-190g were used for these studies. 
5.4.1 Intra-articular injections 
The following procedures were carried out by Dr 0 Sagar. 
Rats were anesthetised with isoflurane (1.5-2% in 66% N20 -33% 
02) and received a single intra-articular injection of monosodium 
iodoacetate (MIA; 1 mg/50J.l1) in saline through the infra-patellar 
ligament of the left knee. The dose of MIA was chosen from the 
previous literature (Bove et al., 2003, Guzman et aI" 2003, 
Kobayashi et aI., 2003, Pomonis et aI" 2005). Control animals 
received a single injection of saline (50J.l1) into the left knee in an 
identical manner. 
5.4.2 Behavioural testing 
The following procedures were carried out by Dr 0 Sagar. 
After surgery, rats were maintained under the same conditions as 
during the pre-operative period. The posture and behaviour of the 
rats were carefully monitored following recovery from the 
anaesthesia and then on the first postoperative (PO) day. Baseline 
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measurements were taken immediately prior to intra-articular 
injection (PO day 0) and then from PO day 2 onwards. Behavioural 
tests assessing changes in weight-distribution and sensitivity to 
mechanical stimuli were performed for up to 28 days post-injection. 
The weight gain and general behaviour of the rats was monitored 
throughout the PO period. 
Effects of joint damage on weight-distribution through the left 
(ipsilateral) and right (contralateral) knee were assessed using an 
incapacitance tester (Linton Instrumentation, U.K.). The two hind-
paws were placed on separate sensors and the force (in grams) 
exerted by each hind-limb was calculated and averaged over a 
period of 3 seconds as previously described (Clayton et aI., 2002, 
Elmes et al., 2005). Each data point was taken as the mean of three 
3 sec readings. Effects of an intra-articular injection of MIA or saline 
on weight distribution were assessed between post-operative days 2-
28. NaIve and saline-treated rats distribute their weight evenly 
between both paws. Changes in weight distribution has been used 
as an indicator of hypersensitivity of the joint (Bove et aI., 2003, 
Kobayashi et al., 2003) and hindpaw (Clayton et aI., 1997). The 
development of tactile allodynia was assessed using von Frey 
monofilaments (Semmes-Weinstein monofilaments of bending forces 
0.6, 1, 1.4, 2, 4, 6, 8, 10 and 15 g). Rats were placed in transparent 
plastic cubicles on a mesh floored table and a period of 
acclimatization was allowed prior to testing. Von Frey monofilaments 
were applied, in ascending order of bending force, to the plantar 
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surface of both hind-paws. Each von Frey was applied for a 3 sec 
period. Once a withdrawal reflex was established, the paw was re-
tested with the next descending von Frey monofilament until no 
response occurred. The lowest weight of monofilament which 
elicited a withdrawal reflex was noted as the paw withdrawal 
threshold (PWT). On post-operative days 14-17 and 28-31, rats 
were killed by stunning decapitation. The spinal cord and hind paw 
tissue were rapidly removed and placed onto dry ice. A laminectomy 
was performed and approximately 2 cm of the lumbar region (L4 and 
L5) of the spinal cord was removed, and bisected into sections 
ipsilateral and contralateral sections. Paw tissue was also removed 
from both the ipsilateral and contralateral paws. In separate 
experiments knee joints were cut horizontally at the end of the femur 
and tibia, and vertically along the tibia and fibula. Muscle was cut 
away and knee joint lifted out. 
5.4.3 Histology 
(Histological studies of joints from MIA or saline-treated rats were 
performed by Dr Rich Pearson at post-operative days 14-17 and 28-
31). Knee joints removed and fixed in 10% formal saline and 
subsequently decalcified in an aqueous ethylenediaminetetracetic 
acid (EDTA) solution (14% in distilled water; pH 7.0, 20°C) until 
completely decalcified. Samples were paraffin embedded, and 5-8 
J.1M sections of the central portion of each MIA ipsilateral and 
contralateral knee joint in the coronal plane were stained by safran in-
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o fast green to show matrix proteoglycan and overall joint 
morphology. Each knee was scored using a modified Mankin 
osteoarthritis grading system by 2 independent observers and a 
mean derived (Mankin et al. 2004). The worst affected area was 
scored; for example, a focal lesion with hypocellularity and 
decreased safranin-O staining would result in a high score even if the 
rest of the jOint looked relatively normal and bare bone scored the 
maximum grade of 6 for structure. The maximum score was 13 (not 
14) as the tidemark is ill defined in the rat. 
5.4.4 Measurement of endocannabinolds 
Endocannabinoid (EC) measurement was carried out using a method 
similar to that of Richardson at al., (2007). Paw and spinal cord 
tissue was stored at -80°C; it was then finely minced and added to 
ice cold acetonitrile containing internal standards (0.42 nmol d8-
anandamide, 1.5 nmol d8-2AG). Samples were shaken at 4°C, 
followed by repeated cycles of centrifugation, and supernatant layer 
collection. Simultaneous measurement of ECs and related 
compounds was then performed using liquid chromatography-
tandem mass spectrometry (LC-MS/MS). Analysis was carried out on 
an Agilent 1100 system (Agilent Technologies, Waldbrunn, Germany) 
coupled to a triple quadrupole Quattro Ultima MS (Waters, 
Manchester, UK) in electrospray positive mode. 
Analytes were separated chromatographically on a C 18 column 
(150)(21. mm internal diameter, 3.5 J,lm particle size; Waters 
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Symmetry, Hertfordshire, UK) with a mobile phase flow rate of 0.3 
ml/min. A gradient elution was used, with mobile phases consisting of 
A (water, 19/L ammonium acetate, 0.1% formic acid) and B 
(acetonitrile, 1 gIL ammonium acetate, 0.1 % formic acid). Samples 
were injected from a cooled auto sampler maintained at 4°C. Multiple 
reaction monitoring of individual compounds, using specific precursor 
and product mass to charge (mlz) ratios allowed simultaneous 
measurement of anandamide (AEA) , 2-arachidonoyl glycerol (2-AG), 
palmitoylethanolamide (PEA) and oleolylethanolamide (OEA). 
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5.5 Results 
5.5.1 MIA-induced changes in pain behaviour 
Intra-articular injection of MIA (1mg) produced significant decreases 
in weight-bearing on the hind-limb ipsilateral to injection, compared to 
pre-injection values and saline-treated rats (Figure 5.3A). There was 
an marked decrease in weight-bearing at PO day 2/3, which was 
followed by a small recovery by PO day 7. A significant decrease in 
weight-bearing was then maintained from PO day 7 to PO day 28. 
Changes in weight-bearing were accompanied by significant 
decreases in paw withdrawal thresholds for ipsilateral hindpaw 
withdrawal, indicative of mechanical allodynia (Figure 5.38). 
Contralateral paw withdrawal thresholds were not altered over the 
course of the study (data not shown). Intra-articular injection of 
saline did not significantly alter paw withdrawal thresholds on the 
ipsilateral paw, compared to baseline values (Figure 5.3A, B) 
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Figure 5.2 Time course of changes in (A) weight distribution on the 
ipsilateral hind-limb and (B) hindpaw-withdrawal thresholds intra-
articular injection of MIA (1-/50J.l1) or saline, Statistical analyses 
comparing MIA-treated rats to saline-treated rats were performed 
using a 2-way ANOVA with a Bonferroni post hoc test. *p<O,05, 
**p<O.01 and ***p<O.001 for MIA-treated rats versus saline. 
Histological analysis of the normal (saline) treated jOints shows clear 
red glycosaminoglycan (GAG) staining of articular cartilage on both 
the femur and tibia. There is also articular cartilage present on the 
meniscus, and dense red staining in the epiphysis, with 
chrondrycytes (nuclei stained blue) present in bone marrow (Figure 
5.5). MIA treated rats at PO day 14 revealed that there is a loss of 
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red staining in the meniscus and superficial zone of articular 
cartilage. There is a loss of dark blue staining of chrondycytes, 
indicating hypocellular bone marrow, and fibrious tissue is also 
present in the meniscus and subchrondral bone on both the femoral 
and tibal side. Horizontal clefts have also appeared between 
cartilage and bone on femoral side. The median Mankin score at 
this time point was 8.08±1.54 (Figure 5.4). By day 28, virtually all of 
the articular cartilage was had lost significant safranin-O staining with 
pronounced loss of articular cartilage and subchondral bone. Fibrous 
tissue is present down to the epiphysis, with large horizontal cleft 
between the bone and cartilage on the femoral side. Furthernore, 
virtually all of the bone marrow present in hypocellular, (Figure 5.5). 
The median Mankin score at this time point was 7.00±1.37 (Figure 5. 
4). 
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Figure 5.4 Box and whisker plot of the range of scores from the 
Mankin osteoarthritis grading system for ipsilateral knee joints from 
saline and MIA (1mg) treated rats. The horizontal line is the median 
score. 
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Figure 5.5 Histologial changes following MIA injection at PO 14 and 
P028. Intra-articular injection of MIA (1 mg / 5 0 ~ 1 ) ) produces 
degeneration of the articular cartilage (C) with a loss of structure in 
the subchondral bone (SS) layer in rats 14 and 28 days post-MIA 
injection. (E) - ephiphyses; (M) meniscus, (F) Fibia , (T) Tibia. 
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5.5.2 levels of Eels in the hindpaw and spinal cord of 
MIA and saline treated rats 
5.5.2.1 Eel levels in rat hindpaw P014 and P028 
levels of Eels and related compounds in the hindpaw and spinal 
cord of rats were measured at PO days 14-17 and PO days 28-31 
following intra-articular injection of MIA or saline. 
Intra-articular injection of saline did not significantly alter levels of 
AEA, 2AG, PEA or OEA in the ipsilateral hindpaw, compared to 
contralateral hindpaw at PO days 14-17 (Figure 5.6). levels of AEA, 
PEA and OEA were significantly elevated in the ipsilateral hindpaw of 
MIA-treated rats, compared to the contralateral hindpaw (Figure 5.6) 
and the ipsilateral hindpaw of saline-treated rats at PO days 14-17 
(Figure 5.6). levels of 2-AG in the ipsilateral hindpaw were 
comparable in the ipsilateral and contralateral hindpaw of MIA-
treated rats, and were consistent with levels in the hindpaw of saline-
treated rats. 
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Figure 5.6: Levels of endocannabinoids and related compounds in 
the skin of the hindpaw taken from rats receiving intra-articular 
injection of MIA ( 1 m g / 5 0 ~ 1 ) ) or saline at post-operative days 14, 
Statistical analyses were carried out using a Mann Whitney test. 
*p<O.05, vs ipsilateral saline-treated rats, &p<O,05, &&p<O.01 vs 
contralateral hindpaw, 
In keeping with the changes seen at the earlier time point, levels of 
AEA, PEA and OEA were significantly elevated in the ipsilateral 
hindpaw, compared to the contralateral hindpaw of MIA-treated rats 
at PO days 28-31 (Figure 5,7), In the case of PEA and OEA, levels 
were also significantly elevated in the ipSilateral hindpaw of MIA-
treated rats, compared to levels in the ipsilateral hind paw of saline-
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treated rats (Figure 5.7). As seen at days P014-17, levels of 2-AG 
were unaltered in the hindpaw in any of the treatment groups. 
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Figure 5.7 Levels of endocannabinoids in the skin from the hind paw 
of MIA (1 m g / 5 0 ~ 1 ) ) and saline-treated rats at post-operative day 28. 
Statistical analyses were carried out using a Mann Whitney test. 
*p<O,05, vs ipsilateral saline-treated rats, &p<O.05, &&&p<O.005 vs 
contralateral hind paw. 
Note, there were significant differences in levels of AEA and PEA in 
the ipsilateral and contralateral hindpaw taken from saline treated 
rats, compared to P028 compared to saline treated rats P014 (table 
5.1). 
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Group AEA pmolg-1 OEA nmolg-1 PEA nmolg-1 2AG nmolg-1 
I 
median (range) median (range) median (range) median (range) I 
Ipsi Contra Ipsi Contra Ispi Contra Ipsi Contra 
PO 14 4.11 (2.81- 4.14 (3.01- 0.27 (0.22- 0.25 (0.22- 0.15 (0.12- 0.14 (0.12- 5.61 (3.20- 5.71 (3.69-
saline 6.51) 5.00) 0.42) 0.41) 0.24) 0.21) 8.38) 9.16) 
I 
I 
PO 14 MIA 5.53 (3.25- 3.86 (2.56- 0.39 (0.22- 0.25 (0.22- 0.23 (0.12- 0.16 (0.12- 6.35 (3.73- 6.52 (3.35- I 
9.57) I 14.39)*# 8.49)$ 0.64) tr# 0.36) 0.39) ** 0.19) 9.51) 
PO 28 5.85 (4.44- 5.62 (3.64- 0.25 (0.22- 0.29 (0.25- 0.17 (0.15- 0.21 (0.18- 6.15 (4.65- 6.29 (4.79-
saline 10.53)# 9.55) 0.44) 0.37) 0.25)* 0.27) $$$ 20.56) 22.53) 
PO 28 MIA 9.12 (5.25- 5.86 (3.84- 0.34 (0.25- 0.26 (0.16- 0.22 (0.17- 0.21 (0.18- 8.10 (4.23- 5.76 (3.62-
13.33)*- 17.99) 0.41) **++ 0.38) 0.29)+ 0.27) AM 29.35) 17.39) 
Table 5.1 Levels of ECs and related compounds in the skin from the hindpawof rats treated with intra-articular injection of MIA or 
saline. Data were analysed using non-parametric Mann-Whitney test. Data expressed as median and range. ·P<0.05, **P<0.01, 
"""'P<O.001 VS. contralateral hindpaw, +P<0.05, ++P<0.01 vs P028 ipsilateral saline, ·p<0.05, "p<0.01 vs ipsilateral P014 saline, $ 
P<O.05, $$$ P<0.005 vs contralateral P014 saline, AMP<0.005 vs contralateral P014 MIA. 
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5.5.3 Eel levels in rat spinal cord P014 and P028 
At the level of the ipsilateral spinal cord, we observed a significant 
increase in levels of PEA, OEA and 2AG in the ipsilateral spinal cord 
of MIA treated rats, compared to the ipsilateral spinal cord of saline-
treated rats, at PO day 14-17 (Figure 5.8). There was a trend 
towards an increase in levels of AEA in the ipsilateral spinal cord of 
MIA-treated rats compared to the ipsilateral spinal cord of saline-
treated rats at PO days 14-17 (Figure 5.8). Levels of 2-AG in the 
ipsilateral spinal cord of MIA treated rats were elevated compared to 
the contralateral spinal cord (Figure 5.8), which was also the case for 
levels of AEA, OEA and PEA. Levels of AEA, PEA and OEA were 
also significantly elevated in the contralateral spinal cord of MIA-
treated ratsm compared to the contralateral spinal cord of saline-
treated rats at PO day 14-17 (Figure 5.8). 
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Figure S,S. Levels of endocannabinoids and related compounds in 
the spinal cord of MIA ( 1 m g / 5 0 ~ 1 ) ) and saline-treated rats at post-
operative day 14. Statistical analyses were carried out using a Mann 
Whitney test. *p<O.05, vs ipsilateral saline-treated rats, &p<O.05, vs 
contralateral hindpaw, ++p<O.01, +++p<O.005 vs contralateral saline-
treated rats. 
At the later timepoint (PO 28-31), there was a trend towards an 
increase in levels of AEA in the ipsilateral spinal cord of MIA-treated 
rats, compared to the ipsilateral spinal cord of saline-treated rats 
(Figure 5.9). Levels of AEA were significantly increased in the 
contralateral spinal cord of MIA-treated rats, compared to saline-
treated rats, at PO days 28-31 (Figure 5.9). Levels of OEA, PEA and 
2-AG were significantly increased in the ipsilateral spinal cord of MIA-
treated rats, compared to the ipsilateral spinal cord of saline-treated 
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rats (Figure 5.9 and Table 5.2). Furthermore, there was a significant 
decrease in levels of OEA and PEA in the ipsilateral spinal cord of 
MIA treated rats at PO days 28-31, compared to MIA treated rats at 
PO days 14-17 (Table 5.2). 
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Figure 5.9: levels of endocannabinoids and related compounds in 
the spinal cord of MIA (1 mg/50fll) and saline-treated rats at post-
operative day 28-31. Statistical analyses were carried out using a 
Mann Whitney test. *p<O.05,**p<O.01 vs ipsilateral saline-treated 
rats, +p<O.05, ++p<O.01, +++p<O.005 vs contralateral saline-treated 
rats 
Note: levels of Eels in the spinal cord at P014 and P028 were 
comparable. 
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Group AEApmolg-' OEA nmolg-1 PEA nmolg-1 2AG nmolg-1 
median (range) median (range) median (range) median (range) 
Ipsi Contra Ispi Contra Ispi Contra Ipsi Contra 
PO 14 37.14 (14.66- 40.75 (26.78- 1.16 (0.60- 2.04 (1.57- 0.62 (0.28- 0.96 (0.78- 35.78 (22.19- 48.33 (41.24-
saline 87.05) 67.94) 3.56) 4.15) 2.39) 2.25) 56.39)* 74.47) 
PO 14 67.87 (50.16- 73.21 (46.85- 3.78 (2.78- 3.20 (2.06- 1.96 (1.43- 1.67 (1.12- 100.6 (71.6- 65.42 (40.8- i 
MIA 100.5) 119.7) $$$ 5.63t+ 4.64)$$ 3.05) ++ 2.59) $$ 131.7)* ++ 103.5) 
PO 28 41.27 (23.88- 37.45 (18.53- 1.45 (1.27- 1.98 (1.52- 0.71 (0.61 0.97 (0.73- 49.68 (27.09- 40.07 (27.77-
saline 76.28) 51.27) 3.26} 7.77} 1.91} 3.21) 78.3) 63.39) $ 
PO 28 56.03 59.15 (49.17- 2.78 (2.77- 5.57 (2.24- 1.52 (1.20- 1.35 (1.06- 87.53 (61.36- 85.37 (54.79-
MIA (39.33-91.36) 88.53) AM 3.58}##% 5 . 4 3 ) ~ ~ 1.76)#1% 2 . 9 5 ) ~ ~ 161.7}- 112.4) AN!. 
Table 5.2 levels of ECls in the spinal cord of rats treated with a intra-articular inje?ion of MIA or saline. Data were analysed uSing 
non-parametric Mann-Whitney test. Data expressed as median and range. P<0.05 vs. contralateral spinal cord, +P<0.05, 
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++P<O.01 vs P014 ipsilateral saline, %P<O.05vs ipsilateral P014 MIA, ·p<O.05, "p<O.01 vs ipsilateral P028 saline, $ P<O.05, $$ 
P<O.01 $$$ P<O.005 vs contralateral P014 saline, ~ P < O . 0 5 , , llIlA P<O.001 vs contralateral P028 saline. 
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The relationship between each of the N-acylethanolamines (AEA, 
OEA, and PEA) and acyl-glycerols (2-AG) in each individual rat in the 
ipsilateral spinal cord of MIA and saline-treated rats, at day P014 
and P028, was investigated with a correlation analysis. Spearman 
rank correlation coefficients (R2) were calculated and are presented 
in Table 5.3, representative correlation graphs are shown in Figure 
5.10. In P014 saline treated rats, there is significant correlation 
between levels of AEA, OEA and PEA, and following MIA injection, 
there is a further correlation of levels of 2-AG with OEA and PEA. In 
saline-treated rats at day there is a correlation of levels of OEA with 
PEA and AEA, as well as levels of 2-AG correlating with AEA. 
However, following MIA treatment there is a loss of correlation 
between AEA, OEA PEA and 2-AG (Figure 5.10). This lack of 
correlation in MIA-treated rats P028 and the further correlation in 
MIA-treated rats at P014 may explain the degree of alloydnia 
observed at each time point. 
R.l 
P014 MIA P014 Saline P028 MIA P028 Saline 
ABAvsPEA 0.92·" 0.95·" 0.00 0.64 
ABA vs 0.93"· 0.90·" 0.12 0.68· 
OEA 
ABA vs 2- 0.61 0.13 0.13 0.70'" 
AG 
OEAvsPEA 0.99·" 0.96"· 0.55 0.93 ..... 
2-AG vs 0.75· 0.20 0.05 0.61 
PEA 
2-AG vs 0.72· 0.30 0.21 0.56 
OEA 
Table 5.3 Spearman Rank coefficient correlating levels of ECs in 
spinal cord of MIA and saline treated rats at days P014 and P028. 
*P<0.05, **P<0.01, ***P<0.005 = significant correlation. 
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In Chapter 2, I describe the development and validation of a sensitive 
LC-MS/MS method for the detection of COX-2 metabolites PG-EAs 
(PGE2-EA, PG02-EA, PGF2a-EA) and PG-GEs (PGE2-GE and 
PGF2a-GE) in biological tissue. This method was employed to 
determine whether COX-2 metabolites of AEA or 2-AG are present in 
the hindpaw or spinal cord following the induction of arthritis. This 
analytical approach was used to identify if alternative catabolism 
pathways for AEA and 2-AG in chronic pain models. Neither COX-2 
metabolites of AEA or 2-AG was detected in either the hindpaw or 
spinal cord of rats treated with single or repeated URB597 and 
intraplantar injection of carrageenan or saline. PG-EA and PG-GE 
were detected if they were spiked into rat brain tissue (Chapter 4, 
Figure 4.26), showing the functionality of the method. The limit of 
detection of PG-EAs and PG-GEs was 10 pmol/g and 100 pmollg 
respectively. On this basis, we assume that if the COX-2 metabolites 
of AEA and 2-AG are present, they are below our limit of detection. 
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Figure 5.10 Representative graphs showing the correlation coefficient between AEA, OEA, PEA and 2-AG in ipsilateral spinal cord 
MIA-treated rats at day P014 (A), and the lack or correlation between AEA, OEA, PEA and 2-AG in ipsilateral spinal cord MIA-
treated rats at day P028 (8). 
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5.6 Discussion 
The major finding of this study is that intra-articular injection of MIA 
produces time-dependent increase in pain behaviour and that these 
effects are associated with increased levels of endocannabinoids and 
related compounds in the hindpaw and spinal cord, which is 
comparable to our recent finding in the synovium OA patients 
(Richardson et al., 2008). 
This is the first study to· assess the effect of MIA-induced joint 
degeneration in relation to changes in pain behaviour and levels of 
Eels. MIA-treated joints show a time-dependant decrease in GAG 
staining, which corresponds to loss of cartilage matrix. There is also 
an increase in hypocellular bone matrix at P014, compared to saline 
treated, with only fibrous tissue present at day 28. At PO 28, there 
were large horizontal clefts present, articular surface was a lot 
thinner, and comprised of mineralized cartilage, or bone, compared 
to saline-treated joints. This type of joint damage is reminiscent of the 
type of damage seen in patients with end stage OA (Pritzker et aI., 
2006), with the main difference in the pathology of rats and humans 
is the presence of an open epiphysis, which is not present in 
humans. Thus, this model has a clinical validity, in terms of joint 
pathology and pain behaviour. 
Intra-articular injection of MIA produced a time-dependant decrease 
in paw withdrawal thresholds and weight bearing on the ipsilateral 
(injured) side. The observed biphasic changes in pain behaviour 
concurs with previous reports of an early robust change in weight 
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bearing (Pomonis et aI., 2005), due to an initial inflammatory phase 
as indicated by mild swelling of the MIA-treated knee joint. Intra-
articular MIA injection results in acute inflammation (Sove et aI., 
2003) which can lead to the release of pro-inflammatory mediators, 
such as TNFa, bradykinin and prostaglandins (Farahat et aI., 1993, 
Nishimura et aI., 2002, Pulichino et aI., 2006) in the knee joint, and 
an increase in the expression of spinal COX-2 mRNA (Prochazkova 
et aI., 2009). The inflammatory response following intra-articular 
injection of MIA has been shown to be largely resolved by day 7 and 
is not expected to playa role in pain at later time points (Guzman et 
al., 2003, Pulichino et aI., 2006). Consistent with this finding, 
administration of the TNF-(X inhibitor etanercept during the first week, 
but not the second week, following intr-articular injection of MIA 
attenuated pain behaviour in MIA-treated rats (Vonsy et al., 2008). 
The sharp decrease in weight bearing on the injured paw in the days 
following MIA injection which we, and others, have observed is likely 
to reflect the initial inflammatory response. Despite the inflammation 
being resolved by PO day 7, hyperalgesia and allodynia is 
maintained until later timepoints (Combe et aI., 2004, Pomonis et al., 
2005). Changes in paw withdrawal thresholds of the hindpaw 
(allodynia) did not develop as early as the changes in weight-bearing, 
This is consistent with previous studies, with a rapid decrease in 
weight placed on the ipsilateral hindpaw (Combe et aI., 2004, 
Fernihough et al., 2004, Pomonis et aI., 2005, Vermeirsch et aI., 
2007). Damage to the joint, includes the initial inflammatory 
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response, and may induce a sensitisation of peripheral receptors with 
changes in the response characteristics of primary afferent fibres 
(Petersen-Felix and Curatolo, 2002) includes decreased thresholds 
of C-fibre mediated of an increased input to the spinal cord (Woolf 
and Salter, 2000). Sustained activation of nociceptive pathways may 
lead to moderate or severe pain as seen in patients with chronic 
pain. Noxious mechanoreceptive inputs from the knee joint are 
processed by dorsal horn neurones, which also receives inputs from 
the paw and skin (Schaible and Grubb, 1993). The articular nerves 
supplying the knee project to superficial lamina I and deep laminae 
V-VII (Schaible and Grubb, 1993), while afferent fibers from rat hind 
paw project predominantly to lamina I II at L4/5 (Abbadie and 
Besson, 1992, Takahashi et aI., 2003, Todd et aI., 2005). 
Previously, sensitisation of joint nociceptors has been shown to 
increase peripheral receptive fields of neurones innervating the knee 
jOint, paw and ankle, presumably due to sensitisation of spinal 
neurones (Neugebauer et aI., 1993). The outcome of these studies 
using animal models are consistent with the referred pain reported by 
osteoarthritic patients (Kean et al., 2004, Kidd, 2006). It has been 
proposed that the bone pathology in the MIA model initiates nerve 
damage and neuropathic type behavioural pain responses 
(Ivanavicius et al., 2007), which may also contribute to changes in 
excitability of spinal neurones. Increased levels of CGRP mRNA and 
TRPV1 receptor mRNA in the DRG innervated by joint afferents have 
been reported at 28 days post MIA treatment (Fernihough et aI., 
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2005), both of which are likely to impact upon excitability of primary 
afferent fibres and post-synaptic responses of spinal neurones. 
Electrophysiological recordings from primary afferent fibres in MIA-
treated rats at the earlier time point (PO day 14) reported increased 
mechanical responses of C and A-rJ fibres (Kelly et aI., 2008, 
Schuelert and McDougall, 2008). Increases in the spontaneous 
activity and noxious-evoked activity of afferent fibres have also been 
demonstrated in the aged (36 month) guinea pig model of OA 
(McDougall et aI., 2009). Thus, changes in spinal neuronal 
responses in MIA-treated rats may arise as the result of increased 
primary afferent input producing long term changes in spinal 
processing of inputs and the appearance of spinal excitability at later 
time points. Increases in neuronal responses can develop from an 
increase in synaptic input from afferent fibres which are sensitised 
during injury and inflammation, which can increase input from both 
injured and non-injured area (peripheral sensitisation). 
It is well known that increases neuronal activity can drive the 
generation of Eels and related compounds. Intra-articular injection 
of MIA increased levels of the endocannabinoid AEA in the ispilateral 
hindpaw of MIA-treated rats both at 14 and 28 days post-injection. 
levels of two related compounds, PEA and OEA, were also elevated 
in the ipsilateral hind paw of MIA-treated rats. The robust changes in 
levels of AEA, PEA and OEA in the hindpaw of the MIA-treated rats 
occurred in parallel with the alloydnia at both P014 and P028. 
Furthermore, we observed an increase in levels of AEA, OEA and 
305 
The role of the endocannabinoid system in MIA model of Osteoarthritis 
PEA, however levels of 2-AG were unaltered following intra-articular 
injection of MIA compared to saline at both P014 and P028. This 
suggests changes in activity of either synthetic or catabolic pathway 
that is specific to the NAEs. Future work will determine whether 
catabolic or synthetic enzyme expression is altered. These data 
demonstrate that the MIA-induced joint damage produces changes at 
sites distal to the jOint. The effects of MIA treatment on levels of 
endocannabinoids and related compounds are reminiscent of 
changes in ECl levels demonstrated in the synovial fluid of OA 
patients, compared to control subjects (Richardson et aI., 2008). 
Currently, the measurement of ECls in the synovial fluid of rats is not 
achievable due to the small sample volume, however future studies 
will attempt to address this issue. 
At the level of the spinal cord, there was a trend towards increases in 
levels of AEA in the ipsilateral spinal cord of MIA treated rats, but 
significance was not reached at either time point. There was, 
however, a significant increase in AEA in the contralateral spinal cord 
of MIA-treated rats at both timepoints. levels of PEA and OEA were 
significantly increased in the ipsilateral and contralateral spinal cord 
of MIA-treated rats, compared to saline-treated rats, at both 14 and 
28 days post-injection. Bilateral changes are also observed in other 
models of chronic pain including CFA model of monoarthritis and CCI 
model of neuropathic pain (Besse et aI., 1992, Malcangio and 
Bowery, 1994, Ibuki et aI., 1997, lombard et aI., 1999). Bilateral 
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decreases in K-opoid binding sites in spinal cord are observed in CFA 
model of monoarthritis (Besse et aI., 1992), as well as a loss of 
GABA-IR in the spinal cord of rats following peripheral nerve injury 
(Ibuki et aI., 1997) and increased spinal substance C in a 
Mycobacterium tubercolusis model of monoarthritis (Malcangio and 
Bowery, 1994). Collectively these changes underlie exaggerated 
sensory processing, and demonstrate bilateral changes at the level 
of the spinal cord following unilateral injury. 
Increases in levels of AEA, 2AG, PEA and OEA in the spinal cord of 
MIA-treated rats may arise as a result of the increased nociceptive 
drive into the spinal cord and spinal excitability increasing the activity 
dependent synthesis of these compounds. Although it has not been 
shown directly, the activity-dependent release of endocannabinoids 
has been suggested from in vitro pharmacological studies (Maejima 
et aI., 2001 b, Wilson and Nicoll, 2001, Gerdeman et aI., 2002, Brown 
et aI., 2003, Oi et aI., 2005). Conversely the elevated levels may be 
due to a decreased catabolism of the endocannabinoids either by 
FAAH or other catabolic enzymes. It is important to note, however, I 
did not detect COX-2 metabolites of AEA or 2-AG in rat hindpaw and 
spinal cord suggesting little contribution of this pathway in MIA 
treated rats. We observed an increase in 2-AG in MIA-treated rats in 
the spinal cord, however not the hindpaw, which maybe associated 
with an increase in 2-AG synthesis via OAGL. OAGL is expressed in 
superficial lamina of the spinal cord, which also coincides with input 
from knee (Schaible and Grubb, 1993, Nyilas et aI., 2009), thus when 
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neuronal activity is increased such as in chronic pain states, lead to 
an activity dependant increase in 2-AG synthesis. Nevertheless, 
despite the increase in Eels in the spinal cord of MIA-treated rats, 
animals still show pain behaviour, at P014 and P028. However, the 
measured increased Eels, may be attenuating pain behaviour 
compared if none were present, if so we may see an exaggerated 
pain state, thus is we were to block CB1 receptor, would we see 
embellished pain behaviour. Indeed, acute administration of 
SR141716 in chronic pain animal models has been demonstrated to 
have hyperalgesic effects (Meng et aI., 1998, Richardson et aI., 
1998a, Strangman et al., 1998, Chapman, 1999) suggesting that 
endogenous cannabinoids serve naturally to modulate the 
maintenance of pain. 
In conclusion, the present study has demonstrated that MIA-induced 
jOint degeneration produced aberrant pain behaviour and is 
associated with increased levels of inhibitory endocannabinoids and 
related compounds in the hindpaw and spinal cord, which have been 
shown to tonically control nociceptive responses in other models of 
pain (Jhaveri et aI., 2007a). 
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Chapter 6 
General Discussion 
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6 General Discussion 
Cannabis-based medicines have been suggested as potential 
treatments for a wide variety of diseases, with positive results in the 
symptomatic relief of neuropathic pain in multiple sclerosis and 
cancer pain, as well as suppressing chemotherapy-induced nausea 
and emesis (Seamon, 2006). Direct targetting of CB1 receptors has 
met with limited success; indeed the selective CB1 receptor 
antagonist rimonabant was withdrawn from the European market due 
to the risk of serious psychiatric problems. However, indirect 
modulation of the endocannabinoid system, by targeting ECl 
metabolism, has been demonstrated to produce anti-nociception in 
models of inflammatory pain (for reviews (Jhaveri et aI., 2007a, Di 
Marzo, 2008). Whilst modulation of ECl synthesis has not been 
investigated in models of pain, it has been shown that disruption of 
ECl synthesising enzymes, such as NAPE-PlD decreases levels of 
ECls. Since the elevation of ECls, through inhibition of metabolism, 
is thought to be the main route of analgesia, decreasing levels would 
presumably be hyperalgesic. Therefore, the identification of 
alternative routes of ECl metabolism and synthesis is essential for 
understanding the mechanisms involving ECl turnover, which could 
lead to the development of alternative medicines. 
The data presented in this thesis demonstrate the presence and 
functionality of the endocannabinoid system in pain pathways in vitro 
and in vivo. Following the successful development of an lC-MS/MS 
method for the simultaneous measurement of ECls and COX-2 
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metabolites of AEA and 2-AG, I was able to use this method to 
quantify levels of AEA, 2-AG, OEA and PEA in cell, hindpaw and 
spinal cord tissue. Using this method, we investigated the effects of 
increased intracellular calcium on the levels of Eels in vitro, levels of 
Eels in rat models of acute and chronic inflammation, and the 
effects of FAAH inhibition on nociceptive behaviour and levels of 
Eels, PG-EA and PG-GE in the carrageenan model of inflammatory 
pain. 
In models of pain and inflammation, Eel levels in tissues involved in 
nociceptive processing (namely the spinal cord, brain and skin of 
rodents) are usually elevated following treatment with irritants and 
inflammatory stimuli (aka et aI., 2006, Jhaveri et aI., 2008b) levels 
are also elevated in animal models of neuropathic 
pain(Mitrirattanakul et aI., 2006, Agarwal et aI., 2007, Petrosino et aI., 
2007) and are thought to represent adaptive changes aimed at 
reducing pain and inflammation. 
What is apparent from the data presented in this thesis is that the 
general conception that an increase in Eel levels is analgesic is 
actually more complex than first anticipated. The impact appears to 
depend greatly on the tissue in question, the disease state, and also 
on the degree of disease progression. In order to manipulate the 
Eel system to provide analgesia, a better understanding of the Eel 
system in various pain states at differing times is needed, which may 
lead to the development of clinically relevant compounds targetted to 
enhance or decrease the activity of the Eel system at certain time 
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points associated with hyperalgesia. Indeed, in the hindpaw, a 
decrease in Eel levels was observed 2 hours post carrageenan, with 
no change in the spinal cord, while at 3 hours post carrageenan, we 
see no change in levels of Eels in the hindpaw, but an increase in 
AEA in the spinal cord. Thus, elevating Eels in tissues specific to 
nociception may be required in order to achieve analgesia. This can 
possibly be achieved through systemic administration of Eel 
metabolising enzyme inhibitors such as URB597, which in theory 
should elevate levels of Eels in tissues specific to nociception. The 
systemic administration of a single injection of URB597 did, however, 
elevate levels of Eels in the spinal cord, but not in the hindpaw, 3 
hours post carrageenan injection, which proved to be analgesic, 
suggesting that an increase in Eel levels is required for analgesia. 
Interestingly, repeated administration of URB597, a more clinically 
relevant dosing regimen, did not elevate levels of Eels in either the 
hindpaw or spinal cord. These data suggest that the dosing 
schedule and possibly the route of administration are key to elevating 
levels of Eel, and thus analgesia. Indeed, intraplantar 
administration of URB597 was reported to elevate levels of Eels in 
the hindpaw, which attenuated hyperalgesia (Jhaveri et aI., 2008b). 
Not suprisingly, the correct dose also appears important to achieve 
analgesia. High oral doses of URB597 (10-50 mg/kg) are required to 
attenuate neuropathic pain (Russo et aI., 2007a), whereas lower i.p 
doses are not effective in this model (Jayamanne et al., 2006b). 
Thus, using the correct dose, and combination of local and systemic 
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administration of FAAH inhibitors may elevate levels of Eels in the 
desired tissues and provide analgesia. 
The lack of effect of repeated administration of URB597 in an acute 
model of inflammatory pain should not be overlooked and may be 
more therapeutically relevant in chronic pain states, such as 
neuropathic pain, where repeated dosing of URB597 has been 
reported to produce anti-nociceptive effects (Russo et al., 2007a). 
In the MIA model of chronic inflammation, elevation of ECls in the 
hindpaw and spinal cord did not produce analgesia. Thus, there is a 
question about whether further elevation of levels, through the use of 
FAAH inhibitors, can produce analgesia, or whether levels are 
elevated beyond physiological levels, perhaps activating other 
targets, such as TRPV1 (Starowicz et aI., 2007). Increased levels of 
Eels are thought, in the case of central neurones, to act to inhibit 
excitatory neurotransmitter release (Pertwee, 2006, Oi Marzo and 
Petrosino, 2007), however high levels/concentrations of CB1 ligands, 
such as Eels (Maione et aI., 2006), or under pathological conditions 
where there is an elevation in ECls, such as nociception, ECls may 
reduce inhibitory neurotransmission, such as through GABAergic 
neurones (Hohmann and Suplita, 2006, Maione et aI" 2006). These 
may elicit a reduced activity of the desired inhibitory nociceptive 
pathway, leading to a decrease in analgesia. Thus, perhaps a 
TRPV1 antagonist, or a GABA agonist, in combination with a FAAH 
inhibitor may elevate ECl levels without activating other off- target 
receptors. 
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High concentrations of URB597 have been found to activate TRPA 1 
channels (Niforatos et aI., 2007) also involved in pain transduction, 
thus potentially altering the analgesic efficacy of this compound. 
Hence there is the need for a more selective FAAH inhibitor, which 
produces analgesia through the elevation of ECls, without hitting 
other, potentially pro-nociceptive targets. 
A lot of attention has been focussed on the use of FAAH inhibitors in 
elevating levels of ECls producing analgesia, however ECls are 
also metabolised by other routes such as COX-2, lOX and CYP450 
(see review (Kozak and Marnett, 2002) and Figure 1.5). Thus, there 
is the potential for other compensatory metabolising pathways to be 
activated when FAAH is inhibited. We found no evidence for COX-2 
metabolism of AEA and 2-AG in the carrageenan model of 
inflammation when FAAH was inhibited, however, further 
development of other analytical methods for the simultaneous 
measurement of ECls and metabolites of ECls, would provide 
additional information on patterns of change, as well as identifying 
potential therapeutic compounds of interest involved in the 
deactivation of the EC system. Thus instead of focussing on 
inhibiting one ECl metabolising enzyme, such as FAAH, the 
combination of FAAH, lOX, COX-2 and/or CYP450 inhibitors may 
better analgesic candidates. 
The ECl levels determined in this thesis are a relatively quick 
'snapshot' in time of inflammatory and pain states. Quantification of 
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Eels using microdialysis sample collection would provide important 
information regarding changes in time. This technique has been 
previously used to measure Eels in awake, behaving rats (Giuffrida 
et aI., 1999, Porter et aI., 2002, Drio et aI., 2009), however, many 
methods do have sufficient sensitivity to measure Eels (particularly 
AEA) in microdialysis samples collected over minute time scales and 
often require pooling of samples. The method developed in this 
thesis may provide the extra sensitivity required to measure small 
amounts of Eels in the low volumes of biological samples obtained 
following acute and chronic inflammation, and, combined with a 
method for global profiling of ECl precursors and metabolites, may 
provide potential therapeutic targets for modulating endocannabinoid 
synthesis and metabolism. 
In summary, an analytical method for the simultaneous quantification 
of AEA, DEA, PEA, 2-AG, and COX-2 metabolites of AEA and 2-AG 
has been developed and applied to the measurement of Eels 
following noxious stimulation. Data obtained in this thesis show an 
increase in Eel levels following noxious stimulation and that 
modulation of the EC system provides a potential therapeutic target 
for the treatment inflammatory pain states. 
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8 Appendix 
Calcium Imaging Buffer 
145 mM NaCl, 
5 mM KCI, CaCI2 
1 mM MgS04.7H20 
10mM HEPES 
10 mM glucose 
Make up to 1 liter dH2037°C, pH 7.4. 
Fura-2-AM 
Appendix 
5 ~ I I of a 10 mg/ml solution in anhydrous dimethyl sulfoxide in 900 ~ I I
Ca2+ buffer with 1 00 ~ I I fetal calf serum. 
Lowry A solution 
2.85 g NaOH 
14.30 9 Na2 C0 3 
Make up to 500 ml in dH20 
Lowry AB solution 
20mls of solution A to 1 O O ~ I I 2% NaK tartrate and 1 O O ~ I I 1 % CUS04 
2.5mM Probenecid Solution 
0.71g probenecid in 5ml1M NaOH + 5ml HBSS 
Brilliant Black Solution 
10 9 prepared to 50mM in dH20 
HEPES buffered saline (HBSS) 
0.22g Sodium Pyruvate 
8.47g NaCI 
1.8g Glucose 
0.37g KCI 
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0.246g MgS04.7H20 
2.384g HEPES 
0.191g CaCI2 
0.126g NaHC03 
Make up to 1L withdH20. pH to 7.45. 
Flu0-4 loading solution 
Appendix 
5 0 ~ g g Fluo-4 to a 1 mM solution in 10% pluronic acid in DMSO ( 2 2 . 8 ~ 1 1
DMSO + 2 2 . 8 ~ 1 1 20% pluronic acid). Add to 20m I loading buffer 
(supplemented HBSS plus final concentration of 2.5mM probenecid 
and 0.5mM brilliant black). 
Transfer buffer 
30.3 9 Tris 
144 9 Glycine 
Dissolve in 8 Ltr dH20, and 2 Ltr methanol 
TBST blocking buffer 0.1 % tween 
30.29 9 Tris 
73.12 9 NaCI 
Dissolve in 11tr dH20 
Adjust pH 7.6 
Make up to 101tr in big container 
Add 10ml Tween 20 to a final conc of 0.1 % 
Lysis Buffer pH 7.6 
12.1 9 Tris 
1,9 9 EGTA 
51.7 9 Sucrose 
5 0 0 ~ 1 1 0.1% Triton X100 
0.021g NaF 
1.08 9 (3-glycerophosphate 
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Dissolve in 500ml DH20 pH 7.6 
Add 1 Protease tablet in 10ml lysis buffer before use 
6X solubalisation Buffer 
2.5ml O.5M Tris 
2.0ml Glycerol 
2.0ml 10%SDS 
2.5ml dH20 
1.0ml J3-mercaptoethanol 
40J.11 2.5% Bromophenol Blue 
Appendix 
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